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SUMMARY 
Alzheimer' s disease (AD) is the most common form of dementia. The pathological 
hallmarks of AD include ~-amyloid (A~) plaques, dystrophic neurites (DNs) and 
neurofibrillary tangles (NFfs). All of these pathological hallmarks involve abnormal 
insoluble proteinaceous aggregates that have the capacity to disturb normal cellular 
functioning. However, there is disagreement within the AD literature as to whether it is 
A~ plaques, soluble A~ or NFTs that are the primary causative agent of AD. 
Irrespective of the initial cause of AD, the burden of A~ plaques and NFfs increases as 
AD progresses, eventually resulting in substantial brain atrophy, which is at least 
partially due to overt neuronal degeneration and death. Thus, a better understanding of 
the aetiology and progression of AD will enable more efficient therapeutics to be 
developed. 
This thesis investigates the role of apoptosis in AD with the aim of ascertaining whether 
apoptosis is involved in disease staging or progression or is a causative agent of AD. No 
increase in immunohistochemical labelling, or change in localisation that distinguished 
between control, preclinical AD and AD cases were present for a range of apoptosis-
related proteins. In addition, mRNA levels of apoptosis-related proteins differed little 
between control, preclinical AD and AD cases when analysed by real time reverse 
transcriptase polymerase chain reaction. There was no difference in the percentage of 
apoptotic-like nuclei in the neocortex between control, preclinical AD and AD cases and 
very few of the nuclei associated with A~ plaques or NFfs were abnormal. Cytochrome 
c (cyto c)-labelling was punctate in cortical neurons, including a subset of NFf-bearing 
neurons, but a subset of DNs demonstrated cytoplasmic cyto c-labelling. These data 
suggest that apoptosis may not play a major role in the pathogenesis or progression of 
AD and that activation of apoptotic pathways can occur in the absence of extensive 
terminal appptosis in the brain. 
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As post-mortem human AD tissue provides only random time points in the dynamic 
process of disease progression, transgenic mouse models of AD are invaluable tools for 
investigating aspects of age-associated disease progression and also for testing potential 
therapeutics for AD. Although, for animal models to be used effectively, a detailed 
understanding of the pathology and disease processes that they model is required. 
Therefore, the AP plaque-associated neuronal pathology in two transgenic AD mouse 
models was investigated to determine whether the neuronal pathology in these mice 
more closely resembles human preclinical AD cases or clinically evident AD cases. 
Using immunohistochemistry the morphology and neurochemistry of the AP plaque-
associated DNs present in the two lines of transgenic AD mice was demonstrated to be 
strikingly similar to that in human preclinical AD cases, but not AD cases. Importantly, 
quantitation demonstrated that the AP plaques in these transgenic AD mice were highly 
axonopathic, and were also associated with displaced or clipped apical dendrites in both 
transgenic mouse models. The results suggest that these mice represent an accurate and 
valuable model of preclinical AD that can be utilised as a platform for testing potential 
therapeutic agents for AD, to be administered prior to extensive neuronal loss. 
Finally, as current treatments for AD only treat the symptoms of the disease and do not 
slow or stop its progression, the potential of a novel therapeutic agent with zinc binding, 
neuroprotective and anti-oxidant properties, metallothionein isoform IIA (MTIIA), was 
investigated. Utilising immunohistochemistry, the A~ and thioflavine s plaque loads 
and the A~ plaque-associated neuronal pathology in 13 and 15 month old Tg2576 mice 
was investigated after three months of metallothionein IIA treatment. Although this 
pilot study did not produce any statistically significant results, there was a trend towards 
lower A~ and thioflavine s plaque loads in MTIIA treated Tg2576 mice. Thus, MTIIA 
warrants further investigation as a potential therapeutic for AD in the future. 
The research in this thesis provides valuable new data on the staging of AD, with 
particular regard to the role of apoptosis in AD and A~ plaque-associated neuronal 
pathology in transgenic AD mice and human AD. The current study indicates that 
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apoptosis does not play a seminal role in the genesis or progression of AD pathology. 
This works has also clarified how two widely studied transgenic AD mice compare to 
the schema of disease progression that occurs in human AD, and strongly suggests that 
these transgenic AD mice mimic human preclinical AD. Finally, a pilot study of MTIIA 
administration to transgenic AD mice did not result in significant differences between 
the treatment and control groups. 
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Chapter 1 - Introduction 
1 INTRODUCTION 
1.1 THE PATHOLOGICAL HALLMARKS OF AD 
Alzheimer's disease (AD) is the most common neurodegenerative disease (Bossy-
Wetzel et al.,_ 2004) and is likely to become an increasing problem as the world's 
population ages (Vickers et al., 2000). The main pathological characteristics of AD are 
B-amyloid CAB) plaques, dystrophic neurites (DNs), neurofibrillary tangles (NFTs) and 
neuropil threads (Braak and Braak, 1991). All of these pathological hallmarks consist of 
abnormal accumulations of proteins within the brain. Plaques are comprised of AB 
protein that undergoes an abnormal conformational change to form insoluble fibrils that 
aggregate into extracellular masses. B-amyloid protein is derived from the B-amyloid 
precursor protein (APP) and is normally synthesised and secreted by neuronal and non-
neuronal cells (Busciglio et al., 1993; Fraser et al., 1993; Haass and Selkoe, 1993; 
Martin et al., 1994; Hartmann et al., 1997; Mesulam, 1999). There are two main 
processing pathways for APP (Reid et al., 2007). The pathway that results in the 
production of Al) begins with the cleavage of APP by 13-secretase, which is usually the 
13-site APP-cleaving transmembrane aspartic protease 1 (BACEl), to produce APPs!), 
the remaining C-terminal fragment is then cleaved by the y-secretase complex to 
produce Al) and the APP intracellular domain (Zheng and Koo, 2006; Reid et al., 2007). 
The y-secretase complex consists of presenilin, nicastrin, anterior pharynx-defective-I 
and presenilin-enhancer-2 in a stable complex (DeStrooper, 2003) and 'Can cleave APP at 
heterogenous sites between 38-43 amino acids to produce the numerous Al) peptides 
(Reid et al., 2007). In the second cleavage pathway APP is cleaved by a-secretase, one 
of several members of the disintegrin and metalloprotease enzyme family, within the Al) 
domain to produce APPsa, and the C-terminal fragment is then cleaved by the y-
secretase complex to yield a 3kDa product and the APP intracellular domain (Zheng and 
Koo, 2006; Reid et al., 2007). B-amyloid plaques are present within the brains of AD 
patients and mildly demented elderly (lwatsubo et al., 1994; Morris et al., 1996; Braak 
and Braak, 1997; Price and Morris, 1999) and can be morphologically characterised into 
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three varieties: diffuse, fibrillar and dense cored (Dickson et al., 1988; Armstrong, 1998; 
Dickson and Vickers, 2001). In contrast to AB plaques, DNs, NFfs and neuropil threads 
all involve abnormal intraneuronal filamentous (neurofibrillary) accumulations of 
altered cytoskeletal proteins. Dystrophic neurites are aberrantly shaped neuronal 
processes, likely of axonal origin, with aberrant accumulations of cytoskeletal proteins 
and cytoskeletal-associated proteins, which are specifically associated with AB plaques. 
However, not all AB plaques are associated with DNs, and the subset of AB plaques that 
are associated with DNs are referred to as neuritic AB plaques. Neurofibrillary tangles 
are intraperikaryal inclusions, principally comprised of altered tau proteins that occur 
within specific subsets of neurons in the cerebral cortex and selected subcortical nuclei. 
Similarly, neuropil threads are also accumulations of abnormal tau proteins that 
principally occur in the dendrites of NFf-bearing nerve cells (Braak and Braak, 1988; 
Braak et al., 1996). 
1.1.1 Controversial pathogenic role of AP in AD 
The 'amyloid cascade hypothesis' asserts that the primary cause of AD is AP protein. In 
this regard, it is proposed that AP plaques may be toxic to nerve cells and their 
processes, which is supported by in vitro studies that demonstrate that aggregated AP is 
particularly toxic to neurons (Pike et al., 1993; Lorenzo and Yanker, 1994; Ivins et al., 
1998; Lambert et al., 1998; Hartley et al., 1999). However, other proponents of the AP 
cascade hypothesis state that it is soluble AP oligomers or protofibrils that are toxic to 
neurons and ultimately result in neurodegeneration (Lambert et al., 1998; Hartley et al., 
1999; Wang et al., 2002; Lanz et al., 2003). Recent research suggests that oligomeric 
AP in particular, affects synaptic transmission (Huang et al., 2006; Lacor et al., 2007; 
Matsuyama et al., 2007). It is also possible that both soluble and aggregated fibrillar AP 
have neurotoxic properties. 
Alternatively, there is the opposing view that AP is not the primary causative agent of 
AD (Martin et al., 1994; Terry, 1996; Joseph et al., 2001). In this respect, 
neurofibrillary changes are emphasised as having a more central pathological role in 
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AD. Thus, there is disagreement as to which pathological hallmark of AD is best linked 
to the dementia phenotype. While the load of neuritic AP plaques in an individual has 
been reported to be the best indicator of the degree of dementia (Cummings and Cotman, 
1995) others have shown that NFTs (McKee et al., 1991; Arriagada et al., 1992; Bierer 
et al., 1995; Mesulam, 1999; Gold et al., 2001; Giannakopoulos et al., 2003), DNs 
(McKee et al., 1991) the density of synaptophysin-labelled synapses (Terry et al., 1991) 
or neuron loss (Bussiere et al., 2003; Giannakopoulos et al., 2003) more reliably 
correlate with cognitive deterioration in AD. However, it is possible that neuritic AP 
plaques, NFTs and synaptic and neuronal cell loss all contribute to the cognitive decline 
in AD. In addition, the temporal and spatial pattern of AP plaque deposition is different 
to that of NFTs (Arriagada et al., 1992; Lue et al., 1996; Knowles et al., 1998; Price et 
al., 1999) making it difficult to ascertain whether one pathology causes or is linked to 
the other. 
Genetic studies, the production of transgenic APP mice and the analysis of human brain 
material all provide general support for the amyloid cascade hypothesis. For example, 
APP, presenilin 1 (PS 1) and presenilin 2 (PS2) gene mutations have been linked to 
familial forms of AD and it has been proposed that all of these gene defects ultimately 
affect the metabolism of APP (Beyreuther and Masters, 1997; Hardy et al., 1998), 
although the precise role of the PS 1 and PS2 gene products in AD pathology is 
controversial. 'Normal' APP processing results in a heterogeneous mixture of proteins, 
including AP (Haas and Selkoe, 1993). However, the presence of such AD-causing 
mutations results in the production of proportionally more of the hydrophobic AP 
protein that is likely to precipitate insoluble AP plaques (for review see Sandbrink and 
Beyreutheris, 1996; Selkoe, 1996; Bossy-Wetzel et al., 2004). Further genetic support 
for the AP cascade hypothesis comes from the study of Downs syndrome. Individuals 
with Downs syndrome have an extra copy of the APP gene and as a result develop AP 
plaques at a very early age, followed by other neuropathological features of AD (Brion, 
1996; Lemere et al., 1996). This implies a staging of AD, with APP abnormalities and 
AP plaque formation preceding, and possibly causing, neurofibrillary degeneration. 
Furthermore, numerous transgenic mouse models of AD expressing a variety of 
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combinations of human APP, PS 1 and PS2 proteins harbouring mutations associated 
with familial AD exhibit AD-associated pathology with aging, including AP plaques, 
DNs, astrogliosis, microgliosis and neurodegeneration, however, these mice do not, 
demonstrate neurofibrillary pathology or extensive neuronal death (Games et al., 1995; 
Hsiao et al., 1996; Borchelt et al., 1997; Sturchler-Pierrat et al., 1997; Holcomb et al., 
1998; Moechars et al., 1999; Janus et al., 2000; Mucke et al., 2000; Chishti et al., 2001; 
Blanchard et al., 2003; Higgins and Jacobsen, 2003; Richards et al., 2003; Cheng et al., 
2004; Kawasumi et al., 2004; Oakley et al., 2006). 
Despite this wealth of information on genetically linked AD, it is important to note that 
the majority of AD cases are sporadic, with genetically linked forms accounting for less 
than 5% of all AD cases (van Leeuwen et al., 1998), however, genetically linked and 
sporadic AD cases may share a common final pathophysiological pathway (Lippa et al., 
1996). For example, when two genetically linked AD cases were compared to sporadic 
cases there was no difference in the pattern of distribution of neuronal loss, AP plaques, 
neuritic AP plaques and NFTs, or in the ratio of neuronal loss to neuritic AP plaques or 
NFTs (Lippa et al., 1996). However, a recent study utilising in vivo imaging techniques 
suggests that human subjects carrying PS 1 mutations that lead to early-onset AD 
demonstrate a different regional pattern of AP plaque deposition to that in sporadic cases 
(Klunk et al., 2007). It has been suggested that sporadic AD cases begin with an 
increase in production of Ap or a decrease in the clearance of Ap, particularly with 
regard to the hydrophobic AP protein (Selkoe et al., 1996), resulting in the aggregation 
of AP into insoluble AP plaques and the onset of degeneration. In support of this 
proposition, the activity of the APP cleaving enzyme P-secretase significantly increases 
with aging (Fukumoto et al., 2004), while the E4 allele of apoplipoprotein E (ApoE), 
which is a major risk factor for sporadic AD, promotes AP precipitation into insoluble 
AP plaques (Mesulam, 1999). 
It has been suggested that low levels of free testosterone may also be a risk factor for 
developing AD, with low levels of testosterone correlating with cognitive dysfunction, 
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including in subjects with mild cognitive impairment and AD (Hogervorst et al., 2004; 
Beauchet, 2006). Furthermore, gonadectomized male 3xTg-AD mice exhibited increased 
accumulation of A~ and deficits in hippocampal function that were attenuated by 
dihydrotestosterone treatment (Rosario et al., 2006). However, other population studies 
have suggested that there was no association between oestrogen or testosterone levels in 
men and the risk of developing AD (Ravaglia et al., 2007). In comparison, the role of 
oestrogen and progesterone as risk factors for women developing AD and as factors that 
influence the pathogenesis of AD are controversial. Some studies suggest that oestrogen 
and progesterone are neuroprotective and decrease the risk of AD (Yue et al., 2005; 
Carroll et al., 2007), while other investigations indicate that increased exposure to 
oestrogen and progesterone increase the risk of developing AD in women (Shumaker et 
al., 2003; Shumaker et al., 2004; Colucci et al., 2006; Ravaglia et al., 2007). 
1.1.2 A "mass effect" variant of the amyloid cascade hypothesis 
Following findings that indicate that DNs, particularly in the earliest stages of AD, 
exhibit morphological and biochemical features that are strikingly similar to the axonal 
response to structural injury (Masliah et al., 1993; Meller et al., 1994; De Witt and Silver, 
1996; Su et al., 1996a; Vickers et al., 1996; Christman et al., 1997; King et al., 1997; 
Nakamura et al., 1997; Dickson et al., 2000; King et al., 2001; Chuckowree and Vickers, 
2003; Dickson et al., 2005) a variant of the amyloid cascade hypothesis was proposed 
(reviewed in Vickers, 1997; King et al., 2000, Vickers et al., 2000). Thus, it is 
hypothesised that AP plaque formation, particularly the more dense AP plaques, causes 
physical deformation and injury to axons, resulting in a cascade of cytoskeletal changes 
that lead to DN formation (King et al., 1997; Vickers, 1997; Dickson et al., 1999, 
Vickers et al., 2000; Dickson et al., 2005). Indeed, only non-neuritic AP plaques are 
present in young transgenic AD mice, while AP plaque-associated DNs do not appear 
until several months later (Mucke et al., 2000). Additionally, fewer dendrites, axons and 
neuronal somata are present within the areas inhabited by AP plaques in human AD 
(DeWitt and Silver, 1996; Knowles et al., 1998; Tomikodoro et al., 2001; Adlard and 
Vickers, 2002), supporting the proposal that AP plaques can be considered as space-
5 
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consuming entities that push other structures aside and/or compress neural elements. 
Thus, individual AB plaques may create a localised "mass effect" within the neuropil. 
However, experimental models of injury generally involve acute axonal injury, after 
which the damaged axons undergo reactive and regenerative changes and the injury is 
eventually resolved. As dense AB plaques are considered to be relatively stable entities 
(Christie et al., 2001; Spires et al., 2005), the physical trauma inflicted upon neurites in 
AD is chronic and may interfere with the "normal" response to axonal irtjury. Thus, it is 
postulated that chronic stimulation of the neuronal reaction to injury by AB plaques, 
perhaps over many years, may cause changes in cytoskeletal elements such as 
neurofilaments (NFs) and tau that lead to the formation of the abnormal insoluble 
filamentous structures, such as those in NFTs (Vickers et al., 1996; Dickson et al., 1999; 
Metsaars et al., 2003). To elaborate on the data leading to the formation of this mass 
effect hypothesis, the following sections of this review focus on the early neuronal 
changes that are specifically associated with AB plaque pathology, and how the staging 
of neuronal alterations provides clues to the pattern of neural degeneration that underlies 
dementia. 
1.2 CYTOSKELETAL PATHOLOGY IN AD 
Neurofibrillary pathology involves specific abnormal alterations in neuronal cytoskeletal 
proteins. The cytoskeleton is a rigid yet dynamic framework of protein polymers that 
determines neuronal morphology and intracellular structure and also plays an important 
role in axonal transport. The cytoskeleton is made up of three classes of protein 
polymers; the microtubules, NFs and microfilaments. The NFs are intermediate 
neuronal filaments that include specific protein classes such as the NF triplet proteins, 
peripherin and a-internexin. The NF triplet proteins include NFL, NFM and NFH (low, 
medium and high molecular weight subunits), which normally co-assemble to form 
intermediate filaments (Smith et al., 2003). Recent research shows that a-intemexin 
also acts as a fourth subunit that co-assembles with the NF triplet proteins in the mature 
central nervous system (CNS) (Yuan et al., 2006). Neurofilament triplet proteins and a-
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intemexin are present in specific subsets of neurons, with NF triplet proteins being 
richly expressed in large neurons especially those with long axonal processes (Su et al., 
1996a; Kirkcaldie et al., 2002; Dickson et al., 2005). In contrast, a-intemexin is more 
widely distributed amongst cortical cell types (Dickson et al., 2005) and is present in a 
substantial proportion of human and rat neocortical cells that are not labelled for the NF 
triplet proteins. As discussed below, alterations in NF proteins, particularly in DNs, may 
provide important insight into the deleterious effects of Af3 plaque formation on the 
neuropil. In addition, there is on-going and substantial interest in the role of the 
microtubule-associated protein, tau, in neuronal degeneration in AD. The normal 
biological role of tau is to promote the assembly of tubulin into microtubules and aid 
microtubule stability, and this is regulated by the phosphorylation state of tau 
(Trojanowski and Lee, 1994; Hardy et al., 1998; Iqbal et al., 2005). Abnormal 
hyperphosphorylation of tau results in the loss of normal tau function, increases. the 
ability of tau to aggregate with itself and other microtubule associated proteins in 
insoluble aggregates, and precedes the accumulation of tau into insoluble masses in AD 
(as reviewed in Iqbal et al., 2005). Abnormal accumulations of tau are found in DNs, 
NFTs and neuropil threads (Trojanowski and Lee, 1994; Johnson and Jenkins, 1999). 
Neurofibrillary tangles can be classified according to their sequential changes in 
morphology (Braak et al., 1994). · Group one or pre-NFT neurons do not exhibit 
established NFTs, but do contain paired helical filament (PHF) tau (Braak et al., 1994). 
Group two and three neurons progressively accumulate intracellular NFTs, and group 
four and five NFTs are present in the extracellular space following the death of the NFT-
bearing neurons (Braak et al., 1994). However, the abnormally phosphorylated form of 
tau that NFTs and neuropil threads are principally comprised of is different to the form 
of tau that is present in DNs (Onorato et al., 1989; Trojanowski and Lee, 1994; Johnson 
and Jenkins, 1999). 
1.3 DYSTROPHIC NEURITE PATHOLOGY IN AD 
Dystrophic neurites are aberrant neuronal processes that can be immunoreactive for both 
phosphorylated and dephosphorylated Nf triplet proteins, APP, ubiquitin, a-intemexin 
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and/or tau (Dickson et al., 1988; Cras et al., 1991; Benzing et al., 1993; Masliah et al., 
1993; Su et al., 1996a; Vickers et al., 1996; King et al., 1997; Nakamura et al., 1997; Su 
et al., 1998; Thal et al., 1998; Dickson et al., 1999; Dickson and Vickers, 2001; Dickson 
et al., 2005). Morphologically, DNs appear as swollen tortuous neurites 10-60µm in 
diameter with a range of shapes that are invariably associated with AP plaques (Benzing 
et al., 1993; Masliah et al., ·1993; Su et al., 1996a; Vickers et al., 1996; King et al., 1997; 
Su et al., 1998; Dickson et al., 1999; Dickson and Vickers, 2001; Dickson et al., 2005). 
Dystrophic neurites immunolabelled for NF triplet proteins and a-intemexin can be 
categorised as bulb- or ring-like structures based on the morphology oflabelled elements 
(Masliah et al., 1993; Su et al., 1996a; Vickers et al., 1996; Su et al., 1998; Dickson et 
al., 1999; Dickson and Vickers, 2001). Bulb-like DNs appear as bulbar swellings 
whereas ring-like DNs are generally smaller and appear as spherical structures with a 
hollow core (Dickson et al., 1999; Dickson and Vickers, 2001). Both ring- and bulb-like 
DNs may either be continuous with an axon or appear as isolated structures (Dickson et 
al., 1999; Dickson and Vickers, 2001). The morphological and biochemical properties 
of DNs differ between the early and late stages of AD (Benzing et al., 199~; Masliah et 
al., 1993; Su et al., 1996a; Vickers et al., 1996; Su et al., 1998; Dickson et al., 1999; 
Dickson and Vickers, 2001; Dickson et al., 2005). 
1.3.1 Characteristics of DNs in preclinical AD 
Defining the key cellular processes involved in AD has been difficult due to the complex 
brain pathology of this degenerative condition (Benzing et al., 1993). However, cases 
with mild dementia exhibit significantly more NFTs and neuritic AP plaques than non-
demented elderly brains (Morris et al., 1996; Price and Morris, 1999). As there is strong 
evidence that AD begins many years before the clinical symptoms are evident, a 
'pathologically aged' or 'preclinical phase' of AD has been defined in which the initial 
signs of the pathological hallmarks of AD are present in the cortices typically associated 
with minor cognitive deficits that may represent incipient AD dementia (Morris et al., 
1996; Price and Morris, 1999; Vickers et ·al., 2000). This 'pathological aging' is 
characterised by the emergence of widespread extracellular AP plaques within the 
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cerebral cortex but no overt nerve cell degeneration or neurofibrillary changes. Thus, 
non-demented or mildly demented elderly brains with numerous AP plaques are studied 
as a potential preclinical stage of AD, and may provide important clues to the initiation 
of neuronal pathology (Benzing et al., 1993; Lue et al., 1996; Vickers et al., 1996; 
Dickson et al., 1999; Dickson and Vickers, 2001). In preclinical AD cases AP plaque-
associated DNs are frequently labelled with antibodies to APP, NF triplet proteins and 
a-intemexin, but not for the abnormal tau protein that characterises neurofibrillary 
pathology in established and end-stage AD (Cras et al., 1991; Benzing et al., 1993; 
Vickers et al., 1996; Su et al., 1998; Dickson et al., 1999; Dickson and Vickers, 2001; 
Dickson et al., 2005). The DNs in preclinical AD cases include ring- and bulb-like 
structures, which are labelled for both a-intemexin and NF triplet proteins (Dickson et 
al., 1999; Dickson et al., 2005). 
1.3.2 Characteristics of DNs in AD 
In contrast, tau-labelled DNs in AD cases are abundant and typically appear as angular, 
elongated structures (Dickson et al., 1999). Interestingly, NF triplet protein and a-
intemexin-labelled bulbous and 'sprouting' DNs are also abundant, but NF triplet 
protein-labelled ring-like dystrophic neurites are rare, while a-intemexin-labelled ring-
like DNs are numerous (Dickson et al., 1999; Dickson et al., 2005). A substantial subset 
of the NF triplet protein and a-intemexin DNs in AD cases exhibit a core of tau 
immunoreactivity (Su et al., 1998; Dickson et al., 1999; Dickson et al., 2005). This 
suggests that DNs may "mature" from NF triplet protein and a-internexin 
immunoreactive DNs into DNs that label for tau only (Su et al., 1998; Dickson et al., 
1999; Dickson et al., 2005). In support of this proposition, two different AD mouse 
models exhibit DNs that are immunoreactive for phosphorylated NF triplet protein 
epitopes several months before phosphorylated tau-labelled DNs appear (Masliah et al., 
2001; Blanchard et al., 2003). Thus, DNs may begin as the NF triplet protein- and a-
intemexin-immunoreactive DNs found in preclinical AD and then develop a core of 
altered tau filaments (Su et al., 1998; Dickson et al., 1999; Dickson et al., 2005). 
Finally, the tau-immunolabelled elements within the DN may develop and expand, 
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eventually replacing all normal cytoskeletal proteins in these axonal segments (Su et al., 
1998; Dickson et al., 1999; Dickson et al., 2005). 
1.3.3 Morphological and biochemical changes in DNs are identical to reactive 
axonal alterations following axonal injury 
Many in vivo and in vitro models of axonal injury produce reactive axonal structures that 
are neurochemically and morphologically similar to the neurofilamentous DN pathology 
in AD. Both phosphorylated and dephosphorylated NF triplet proteins and a.-internexin-
labelled ring- and bulb-like structures similar to those in AD brains are observed 
following axonal injury (Masliah et al., 1993; Meller et al., 1994; DeWitt and Silver, 
1996; Su et al., 1996a; Vickers et al., 1996; Christman et al., 1997; King et al., 1997; 
Nakamura et al., 1997; Dickson et al., 2000; King et al., 2001; Chuckowree and Vickers, 
2003; Dickson et al., 2005; Table 1.1). The presence of dephosphorylated NF triplet 
protein in DNs is particularly interesting as these proteins are normally located in the 
somatodendritic neuronal domain (Rosenfeld et al., 1~87), but are abnormally present in 
axons following physical trauma (Meller et al., 1994; King et al., 1997; Dickson et al., 
1999; King et al., 2001). 
Previous studies have demonstrated that ring- and bulb-like structures immunolabelled 
for NF triplet protein and/or a.-internexin represent a stereotypical reactive response of 
axons to damage in both a model of structural injury to adult rat neocortex as well as 
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Table 1.1 The morphology and neurochemistry of DNs in AD are strikingly similar to 
the to the reactive axonal alterations that occur following axonal injury. 
Neurochemical profile of 
DNs in AD 
NF triplet proteins Benzing et al., 1993 
Masliah et al., 1993 
a-internexin 
Tau 
GAP43 
Su et al., 1996a 
Kinget al., 1997 
Su et al., 1998 
Nakamura et al., 1999 
Dickson et al., 1999 
Dickson and Vickers, 2001 
Dickson et al., 2005 
Dickson et al., 2005 
Su et al., l 996a 
Dickson et al., 1999 
Dickson and Vickers, 2001 
Masliah et al., 1991 
Masliah et al., l 992b 
GAP43, growth associated protein 43 
Neurochemical profile of injured axons 
In vitro In vivo 
Dickson et al., 2000 Meller et al., 1994 
Chuckowree and Vickers, 2003 King et al., 1997 
Dickson et al., 2005 
Dickson et al., 2005 
Dickson et al., 2000 
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King et al., 2001 
Dickson et al., 2005 
Dickson et al., 2005 
Meller et al., 1993 
Li et al., 1996 
Christman et al., 1997 
Hou et al., 1998 
Schmitt et al., 1999 
King et al., 2001 
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following axotomy of cortical neurons maintained in long-term culture (Dickson et al., 
2000; King et al., 2001; Chuckowree and Vickers, 2003; Dickson et al., 2005). In both 
models of axonal injury, the appearance of ring-like neurofilamentous structures 
precedes the appearance of bulb-like structures (Dickson et al., 2000; Chuckowree and 
Vickers, 2003). The proportion of NF triplet protein and a-intemexin immunoreactive 
ring-like structures is relatively constant prior to their disappearance (Dickson et al., 
2005). Thus, the continued presence of a-intemexin ring-like DNs in end-stage AD 
may indicate a distinct subset of neurons that are damaged relatively late in AD 
progression (Dickson et al., 2005), whereas the subset of neurons immunoreactive for 
both a-intemexin and the NF triplet protein may be affected relatively earlier. This 
potential staging of disease progression may explain why the neurons that selectively 
express NF triplet proteins are particularly susceptible to NFT formation (Bussiere et al., 
-2003), as they are also the neurons initially compelled to respond to the damaging 
effects of A~ plaque formation (Vickers et al., 2000). Alternatively, the NF triplet 
protein-labelled neurons may possess a specific cytoskeletal profile that contributes 
towards susceptibility to NFT formation, whereas those neurons that labelled only with 
a-intemexin may degenerate more rapidly without developing classical intraperikaryal 
neurofibrillary pathology. 
The bulbous and swollen processes labelled for NF triplet proteins after axotomy in vivo 
are strikingly similar to those observed associated with A~ plaques in AD (King et al., 
2001). The presence of axonal clubs following trauma in humans and experimental 
models of axonal injury has been well documented since early last century (for review 
see Sahuquillo and Poca, 2002). As axoplasmic flow continues following axotomy, 
these axonal clubs consist of accumulated organelles (see Sahuquillo and Poca, 2002), 
such as vesicular and multi-lamellar bodies and mitochondria (King et al., 2001). 
Ultrastructural analysis of A~ plaque-associated DNs in AD cases found that they 
contain clear vesicles, abundant mitochondria, multivesicular and lamellar bodies and 
filaments, which are characteristic of reactive, regenerative and dystrophic axonal 
changes in response to injury (Masliah et al., 1993). Meanwhile, other DNs show 
ultrastructural changes consistent with degenerating neurons (Masliah et al., 1993). 
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1.4 fl-AMYLOID PLAQUES DISRUPT THE NEUROPIL 
1.4.1 More compact/fibrous Ap plaques are associated with neuritic pathology 
The different morphological types of AP plaques in AD arise independently and affect 
the surrounding neurites to varying degrees (Dickson et al., 1988; Armstrong, 1998; 
Dickson and Vickers, 2001). P-amyloid plaques can be categorised as 'spherical 
diffuse', 'fibrillar' or 'dense-cored' depending on their three dimensional structure and 
packing density of AP fibrils (Dickson and Vickers, 2001). In vivo imaging provides 
evidence that AP plaques in Tg2576 mice (Table 1.2) are reasonably stable structures 
(Christie et al., 2001; Spires et al., 2005). Over extended periods of time, the vast 
majority of AP plaques do not change in size, however, new AP plaques do sometimes 
appear and rare AP plaques grow or shrink (Christie et al., 2001). The proportion of 
diffuse, fibrillar and dense-core AP plaques is different in preclinical AD and AD cases 
(Fukumoto et al., 1996; Dickson and Vickers, 2001). There is a lower proportion of 
diffuse and dense-core AP plaques in AD cases compar~d to preclinical AD cases, 
whereas the proportion of fibrillar AP plaques is increased in AD cases (Dickson and 
Vickers, 2001). In addition, the percentages of diffuse and fibrillar AP plaques 
associated with DN s are lower in preclinical stages as compared to the later stages of 
AD (13-24% and 47-82%, respectively), while the percentage of dense-core AP plaques 
that are neuritic is slightly decreased in AD compared to preclinical AD cases (82-76%; 
Dickson and Vickers, 2001). Overall, AD brains contain a higher relative proportion of 
fibrillar and dense-core AP plaques than preclinical AD cases, and it is these AP plaque 
types that are more regularly associated with DNs both in human brains and in 
transgenic mouse models of AD (Dickson et al., 1988; Fukumoto et al., 1996; Su et al., 
1996a, Dickson and Vickers, 2001; Brendza et al., 2003; Noda-Saita et al., 2004; 
Dickson et al., 2005). Similarly, in vitro experiments show that fibrillar, but not 
amorphous Ap, results in DN formation, somatic shrinkage and significant synaptic and 
neuron loss in hippocampal cultures (Pike et al., 1993; Lorenzo and Yanker, 1994; Ivins 
et al., 1998). These data are consistent with the hypothesis that it is the more densely 
packed, highly fibrillar AP plaques that are likely to cause the displacing and 
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Table 1.2 Transgene expression and genetic background of mouse models of AD. 
Type Name Transgene/ promoter Genetic Background Primary reference 
APP Tg2576 human APP695 With Swedish (K670N/M671L) C57BL/6 APPsw Hsiao et al , 1996 
mutation/ hamster pnon protem gene promoter xB6SJL FI 
PDAPPLine human APP m1mgene with Indiana (V717F) C57B6xDBA2 Games et al, 1995 
109 mutation/ platelet denved growth factor-P FI hybnd 
APP23 human APP751 With Swedish (K670N/M671L) C57BL/6J Sturchler-P1errat et 
mutation/ Thy! 2 promoter al, I997 
TgCRNDS human APP With Swedish (K670N/M671L) and Indiana HybndC3H/ Ch1sht1 et al , 2001 
(V717F) mutations/ Synan hamster pnon promoter He-C57BL/6 
APP Lon human APP770 With Swedish (K670N/M671L) and FVB and C57Bl/6 Moechars et al , 
London (V717I) mutauon/ munne Thy! promoter 1999 
PDAPPSwe/ hAPP with Swedish (K670N/M671L) and Indiana C57BL/6 x DBN2 FI Mucke et al , 2000 
Ind (J20) (V717F) mutat10ns/ platelet denved growth factor p promoter 
APPSw/Ind human APP with Swedish (K670N/M671L), Indiana (V717F) C57BL/6J Cheng et al , 2004 
/Arc and Arctic (E22G) mutat10ns/ platelet denved growth factor 
P promoter 
Tau rTg (tauP301 human 4R tau with (P301L) mutat10n/ calcmm calmodulm 129S6, FVB/N Santacruz et al , 
L) 4510 kmase promoter system With a tetracyclme-operon 2005 
Double PS APP Tg2576xPSl Lme5 l (Duffetal, !996),humanAPP695 (C57BL/6 APPsw Holcomb et al, 1998 
with Swedish (K670N/M671 L) mutat10n x human PS 1 x B6SJL FI) 
(M146L)/ hamster pnon protem gene promoter and x (Swiss Webster 
platelet denved growth factor p2, respectively xB6D2FI) 
APPSwe/ Tg2576 mice (Hsiao et al , 1996) x human 4R tau With (C57BL6xSJL) x Perez et al , 2005 
Tauv/w mutat10ns (G272V, P301L, R406W) I hamster pnon (C57BL6xCBA) 
promoter 
TAPP Tg2576 mice (Hsiao et al , 1996) x human tau With mutat10n (C57BL/6 APPsw x Lewis et al , 200 I 
(P30 I L) JNPL3 (LeWJs et al , 2000)/ hamster pnon B6SJL FI) 
protem promoter, munne pnon promoter, respectively x C57BL/DBA2/SW 
Triple 3xTg-AD human APP695 With Swedish (K670N/M671L) mutat10n, 129/C57BL6 Oddo et al , 2003a 
human four repeat tau with the P30 I L mutallon and 
PSI Ml46V/ Thy-I 2 promoter 
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compressive forces sufficient to damage axons. 
There is a decrease in the density of axons and dendrites within AP plaques compared to 
the surrounding neuropil (De Witt and Silver, 1996; Knowles et al., 1998; Le et al., 2001; 
Tomidokoro et al., 2001; Adlard and Vickers, 2002; Moolman et al., 2004; Tsai et al., 
2004). Specific types of AP plaques, defined by their morphology and packing density, 
affect normal axons and dendrites differentially (Le et al., 2001; Adlard and Vickers, 
2002). Diffuse AP plaques do not affect the density of dendritic labelling in either AD 
or preclinical AD brains (Knowles et al., 1998; Adlard and Vickers, 2002). However, 
more fibrillar AP plaques exhibit significantly decreased dendrite labelling within the 
AP plaque area in comparison to the surrounding neuropil (Le et al., 2001; Adlard and 
Vickers, 2002). Interestingly, the density of dendrites within fibrillar AP plaques is not 
significantly decreased in preclinical AD cases (Adlard and Vickers, 2002). 
Specifically, the dendrites that remain within fibrillar and dense core AP plaques exhibit 
decreasing calibre, spine density, and deflect around the AP plaque and while other 
dendrites terminate (appear to be 'clipped') at the AP plaque margins (Adlard and 
Vickers, 2002; Grutzendler et al., 2007). Additionally, dendrites within AP plaques that 
are free of NFTs and neuropil threads have dramatically and significantly increased 
curvature (Knowles et al., 1999b ). Furthermore, observations of the deflection of 
dendrites around dense and fibrillar AP plaques supports the concept that densely packed 
AP plaques act as space-forming lesions (Adlard and Vickers, 2002). 
In vivo imaging of A~ plaques in combination with neuronal processes in Tg2576, 
PDAPP and PSAPP transgenic AD mice models (Table 1.2) shows that diffuse A~ 
plaques subtly change neurite geometry, while fibrillar A~ plaques dramatically alter 
neurite trajectories and result in dendritic spine loss, shaft atrophy and axonal 
variscosities (Le et al., 2001; D'Amore et al., 2003; Stem et al., 2004; Tsai et al., 2004; 
Spires et al., 2005; Garcia-Alloza et al., 2006; Grutzendler et al., 2007). All dendrites 
that pass through fibrillar A~ plaques in PSAPP mice exhibit spine loss and reduced 
shaft diameter, and a significantly higher percentage of dendrites terminate in the 
vicinity of fibrillar A~ plaques than further away (Tsai et al., 2004). This reduction in 
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the number of dendrites passing through fibrillar A~ plaques in PSAPP mice is age-
dependent and led to neurite breakage and the permanent disruption of neuronal 
connections in PSAPP mice (Tsai et al., 2004). Interestingly, even though the average 
thioflavine s-stained plaque radius in PDAPP mice is lOµm there appears to be an 
approximately 40-SOµm zone surrounding the plaques in PDAPP and PSAPP mice in 
which nearly half of the neuronal processes are disrupted (D' Amore et al., 2003; 
Grutzendler et al., 2007). The presence of A~ plaques and the alterations in geometry of 
A~ plaque-associated neurites results in an impairment of the magnitude and precision 
of the evoked synaptic response of neurons to transcallosal stimuli in Tg2576 mice in 
comparison to wild type age-matched controls (Stern et al., 2004). As the data also 
suggests that A~ plaques do not affect the overall levels of synaptic innervation, these 
results indicate that A~ plaques disrupt the synchrony of convergent inputs and reduce 
the ability of neurons to successfully integrate and propagate information (Stern et al., 
2004). However, a recent study asserts that the density of synaptophysin-labelled 
boutons is significantly decreased within 200µm of fibrillar A~ plaques in Tg2576 mice 
(Dong et al., 2007). In addition, other investigators report that dendritic spine density is 
significantly decreased in Tg2576 compared to age-matched wild type controls prior to 
the deposition of A~ plaques, suggesting that expression of the APP transgene may also 
contribute to dendritic spine loss independently of A~ plaque formation (Jacobsen et al., 
2006). 
1.4.2 P-amyloid plaques associated with familial AD cases 
There are two additional AP plaque types observed in hereditary AD cases that are 
associated with mutations in PS 1, namely "inflammatory" and "cotton wool" AP 
plaques. Inflammatory AP plaques have recently been described in PS 1 AD cases, and 
have dense cresyl violet-, silver- and thioflavine s-stained cores that are not 
immunoreactive for Ap, tau, ApoE and PSI, and are also associated with reactive 
microglia and astrocytes (Shepherd et al., 2005). "Cotton wool" AP plaques are 
numerous large rounded diffuse AP plaques in the frontal cortex of AD cases with PS 1 
mutations, and are relatively free of tau-labelled neuritic and glial components, despite 
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the presence of many NFTs and neuropil threads in nearby neuropil (Boulden et al, 
2000; Mann et al., 2001; Steiner et al., 2001; Kwok et al., 2003). However, fine neurites 
labelled with hyperphosphorylated tau (Steiner et al., 2001; Shepherd et al., 2004) and 
globular DNs labelled for non-hyperphosphorylated tau are associated with cotton wool 
AJ3 plaques (Takao et al., 2002; Shepherd et al., 2004). Cotton wool AJ3 plaque 
pathology is potentially related to abnormally high production of AJ31-42 (Houlden et 
al., 2000; Steiner et al., 2001), which is mainly due to the PSl mutations, and in many 
cases amyloid fibrils within these AJ3 plaques are rare (reviewed in Tabira et al., 2002). 
However, not all cases with hereditary AD caused by PS 1 mutations exhibit cotton wool 
AP plaques (Janssen et al., 2001) and cotton wool AP plaques are also present in 
sporadic AD cases (Le et al., 2001 ). 
1.4.3 Biochemical characteristics of neuritic and non-neuritic AP plaques 
Recent research suggests that there may be biochemical differences in different AJ3 
plaque types, and between neuritic AJ3 plaques and non-neuritic AJ3 plaques. For 
instance, Apx-40 immunoreactivity is mainly restricted to cored Ap plaques, while 
diffuse AJ3 plaques and cored AJ3 plaques demonstrate immunoreactivity for AJ3x-42 
(Jimenez-Huete et al., 1998; R.abano et al., 2005). However, labelling with a novel 
antibody suggests that the principal component of diffuse AP plaques might be APx-17 
peptides (Rabano et al., 2005). Interestingly, when transgenic mice that selectively 
express high levels of APl-40 are crossed with mice selectively expressing AJ31-42 or 
Tg2576 mice, the double transgenic mice show 60-90% decreases in AP plaque 
deposition, suggesting that APl-40 inhibits AJ3 deposition (Kim et al., 2007). In 
addition, an antibody that detects the internal residues AJ311-16 specifically labels 
vascular amyloid and neuritic AJ3 plaques in AD cases (Rabano et al., 2005). An 
antibody that specifically recognises the oligomeric Ap structure has also relatively 
recently become commercially available, and should provide some interesting 
information regarding which species of AJ3 is detrimental to neuronal health. 
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1.5 ABERRANT REGENERATION IN AD MAY BE RELATED TO THE 
STEREOTYPICAL RESPONSE OF NEURONS TO INJURY 
Following axonal injury, a regenerative sprouting response is observed both in vitro and 
in vivo that is characterised by the presence of neurites expressing growth associated 
protein 43 (GAP43), APP and ApoE that share similarities with DNs in AD (Masliah et 
al., 1991; Otsuka et al., 1991; Masliah et al., 1992a, Masliah et al., 1992b; Benzing and 
Mufson, 1995; Li et al., 1996; Christman et al., 1997; Dickson et al., 1997; Thal et al., 
1997; Hou et al., 1998; Dickson et al., 2000; Gomez-Ramos, et al., 2001; King et al., 
2001; Chung et al., 2003; Sabo et al., 2003; Dickson et al., 2005) albeit, the DNs in AD 
have aberrant morphology. Accordingly, neurodegeneration in AD may be linked to 
abnormal stimulation of regenerative changes in neurons, leading to a re-expression of 
proteins and pathways linked to early neuronal and neurite development. Thus, 
neurodegeneration in AD may be closely linked to aberrant cellular plasticity. 
1.5.1 Dystrophic neurites in AD are labelled for GAP43 
In this regard, GAP43 has been widely used as a marker for neuritic outgrowth, 
including the regeneration of axons following injury (Masliah et al., 1992b; Li et al., 
1996; Christman et al., 1997; Hou et al., 1998; Dickson et al., 2000; King et al., 2001). 
Sprouting neurites labelled with GAP43 and NF triplet protein are present following 
transection of axonal bundles in vitro (Dickson et al., 2000; King et al., 2001; 
Chuckowree and Vickers, 2003) and GAP43 messenger ribonucleic acid (mRNA) is 
upregualted in neurons in Clarke's nucleus following axotomy in vivo, even if they are 
destined to degenerate (Schmitt et al., 1999). GAP43-labelled A~ plaque-associated 
DNs and GAP43 immunoreactive fine caliber neurites are also present in AD cases 
(Masliah et al., 1991; Masliah et al., 1992b), with approximately 50% of thioflavin s-
stained plaques in AD cases containing GAP43-labelled neurites (Masliah et al., 1991). 
This sprouting response appears to be more prominent in the hippocampus of AD 
patients than in the neocortex as approximately 80% of thioflavine s-stained plaques in 
the hippocampus are associated with GAP43-labelled neurites (Masliah et al., 1991). 
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Additionally, fine fibrillar staining for GAP43 is increased in the neuropil in the AD 
hippocampus; especially in areas with decreased synaptophysin-labelling (Masliah et al., 
1991) suggesting a sprouting response to AP plaques is associated with dendritic loss 
(Adlard and Vickers, 2002). 
1.5.2 P-amyloid precursor protein is present in DNs in AD 
The presence of APP in AD brains may also indicate the occurrence of post-injury 
regenerative processes. The APP is thought to play an important role in neurite 
outgrowth in development and following injury, with evidence suggesting that a-
secretase cleaved APP and the APP intracellular domain may be neuroprotective and 
improve memory and long-term potentiation (Goodman and Mattson, 1994; Furukawa et 
al., 1996; Stein et al., 2004; Ma et al., 2007a; Ring et al., 2007). P-amyloid precursor 
protein immunoreactive spherical and club-like axonal swellings are widely used as a 
marker for axonal injury following various models of traumatic brain injury (Stone et al., 
2001). For example, APP is present in neurons following a weight-drop model of 
traumatic brain injury (Lewen et al., 1995), in axons following an impact-acceleration 
head injury model of diffuse traumatic brain injury (Marmarou et al., 2005), and in 
axons and dystrophic axonal swellings after needle stab injuries in the rat brain (Otsuka 
et al., 1991). The co-localisation of GAP43, NF triplet protein and APP in a 
subpopulation of outgrowing neurites in the neonatal rat (Masliah et al., 1991; Masliah 
et al., 1992a) and the concentration of an APP complex that is likely to have a role in 
membrane motility regulation in the growth cones of neurons (Sabo et al., 2003), both 
suggest a role for APP in neuritic outgrowth. p-amyloid precursor protein 
immunoreactive Ap plaque-associated DNs and pyramidal cell bodies are also present in 
AD (Masliah et al., 1992b). In AD over half of the DNs associated with AP plaques are 
intensely immunoreactive for APP and APP-labelling is also more intense in pyramidal 
neurons in the frontal cortex of AD patients than in control brains (Masliah et al., 
1992b). Additionally, the increase in APP levels that occur in aged rat motor neurons 
following axonal injury (Sola et al., 1993; Xie et al., 2003) is associated with increased 
survival of these cells (Xie et al., 2003). As pyramidal cells appear to be selectively 
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vulnerable to degeneration in AD (Morrison et al., 1987; Hof, 1997; Vickers et al., 1997; 
Bussiere et al., 2003), increased APP in pyramidal neurons in AD may indicate an 
increase in regenerative neuritic plasticity in this vulnerable cell population. 
1.5.3 Apolipoprotein E is associated with several of the pathological hallmarks 
of AD 
There is also evidence to suggest that ApoE has an important role in the development 
and regeneration of the nervous system (Poirier, 1994; Masliah et al., 1995; Strittmatter 
and Roses, 1995; Masliah et al., 1996a), however, the role of ApoE in AD is still 
unclear. ApoE plays important roles in the development, regeneration and aging 
processes of the nervous system (for review see Masliah et al., 1996a) probably due to 
its involvement in cholesterol uptake and redistribution and its putative role in the 
stabilisation of microtubules (Strittmatter and Roses, 1995). In vitro ApoE alleles apos2 
and £3, but not e4, bind to the microtubule binding domains of microtubule associated 
protein-2 (MAP2) and tau, and may stabilise the interactions of these two microtubule 
associated proteins with tubulin (Strittmatter and Roses, 1995). In support of this, the 
neurite outgrowth of a neuronal cell line was increased by the presence of apos3 but not 
by apo~4 (Holtzman et al., 1995), and apos3, but not apos4, expression fully restored 
mossy fibre sprouting in ApoE knockout hippocampal slice cultures (Teter et al., 1999) 
and increased post-injury sprouting in the entorhinal cortex (White et al., 2001). 
Meanwhile, the delayed reinnervation of the dentate molecular layer after perforant 
pathway interruption in ApoE knock out mice strongly suggests a specific role for ApoE 
in regeneration following injury (Masliah et al., 1994). Furthermore, a neuroprotective 
role for ApoE has also been intimated, as the expression of human apos3, but not apos4, 
in Apoff1- mice protects neurons from excitotoxic damage and age-dependent 
neurodegeneration (Buttini et al., 1999). 
ApoE-labelled AP plaques, NFT-bearing neurons and possibly DNs are also present in 
AD (Benzing and Mufson, 1995; Dickson et al., 1997; Thal et al., 1997; Gomez-Ramos, 
et al., 2001). ApoE is present in all neuritic AP plaques in AD and preclinical AD cases 
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and some AB plaques that are not associated with DNs, suggesting that either ApoE 
enhances the ability of certain AB plaques to damage the surrounding neuropil or that 
ApoE is deposited in certain AB plaques after axonal injury during the process of 
attempted neurite regeneration (Dickson et al., 1997). As no fibrillar AB plaques or 
neuritic degeneration is observed in the brains of knockout ApoE mice expressing 
mutated human APP it is more likely that ApoE facilitates the formation of fibrillar AB 
plaques and the associated neuritic pathology (Holtzman et al., 2000). Indeed, 
intracerebral administration of lentiviral vectors expressing apoE4 and apoE2 in PDAPP 
mice increases and decreases hippocampal A~ burdens, respectively (Dodart et al., 
2005). ApoE-labelled DN-like structures that are not immunoreactive for tau, ubiquitin 
or NF triplet proteins are also observed in AD and preclinical AD cases (Dickson et al., 
1997). While one study reports that nearly all ApoE-labelled cells in the nucleus basalis 
of Meynert and layer II of the entorhinal cortex of AD are co-localised with PHFs of tau 
(Benzing and Muf son, 1995), other studies found that ApoE is only occasionally co-
localised with pre-NFT PHFs and intracellular NFTs (Dickson et al., 1997; G6mez-
Ramos, et al., 2001). This suggests that ApoE mainly binds to NFTs once they are in the 
extracellular space, perhaps in a comparable way to the binding of ApoE to extracellular 
A~ plaques (Gomez-Ramos et al., 2001). However, mice expressing apoE4 under the 
neuron specific enolase promoter develop intraneuronal inclusions of phosphorylated tau 
that are barely detectable in mice expressing apoa3 under the same promoter (Bretch et 
al., 2004). 
1.5.4 Chronic aberrant piasticity may result in neurofibrillary pathology 
A high phosphorylation state of tau is thought to be crucially involved in the formation 
of PHFs, which are the major constituents of NFTs and neuropil threads (Arendt, 
2003a). Interestingly, a highly phosphorylated form of tau similar to PHF-tau is present 
distinctly in association with synaptic plasticity. This PHF-like tau is increased in 
animals during hibernation and arousal in association with the regression and re-
establishment of synaptic contacts of mossy fibres with hippocampal comu ammonis 3 
(CA3) apical dendrites (Arendt et' al., 2003). Foetal tau also exists in a similar 
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phosphorylation state to PHF-tau (Trojanowski and Lee, 1994). These findings point 
towards a high phosphorylation state of tau being a physiologically normal event that is 
associated with neuronal plasticity (Trojanowski and Lee, 1994; Arendt et al., 2003). 
Perhaps the chronic stimulation of regenerative processes that require neuronal plasticity 
and place the neuron under metabolic stress in the AD brain result in the formation of an 
abnormally phosphorylated form of tau that leads to the formation of PHFs and 
consequently NFTs. Multiple kinases including activated microtubule-associated 
protein kinase, microtubule affinity regulating kinase, glycogen synthase kinase 3P 
(GSK3P), cyclin-dependent kinase 5 (cdk5) and cdc2/cyclin Bl kinase co-localise with 
PHF-tau suggesting that these kinases may be responsible for the abnormal 
phosphorylation of tau (Yamaguchi et al., 1996; Vincent et al., 1997; Knowles et al., 
1999a; Chin et al., 2000; Noble et al., 2003). There is growing evidence that the 
dysregulation of cdk5 activation contributes to the abnormal phosphorylation of tau and 
perhaps the production of AP in AD, with an emerging role for cdk5 in APP processing 
(as reviewed in Lau and Ahlijanian, 2003; Cruz and Tsai, 2004). Ischemic or oxidative 
damage, AP treatment and other neurotoxic stimuli can elevate intracellular calcium and 
activate calpain (Cruz and Tsai, 2004), which can cleave cdk5 activator p35 into a p25 
cleavage product that causes prolonged activation of cdk5 (Tseng et al., 2002) due to its 
longer half life (Cruz and Tsai, 2004). The ratio of p25 to p35 is higher in the AD 
hippocampus, frontal, inferior and parietal cortices than in control brains (Tseng et al., 
2002). Furthermore transgenic mice overexpressing cdk5 activator p25 and mutant 
human tau accumulate significantly more aggregated tau and NFTs than tau-only 
transgenic mice, along with tau hyperphosphorylation at several sites (Noble et al., 
2003). Additionally, data suggests that stress activated protein kinases, which may be 
activated in AP plaque-associated neurites in AD, are a likely candidate for the 
pathological phosphorylation of tau proteins (Buee et al., 2000). 
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1.5.5 Chronic neuronal plasticity may also result in loss of differentiation 
control and cell cycle re-activation in AD 
It has also been proposed that the continuous need for neuronal plasticity and re-
organisation in AD results in aberrant neuritic outgrowth (Arendt, 2003). For example, 
many GAP43-labelled ectopic entorhinal boutons associated with AP plaques are 
observed in the hippocampus, thalamus and white matter tracts of aged APP23 mice 
(Table 1.2; Phinney et al., 1999). It has further been postulated that this is due to de-
differentiation of neurons in AD and the re-expression of developmental proteins in 
neurons that are involved in morphoregulation (Arendt, 2001; Arendt, 2003). There is 
accumulating evidence that proteins associated with AD such as APP, ApoE and the 
presenilins play an important role in the regulations of neuronal morphology (Arendt, 
2003; Ji et al., 2003). Furthermore, loss of differentiation control, progressive 
morphodysregulation and cell cycle re-activation have all been linked to cell death in 
AD (Arendt, 2001). Cell cycle regulatory molecules including cdc2, cdk4, proliferating 
cell nuclear antigen, cyclin B and cyclin D, are re-expressed in neurons in AD but are 
rarely observed or not observed at all in control brains (McShea et al., 1997; Vincent et 
al., 1997; Busser et al., 1998; Ogawa et al., 2003; Yang et al., 2003). Specifically, 
cyclin B and cdc2 co-localise with each other and their M-phase specific tau-
phosphoepitopes in hippocampal neurons with NFTs and neurons susceptible to NFT 
formation in AD cases (Vincent et al., 1997; Busser et al., 1998). Additionally, aged 
mice expressing non-mutant human tau in the absence of mouse tau develop NFTs and 
are labelled for cyclin D1, ki67 and proliferating cell nuclear antigen, while the brains 
from age-matched wild type controls are negative for NFTs and these cell-cycle 
regulating proteins (Andorfer et al., 2005). Of interest is a recently developed transgenic 
mouse that conditionally expresses the simian virus 40 large T antigen oncogene, which 
forces cell cycle activation in post-mitotic neurons (Park et al., 2007). These mice 
exhibit tau phosphorylation, pre-tangles, diffuse AP plaque deposition, although a small 
number of fibrillar AP plaques, neurodegeneration and cell cycle changes similar to 
those in human AD supporting the suggestion that aberrant cell cycle activation may 
generate AD pathology (Park et al., 2007). 
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With respect to the underlying hypothesis that AP plaques cause structural injury to 
axons, the cell-wide response of neurons to damage involves sprouting and regenerative 
changes (Vickers et al., 2000). The persistence of the AP plaque structure and its 
interference with a 'normal' regenerative response may all contribute to 'pushing' 
neurons into an aberrant regenerative state, leading to profound cytoskeletal changes, 
characteristic tau modifications and, ultimately, neuronal degeneration. 
1.6 ACCUMULATION OF AD-ASSOCIATED PATHOLOGY AND CELL 
DEATH IN AD 
AD-associated hallmarks tend to appear first in the limbic and basal areas in the frontal, 
temporal and occipital cortices, and subsequently spread to the remaining areas of the 
cerebral cortex (Braak and Braak, 1991). However, the temporal and spat~al pattern of 
NFT and neuropil thread distribution is different to that of AP plaque deposition (Braak 
and Braak, 1991; Lue et al., 1996; Knowles et al., 1998; Price et al., 1999). 
Neurofibrillary tangles and neuropil threads first appear in the entorhinal cortex and 
hippocampus, followed by an inferior to superior spread of pathology throughout the 
association cortices, and subsequently throughout the primary cortical areas (Pearson et 
al., 1985; Lewis et al., 1987; Arnold et al., 1991; Braak and Braak, 1991). Additionally, 
NFTs are mainly localised to neocortical layers III and V (Pearson et al., 1985; Lewis et 
al., 1987; Arnold et al., 1991; Arriagada et al., 1992; Hof et al., 1992). In comparison, 
AP plaque deposition is first observed in the basal portions of the frontal, temporal and 
occipital lobes, and as AD progresses deposition occurs in the hippocampus and all 
isocortical areas, with the primary cortices being affected last (Braak and Braak, 1991). 
P-amyloid plaques are deposited mostly in layer II, III, VI and the adjacent portion of 
layer V (Braak and Braak, 1991). Neuritic AP plaques also show a different pattern of 
distribution from that of NFTs, neuropil threads and AP plaques (as reviewed in Braak 
and Braak, 1997), and are predominantly localised to neocortical layers II, III, IV and V 
(Pearson et al., 1985; Lewis et al., 1987; Arnold et al., 1991). Interestingly, the patterns 
of neurofibrillary pathology and AP plaque distribution indicate that the populations of 
neurons that develop NFTs have neuronal processes that extend into the areas inhabited 
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by AP plaques (Hof, 1997). As the density of AD-associated pathology increases with 
disease progression, the limbic and basal isocortical areas in which pathological 
hallmarks first appear are the most severely affected in end-stage disease. However, 
there is still much debate as to whether it is the AP plaques or neurofibrillary pathology 
that initiates neuronal damage and degeneration in AD. 
Overt neuronal loss occurs in the entorhinal cortex, hippocampus and neocortex of AD 
cases compared to control cases (Hof et al., 1990; Lippa et al., 1992; West et al., 1994; 
Fukutani et al., 1995; Gomez-Isla et al., 1996; Kril et al., 2002; Kril et al., 2004). In the 
entorhinal cortex, an area severely affected by AD pathology, a decrease of 45-75% in 
neuronal numbers occurs in AD cases compared to control cases, which show no age-
related neuron loss (Lippa et al., 1992; Fukutani et al., 1995; Gomez-Isla et al., 1996). 
Similarly, a different pattern of neuron loss is detectable in the hippocampal subfields of 
AD cases compared to aged control cases, with the CAl zone of the hippocampus being 
most severely affected (West et al., 1994; Kril et al., 2002; Kril et al., 2004). Some 
studies have stated that the degree of neuron loss in AD is equivalent to the extent of 
NFT formation (Hof et al., 1990; Cras et al., 1995; Fukutani et al., 1995; Cullen and 
Halliday, 1998), suggesting that NFT-formation may cause cell death. For instance, the 
overall loss of neurons in the entorhinal cortex is reported to correlate with the density of 
NFTs and neuritic AP plaques in some studies, while the dramatic loss of neurons in 
layer II and IV of the entorhinal cortex paralleled the specific accumulation of NFTs in 
these entorhinal laminae (Lippa et al., 1992; Gomez-Isla et al., 1996). In contrast, others 
assert that NFTs only account for 38-55% of variability in neuronal numbers in 
hippocampal areas in AD (Von Gunten et al., 2006). Additionally, when the numbers of 
intracellular and extracellular NFTs are assessed in the hippocampal CAl and the 
superior frontal gyrus (SFG) and inferior temporal gyrus (ITG) of the neocortex, NFT 
formation seems likely to account for only a small proportion of neuron loss (Gomez-
Isla et al., 1997; Kril et al., 2002; Vickers et al., 2003). In addition, Salehi and 
colleagues (1998) report that while neuronal density in areas surrounding ,neuritic AP 
plaques in the CAl is 16-19% lower than in the unaffected neuropil, this would only 
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account for 2.6% of the neuronal loss that occurs in the CAI region. Thus, A~ plaques 
and NFTs may both contribute the neuronal cell death that occurs in AD. 
1.6.1 Neurons that express NF triplet proteins are selectively vulnerable to 
degeneration in AD 
The neuronal loss observed in AD affects certain sub-populations of neurons. Pyramidal 
neurons, especially those labelled with NF triplet proteins, are selectively vulnerable to 
degeneration in AD (Morrison et al., 1987; Hof et al., 1990; Vickers et al., 1992; 1994a; 
Hof, 1997; Vickers et al., 1997; Bussiere et al., 2003). In comparison non-pyramidal 
cortical neurons, typically intemeurons, expressing calcium-binding proteins such as 
parvalbumin, calretinin and calbindin are relatively resistant to AD pathology (Hof et al., 
1990; Ferrer et al., 1991; Hof et al., 1991a; Hof et al., 199lb; Hof et al., 1993; Sampson 
et al., 1997; Leuba et al., 1998). Originally it was assumed that calcium binding proteins 
were neuroprotective, but the discovery of a subset of calretinin-labelled neurons that are 
also labelled for NF triplet proteins and are susceptible to NFT formation, lead to the 
suggestion that NF triplet protein alterations may enable or be necessary for NFT 
formation and/or degeneration (Vickers et al., 1992; Vickers et al., 1994; Vickers et al., 
1996; Sampson et al., 1997). 
1.7 MECHANISM OF CELL DEATH IN AD 
Despite evidence of neuron loss in the AD brain, there are numerous, varied and 
opposing views regarding exactly how these neurons die. The most prominent premise 
is that neuronal death occurs via apoptosis. The next section of this review details the 
characteristics of apoptosis and the in vitro and in vivo data regarding neuronal apoptosis 
in AD. In addition, the data regarding neuronal apoptosis in AD is not at odds with the 
"mass effect" hypothesis, as apoptotic changes have also been observed in neurons 
following neurite injury (Berkelaar et al., 1994; Pravdenkova et al., 1996; Hou et al., 
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1998; Springer et al., 1999; Bilki et al., 2000; Smith et al., 2000; Wingrave et al., 2003; 
DeRidder et al., 2006). 
1. 7.1 The morphological and biochemical characteristics of apoptosis 
Programmed cell death has been described and defined by many overlapping schemas; 
as apoptotic, autophagic, necrotic, energy-dependent and energy-independent, active and 
passive. While apoptotic, autophagic and necrotic cell death were once thought of as 
being separate and defined cell death programs, there is now increasing evidence that 
these cell death programs are not mutually exclusive, but may occur as a continuum and 
even co-exist in the same cell (as reviewed in Bursch, 2004; Stefanis, 2005). 
Morphologically and biochemically apoptosis involves cytoplasmic shrinkage, 
chromatin condensation, deoxyribose nucleic acid (DNA) fragmentation, early 
dissolution of the nucleolus, alterations of cell membrane composition, membrane 
blebbing, the formation of apoptotic bodies (Su et al., 1996b; Bratton et al., 2000) and 
caspase-activation (Stefanis, 2005). Caspases are a family of cysteine proteases that are 
activated in a cascade-like fashion and cleave key cellular proteins that result in 
apoptotic cell death. Two pathways activate the apical caspases of this cascade: the 
intrinsic or mitochondrial pathway and the extrinsic or death receptor pathway (Figure 
1.1). 
In the intrinsic apoptotic pathway cytochrome c ( cyto c) is released from the 
mitochondria and associates with Apaf-1, dATP and caspase-9 to form the cytoplasmic 
apoptosome complex. Formation of the apoptosome complex then results in the 
activation of caspase-9 and the subsequent activation of effector caspases such as 
caspase-3. Release of cyto c from the mitochondria is regulated by the Bcl-2 family of 
proteins, which includes both pro-apoptotic (Bax, Bad, Bak, Bid) and anti-apoptotic 
(Bcl-2, Bcl-xL) members. In turn, the Bcl-2 family is regulated by cytokines and other 
death-survival signals such as the p53-mediated damage response (as reviewed in 
Adams and Cory, 2001). Anti-apoptotic Bcl-2 and Bcl-x1 inhibit the release of cyto c by 
blocking the opening of the mitochondrial permeability transition pore, whereas pro-
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Apoptosis can be initiated through the activation of either the intrinsic or extrinsic 
apoptotic pathways. The intrinsic or mitochondrial apoptotic pathway is regulated by 
the relative levels of pro- (eg. Bax) and anti-apoptotic (eg. Blc-2) proteins, which are 
members of the Bcl-2 protein family. In turn, the Bcl-2 family of proteins are regulated 
by cytokines and other death-survival signals. Pro-apoptotic Blc-2 family members 
inhibit the opening of the mitochondrial permeability transition pore, while pro-
apoptotic Bcl-2 family members induce the opening of mitochondrial membrane pores. 
If pores in the mitochondrial membrane are opened cyto c is released from the 
mitochondria and associates with Apaf-1, dATP and caspase-9, which results in the 
activation of caspase-9, and the subsequent activation of effector caspases such as 
caspase-3. 
The death receptor or extrinsic apoptotic pathway involves extracellular ligands binding 
to death receptors in the cell membrane (eg. Fas, Tumour necrosis factor receptor 1, 
TNFRl). Ligands binding to death receptors cause conformational changes in the 
receptors, resulting in the recruitment of various adaptor proteins to form several death 
receptor complexes. Different death receptor complexes recruit and activate different 
apical caspases, which then activate effector caspases such as caspase-3. For instance, 
the activated TNFRl recruits TNF receptor-associated death domain (TRADD), which 
can recruit Fas associated death domain (FADD) and caspase-8, resulting in the 
activation of caspase-8. 
TNF 
withdrawal of growth ~ 
factors r cytokines--~-T-NFl 
~ 
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apoptotic Bcl-2 family members induce the opening of pores in the mitochondrial 
membrane including the permeability transition pore (as reviewed in Jordan et al., 2003; 
Tatton et al., 2003). Bel-XL may also bind to Apaf-1 and prevent it from activating 
caspase-9 (Adams and Cory, 2001). Thus, the balance of pro-apoptotic and anti-
apoptotic Bcl-2 family members may be critical to the survival of an individual cell 
(Shimohama, 2000). 
Activation of the death receptor or extrinsic pathway involves the binding of 
extracellular ligands to death receptors in the cell membrane, which cause 
conformational changes in the receptors and the formation of intracellular death protein 
complexes. These death protein complexes then recruit and activate caspase-8, which 
subsequently activates effector caspases. Death receptors are members of the tumour 
necrosis factor receptor (TNFR) superfamily and include Fas, TNFRl/2 and TNF-related 
apoptosis-inducing ligand-receptors 112 (Bratton et al., 2000). Different receptors 
recruit different adaptor proteins and form different death receptor complexes that can 
recruit and activate different caspases. For instance, the ligand bound Fas receptor can 
recruit Fas associated death domain (F ADD) proteins that associate with caspase-8 
(Muzio et al., 1998). Whereas the activated TNFRl can recruit TNF receptor-associated 
death domain (TRADD), which recruits FADD and caspase-8, or TRADD can bind 
receptor-interacting protein, which recruits receptor-interacting protein-associated ICH-
1/CED-3 homologous protein with a death domain/caspase receptor-interacting protein 
with a death domain and then caspase-2 (Duan et al., 1997). There is also some cross 
talk between the intrinsic and extrinsic apoptotic pathways in some cell types, as 
activated caspase-8 can cleave and activate Bcl-2 family member Bid, which 
translocates to the mitochondria and induces cyto c release (Stefanis, 2005). 
1.7.2 Apoptosis in neurons 
Neurons predominantly use the intrinsic pathway of apoptosis, but in some cases 
neurons can use the extrinsic pathway or undergo autophagy, caspase-independent non-
apoptotic cell death involving other proteases (eg. calpains), mitochondrial alterations 
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( eg. energy depletion) or the generation of free radicals and permeability transition pore 
( 
opening that releases cytotoxic proteins (as reviewed in Stefanis, 2005). Apoptotic 
pathways may also differ depending on the death stimulus and cell type, so that the 
presence of caspase-activation or the morphological features of apoptosis do not always 
equate to cell death (Stefanis, 2005). Interestingly, there is also increasing evidence that 
caspases may have apoptosis-independent roles in proliferation, cell cycle regulation, 
differentiation and other cellular processes, perhaps by cleaving a limited number of 
selected substrates (as reviewed by Schwerk and Schulze-Osthoff, 2003). 
1. 7.3 P-amyloid-induced neuronal apoptosis in vitro 
Many in vitro models have shown that treating primary neuronal cultures and cell lines 
with fibrillar or soluble AP or fragments of AP result in apoptotic cell death (Y anker et 
al., 1990; Forloni et al., 1993; Loo et al., 1993; Pike et al., 1993; Lambert et al., 1994; 
Gschwind and Huber, 1995; Pike et al., 1995; Paradis et al., 1996; Estus et al., 1997; 
Lambert et al., 1998; Ivins et al., 1999; Pillot et al., 1999; Selznick et al., 2000; 
Morishima et al., 2001; Jang and Surh, 2002; Wei et al., 2002; Cantarella et al., 2003; 
Hoshi et al., 2003; Lu et al., 2003; Sola et al., 2003; Sponne et al., 2003; Gestwicki et 
al., 2004; Movsesyan et al., 2004; Paradisi et al., 2004; Bloom et al., 2005; Caraci et al., 
2005; Jang and Surh, 2005; Millet et al., 2005; Ohyagi et al., 2005; Ramirez et al., 2005; 
Yao et al., 2005; St John, 2007). Some studies indicate that AP induces apoptosis via 
the intrinsic pathway (Paradis et al., 1996; Selznick et al., 2000; Sola et al., 2003; Keil et 
al., 2004; Movsesyan et al., 2004; Caraci et al., 2005; Jang and Suhr, 2005; Ohyagi et 
al., 2005; Yao et al., 2005; Biswas et al., 2007), while other studies present evidence that 
it acts via the extrinsic apoptotic pathway (Ivins et al., 1999; Wei et al., 2002; Cantarella 
et al., 2003; Lu et al., 2003; Su et al., 2003; Suen et al., 2003). There is also 
disagreement as to whether it is soluble oligomeric/protofibrillar (Roher et al., 1996; 
Lambert et al., 1998; Hartley et al., 1999; Pillot et al., 1999; Hoshi et al., 2003; 
Blanchard et al., 2004; Barghom et al., 2005; Piccini et al., 2005; Walsh et al., 2005; 
Whalen et al., 2005), or aggregated/fibrillar (Forloni et al., 1993; Loo et al., 1993; Pike 
et al., 1993; Lorenzo and Yanker, 1994; Howlett et al., 1995; Pike et al., 1995; Paradis et 
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al., 1996; Estus et al., 1997; Walsh et al., 1999; Gestwicki et al., 2004; Paradisi et al., 
2004; St John, 2007) AP that is the neurotoxic species of Ap. 
Although data suggests that AP causes neuronal apoptosis in vitro this may not be 
representative of the in vivo milieu. Jn vitro models are often not representative of the in 
vivo environment due to the use of supra-physiological concentrations of Ap, the lack of 
glia-neuron interactions and the use of relatively immature neurons. The concentration 
of synthetic AP or AP fragments used to treat neurons in vitro is typically around 20-
30µM (Pike et al., 1992; Lorenzo and Yanker, 1994; Estus et al., 1997; Pillot et al., 
1999; Paradisi et al., 2004; Caraci et al., 2005; Whalen et al., 2005; Yao et al., 2005), 
however, the level of AP present in the CSF of humans is 4nM (Paradis et al., 1996; 
Marques et al., 2003). Additionally, treating primary human neuronal cultures with 
lOOnM fibrillar APl-40 or APl-42 results in little neuronal apoptosis (Paradis et al., 
1996). Although, nanomolar concentrations of soluble AP oligomers can 'kill neurons 
(Lambert et al., 1998). Furthermore, most AP toxicity models do not account for the 
complex interactions between neurons and glia that occur in vivo. The rate of neuronal 
death differs following AP treatment when· neurons are cultured alone compared to when 
they are co-cultured with astrocytes or microglia (Roher et al., 1996; Paradisi et al., 
2004; Caraci et al., 2005; Ramirez et al., 2005). Many in vitro models also utilise 
primary neurons that are cultured for up to one day (Pike et al., 1992; Pike et al., 1993; 
Pike et al., 1995; Gestwicki et al., 2004), two to six days (Yanker et al., 1990; Loo et al., 
1993; Lorenzo and Yanker, 1994; Ivins et al., 1999; Sponne et al., 2003; Paradisi et al., 
2004; Whalen et al., 2005; Yao et al., 2005) or seven to 10 days (Paradis et al., 1996; 
Pillot et al., 1999; Sponne et al., 2003; Ramirez et al., 2005; Whalen et al., 2005) in vitro 
before the AP treatment is initiated. Recent results indicate that primary neuron cultures 
\ 
develop a more mature phenotype when they have spent 21 days in vitro (King et al., 
2006). Treating primary neuron cultures with concentrations of AP that are more similar 
to those in vivo and aging neuron cultures for at least 21 days in vitro may provide a 
more accurate model in which to assess the toxic effects of AP on neurons. 
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1.7.4 Apoptosis in AD 
The final pathway to cell death in AD may involve NFT formation, cell cycle or 
plasticity dysregulation, apoptosis or cell death that is neither classical necrosis nor 
apoptosis (reviewed in Vickers et al., 2000; Jellinger and Stadelmann, 2001). To 
ascertain whether apoptosis is involved in AD-associated degeneration studies have 
focused on the presence of DNA fragmentation, frank apoptotic morphology, changed 
levels of pro- and anti-apoptotic proteins, caspases and caspase-cleavage products. 
1. 7.4.1 DNA fragmentation and apoptotic nuclear morphology in AD 
Many studies report increased DNA fragmentation in the hippocampal formation, 
frontal, temporal, parahippocampal and entothinal cortices of AD cases compared to 
controls (Su et al., 1994a; Dragunow et al., 1995; Smale et al., 1995; Cotman and Su, 
1996; Lassmann, 1996; Troncoso et al., 1996; Lucassen et al., 1997; Sugaya et al., 1997; 
Masliah et al., 1998; Sheng et al., 1998; Stadelmann et al., 1998; Overmyer et al., 2000; 
Pompi et al., 2003). However, other studies observe similar levels of DNA 
fragmentation in the AD and control temporal cortex and variable levels in the occipital 
cortex (Lucassen et al., 1997). Meanwhile, classical apoptotic morphology is observed 
rarely or not at all in AD (Lassmann et al., 1995; Troncoso et al., 1996: Lucassen et al., 
1997; Tompkins et al., 1997; Stadelmann et al., 1998; Stadelmann et al., 1999; 
Nurtomura and Chiba, 2000; Jellinger and Stadelmann, 2000; Jellinger and Stadelmann, 
2001; Raina et al., 2001; Raina et al., 2003). However, both DNA fragmentation and 
classical apoptotic morphology can occur independent!~ of apoptosis (Kaasik et al., 
1999; Raina et al., 2003; Tatton et al., 2003). 
1. 7.4.2 Apoptotic-related proteins in AD 
Similar contrasting and conflicting results are also reported when the levels/and or the 
number of cells containing Bcl-2, Bax, active and inactive caspase-3, -8 and -9 are 
analysed in AD and control brains (Table 1.3). Interestingly, one study found no Bax in 
the membranous fraction of the temporal co~ex of AD brains (Kitamura et al., 1998), 
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Table 1.3 Summary of the levels of apoptotic-related proteins present m AD brains 
compared to control brains. 
Apoptotsis Change Cerebral area Method Reference 
marker AD vs control 
caspase-9 Increased entorhmal cortex mRNAprobe Pompi et al , 2003 
Decreased cerebellum WB, 1mmunolabellmg Eg1dawork et al , 200 I 
No difference frontal cortex WB, 1mmunolabellmg Eg1dawork et al, 2001 
nucleus basal1s ofMeynert 1mmunolabelhng Wu et al , 2005 
active caspase-9 Increased frontal cortex WB Lu et al , 2000 
h1ppocampus 1mmunolabellmg Rohn et al , 2002 
caspase-8 Increased entorhmal cortex mRNAprobe Pompi et al , 2003 
Decreased frontal cortex, cerebellum Immunolabelhng Eg1dawork et al., 2001 
No difference frontal cortex, cerebellum WB Egidawork et al., 200 I 
nucleus basal1s of Meynert Immunolabellmg Wu et al., 2005 
active caspase-8 Increased h1ppocampus Immunolabelhng Rohn et al, 2001a 
caspase-3 Increased neurons m frontal cortex Immunolabelhng Mashah et al , 1998 
h1ppocampal neruons Immunolabelhng Jellmger & Stadelmann, 2001 
entorhmal cortex mRNAprobe Pompi et al , 2003 
Decreased frontal cortex, cerebellum WB, 1mmunolabelhng Egidawork et al, 2001 
No d1 fference medial temporal lobe Immunolabelhng Rama et al , 2001 
nucleus basal1s ofMeynert Immunolabellmg Wu et al , 2005 
active caspase-3 Increased h1ppocampus, sub1culum, temporal immunolabellmg Stadelmann et al , 1999 
1socortex 
h1ppocampus, entorhmal cortex, WB Zhao et al , 2003a 
temporal cortex 
h1ppocampus, entorhmal cortex, WB, 1mmunolabelhng Zhao et al , 2003b 
SFG 
mcreased m cells of the cortex Immunolabellmg Kang et al , 2005 
No difference entorhinal cortex, hippocampus, 1mmunolabelhng, mass Gastard et al , 2003 
subiculum spectroscopy 
Bax Increased hippocampus, subiculum, dentate immunolabelhng Nagy and Esm, 1997 
gyrus 
hippocampal fonnation 1mmunolabelhng Su et al., 1997 
NFf-free neurons in the 1mmunolabelhng ' 
h1ppocampal fonnal!on, G1annakopo1ous et al., 1999 
SFGand ITG immunolabelling Blanchard et al., 2003 
No difference Hippocampal dentate granule cells 1mmunolabellmg MacGibbon et al., 1997 
frontal cortex semi-quant RT-PCR Desjardins and Ledoux, 1998 
cystolic fraction of temporal cortex WB Kitamura et al., 1998 
nucleus basalis of Meynert immunolabelhng Wuetal.,2005 
Bcl-2 Increased entorhmal cortex, sub1culum, immunolabelling Satou et al., 1995 
h1ppocampus 
hippocampal fonnation immunolabelhng Su et al., 1996b 
membranous fraction, temporal WB Kitamura et al , 1998 
cortex 
h1ppocampal fonnation immunolabellmg Su et al , 1997 
neurons in frontal cortex immunolabelhng Masliah et al., 1998 
No difference hippocampus, sub1culum dentate immunolabelling Nagy and Esiri, 1997 
"' rus 
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Marker 
Bcl-2 
TRADD 
WB, western blottmg 
Change AD vs Cerebral area 
Control 
No difference frontal cortex 
CA I, subhcular/entorhinal regions 
Increased h1ppocampus, entorhmal cortex, 
SFG 
hippo campus 
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Reference 
Desjardins and Ledoux, 1998 
Stadelmann et al., 1998 
Zhao et al., 2003b 
Del Villar and Miller, 2004 
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suggesting that Bax had not been translocated to the mitochondrial membrane. Increases 
in other less frequently studied apoptosis-associated proteins such as Bel-XL (Nagy and 
Esiri, 1997; Kitamura et al., 1998), Blc-x~, (Kitamura et al., 1998), Bak (Kitamura et al., 
1998), Bad (Kitamura et al., 1998), p53 (De la Monte et al., 1997), Fas/FasL (De la 
Monte et al., 1997; Su et al., 2003), TRADD (Zhao et al., 2003b; Del Villar and Miller, 
2004), cyto c (Blanchard et al., 2003), X-inhibitors of apoptosis protein (IAP) (Christie 
et al., 2007), caspase-cleaved APP (Zhao et al., 2003a), caspase-cleaved fodrin (Rohn et 
al., 2001b), active caspase-6 (Guo et al., 2004) and caspase-1, -2L, -5, -6 and-7 mRNA 
(Pompi et al., 2003) are reported in AD or APP-overexpressing mice compared to 
control brains. However, other studies report that Bel-XL (Giannakopoulos et al., 1999), 
Bcl-x (Desjardins and Ledoux, 1998; Wu et al., 2005), Apaf-1 (Engidawork et al., 
2001), cyto c (Engidawork et al., 2001), caspase-1 (Masliah et al., 1998), -6 and -7 
(Raina et al., 2001), NIAP (Christie et al., 2007), cIAP-2 (Christie et al., 2007), and 
Fas/FasL (Ferrer et el., 2001; Wu et al., 2005) levels are unchanged or decreased. 
Additionally, when preclinical or early AD cases are compared to control cases increases 
in DNA fragmentation (Troncoso et al., 1996), levels of Bax (Nagy and Esiri, 1997: Su 
et al., 1997), Bcl-2 (Satou et al., 1995; Su et al., 1997), active-caspase-3 (aC3; Gastard et 
al., 2003; Zhao et al., 2003a) and caspase-1 and -7 mRNA (Pompi et al., 2003) and 
similar levels of TRADD (Zhao et al., 2003b) and NAIP (Christie et al., 2007) are 
detected. 
It is also important to note that the presence of apoptotic markers in AD brains may not 
necessarily equate to apoptosis. For instance, ifthe presence of pro-apoptotic proteins or 
DNA fragmentation resulted in apoptosis, a substantial neuronal loss would occur within 
a short period of time (Perry et al., 1998). Thus, it is plausible that apoptotic pathways 
are activated in the cells exhibiting apoptotic changes but do not proceed to completion 
(Raina et al., 2001; Raina et al., 2003; Wu et al., 2005) due to sublethal activation of 
apoptotic pathways (as reviewed in Cotman, 1998) including a lack of apoptotic signal 
propagation to downstream effector caspases (Raina et al., 2001; Raina et al., 2003), or 
cells mounting an effective defence against apoptotic cell' death (Perry et al., 1998; 
Raina et al., 2003). For instance, long-term survival of neurons labelled for activated 
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caspases is not unheard of. In a model of long-term experimental diabetes, sensory 
neurons express aC3, but show -no signs of ongoing apoptosis in terms of DNA 
fragmentation, nuclear morphology or cell loss (Cheng and Zochodne, 2003). Finally, 
there is also evidence that aberrantly activated caspases can be present in neurons 
uncommitted to apoptosis, which over long periods, may lead to aberrant processing of 
proteins (LeBlanc et al., 1999) such as tau (Gamblin et al., 2003; Rissman et al., 2004; 
Kang et al., 2005) and APP (as reviewed in Tanzi, 1999). 
1. 7.4.3 Association between apoptosis-related changes and AD pathology 
Investigations into the association of apoptotic-related changes with the pathological 
hallmarks of AD also yield variable results. Numerous studies have investigated the co-
localisation of NFTs with apoptotic markers. A subset of NFT-bearing neurons also 
exhibit DNA fragmentation (Su et al., 1994a, Lassmann et al., 1995; Sugaya et al., 1997; 
Sheng et al., 1998; Broe et al., 2001; Jellinger and Stadelmann, 2001), apoptotic nuclear 
morphology (Su et al., 1994a), Fas/FasL (Ferrer et al., 2001), Bax (Giannakopolous et 
al., 1999; Blanchard et al., 2003), Bcl-2 (Tortosa et al., 1998), Bcl-xL (Giannakopolous 
et al., 1999), FADD (Wu et al., 2005), caspase-cleaved tau (Guo et al., 2004), caspase-8 
and -9 (Raina et al., 2001) and active caspase-3 (aC3, Gastard et al., 2003; Kang et al., 
2005), -6 (Guo et al., 2004; Albrecht et al., 2007) and -8 (Rohn et al., 2001a; Su et al., 
2002). However, DNA fragmentation (Su et al., 1994a; Lassmann et al., 1995; Sheng et 
al., 1998), apoptotic nuclear morphology (Su et al., 1994a), FADD (Wu et al., 2005), 
Fas/FasL (Ferrer et al., 2001), Bcl-2 (Tortosa et al., 1998) and aC3 (Gastard et al., 2003) 
are also present in a subset of the NFT-free neurons in AD. Caspase-8, -9 (Raina et al., 
2001) and Bax-labelling (MacGibbon et al., 1997) is reportedly strong in NFT-bearing 
and weak in NFT free neurons. In contrast other studies assert that NFT-bearing 
neurons exhibit reduced or no labelling for Bax (Nagy and Esiri, 1997; Su et al., 1997), 
Bcl-2 (Satou et al., 1995; Su et al., 1996b), p53 (De la Monte et al., 1997) and TRADD 
(Del Villar and Miller, 2004), while pre-NFTs demonstrate strong labelling for Bax (Su 
et al., 1997) and weak labelling of Bcl-2 (Su et al., 1996b) and p53 (De la Monte et al., 
1997). Yet other studies observe no difference between NFT-bearing and NFT-free 
35 
Chapter I - Introduction 
neurons for Bax and Bcl-2-labelling (Tortosa et al., 1998; Kobayashi et al., 2004). 
Additionally, co-localisation of NFTs and caspase-cleaved fodrin, APP and tau are also 
observed (Rohn et al., 2001b; Rohn et al., 2002; Zhao et al., 2003a; Rissman et al., 2004; 
Kang et al., 2005). Interestingly, it has been hypothesised that caspase activation may 
link AP and neurofibrillary pathology in AD, with AP activating caspases, which then 
cleave tau and initiate or potentiate NFT formation (see Jellinger, 2006). 
The distribution of AP plaques is not correlated with DNA fragmentation and apoptotic-
like nuclei (Lassmann et al., 1995; Lucassen et al., 1997; Broe et al., 2001), but DNA 
fragmentation is positively correlated with AP plaque load (Jellinger and Stadelmann, 
2001). Bax-labelling is highly variable adjacent to AP plaques (Nagy and Esiri, 1997), 
although some studies describe Bax-labelled glia in association with AP plaques 
(MacGibbon et al., 1997; Su et al., 1997; Giannakopolous et al., 2001). Additionally, 
the number of Bcl-2-labelled neurons or intensity of Bcl-2-labelling present in the AD 
brain correlates with AP plaque load (Satou et al., 1995; Kobayashi et al., 2004). Bax, 
Bel-XL, cyto c, p53, FasL, FADD, caspase cleaved tau and active caspases-8 and-9 are 
also observed in a subset of DNs in AD (De la Monte et al., 1997; MacGibbon et al., 
1997; Nagy and Esiri et al., 1997; Tortosa et al., 1998; Giannakopolous et al., 2001; 
Rohn et al., 2002; Su et al., 2002; Blanchard et al., 2003; Su et al., 2003; Guo et al., 
2004; Wu et al., 2005; Albrecht et al., 2007). 
The variability, discrepancies and contradictions present in the current literature 
regarding apoptosis in AD may be' due to the different cerebral areas and cell 
populations analysed, the different techniques and/or antibodies used and even 
differences between fixation methods or the cohort of brain cases analysed ( eg. Table 
1.3). Although evidence supporting a direct role for apoptosis in AD degeneration has 
accumulated it remains difficult to draw conclusions from the current literature (Roth, 
2001; Raina et al., 2003). A comprehensive analysis of several apoptotic-related 
proteins and apoptotic morphology in the same cohort of cases and their association with 
the pathological hallmarks of AD may shed light on this contentious area of AD 
research. 
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1.8 ANIMAL MODELS OF AD 
Animal models present the opportunity to examine the effects of overexpression of 
disease associated genes and genetic mutations, disease progression and provide models 
in which potential therapeutics can be screened and tested. Now that initial difficulties 
in producing AD mouse models that closely resemble AD-pathological features 
(reviewed in Vickers et al., 2001) have been overcome, numerous mouse models of AD 
have been developed and many are now commercially available. Transgenic mouse 
models of AD express a variety of combinations of human APP alone or in combination 
with PS 1/PS2 and/or tau proteins harbouring mutations associated with familial AD, and 
demonstrate diffuse and dense AP plaques, DNs, gliosis and neurodegeneration that are 
not observed in wild type littermates, but not neurofibrillary pathology or extensive 
neuronal death (Games et al., 1995; Hsiao et al., 1996; Borchelt et al., 1997; Sturchler-
Pierrat et al., 1997; Holcomb et al., 1998; Moechars et al., 1999; Janus et al., 2000; 
Mucke et al., 2000; Chishti et al., 2001; Blanchard et al., 2003; Higgins and Jacobsen, 
2003; Richards et al., 2003; Cheng et al., 2004; Kawasumi et al., 2004; Oakley et al., 
2006). Transgenic tau mice have also been developed that express human tau 
harbouring mutations associated with hereditary parkinsonism and frontotemporal 
dementia (Lewis et al., 2000; Gotz et al., 2001; Zhang et al., 2004a; Santacruz et al., 
2005; Terwel et al., 2005). The most widely used mouse models of AD have differing 
characteristics and, thus, there are advantages and disadvantages associated with each 
mouse model. 
1.8.1 P-amyloid precursor protein transgenic mouse models 
There are many widely utilised mouse models of AD that express human APP with 
various familial associated mutations under the control of differing promoters (Table 
1.2). The most frequently used APP-expressing AD mouse models include Tg2576 
(APPSwe), PDAPP, APP23 and TgCRND8 mice. The expression of various familial 
associated APP mutations and the different levels and localisation of transgene 
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expression in AD mouse models result in variability in the temporal and region specific 
pattern of AD-associated pathology. However, differences between transgenic AD 
mouse models can be attributed not only to the different promoters and transgenes with 
varying disease-associated mutations, but the genetic background of the mouse in which 
the transgene is expressed also affects the phenotype (Ali et al., I 996; Carlson et al., 
I997). 
1.8.1.1 Tg2576 transgenic AD mice 
Tg2576 mice were one of the first successful transgenic AD mouse models (Hsiao et al., 
I996; Higgins and Jacobsen, 2003). Tg2576 mice develop age-dependent AJ3 plaque 
deposition beginning at seven months of age, which progressively increases and is 
severe by 23 months of age (Kawarabayashi et al., 200I; Noda-Saita et al., 2004). 
Compared to other APP transgenic mice, Tg2576 mice accumulate pathology over a 
relatively long period of time, providing a mouse model that more closely resembles the 
chronic time course of human AD. J3-amyloid plaques are present in the hippocampal 
formation and entorhinal cortex, cerebral cortex, cerebellum and cerebral vasculature of 
Tg2576 mice, with rare AJ3 plaque deposition in the internal capsule and basal ganglia 
(Hsiao et al., I996; Irizarry et al., I997; Frautshcy et al., I998; Kawarabayashi et al., 
200I; Le et al., 200I; Tomidokoro et al., 200I). J3-amyloid plaques in Tg2576 mice are 
associated with tau- (with variable phosphorylation), PHF-tau-, NF triplet protein-, 
MAP2-, dephosphorylated NF triplet protein-, APP-, PSI-, synaptophysin-, a-synuclein-
and ubiquitin-labelled DNs (Irizarry et al., I997; Le et al., 200I; Tomidokoro et al., 
200I; Motoi et al., 2004; Noda-Saita et al., 2004), reactive astrocytes (Hsiao et al., I996; 
Irizarry et al., I997; Motoi et al., 2004) and microglia (Frautschy et al., I998; Sasaki et 
al., 2002). No neuropil threads or NFTs are present in the Tg2576 mouse model (Noda-
Saita et al., 2004). Results regarding neuron loss in Tg2576 mice are contradictory. 
One study reports no neuronal loss in the hippocampal CAI (Irizarry et al., 1997), yet 
another study detects a significant decrease of neuronal numbers in areas containing 
dense cored AJ3 plaques compared with the corresponding areas in wild type control 
mice (Tomidokoro et al., 200I). Although memory deficits in Tg2576 mice were 
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originally reported to commence at nine months of age (Hsiao et al., 1996), more recent 
studies detected age-related memory deficits in Tg2576 mice at six-nine months of age, 
which does not correlate with the initiation of AP plaque deposition, but may be 
associated with AP assemblies within the brain (Kotilinek et al., 2002; Westerman et al., 
2002; Arendash et al., 2004a; Jacobsen et al., 2006; Middei et al., 2006). 
1.8.1.2 PDAPP and APP23 transgenic AD mice 
Two comparable and .widely used mouse models of AD that develop age-related AD-
like pathology earlier than Tg2576 mice are the PDAPP and APP23 mouse models of 
AD. P-amyloid plaque deposition initiates at approximately six months of age in both 
PDAPP and APP23 mice (Games et al., 1995; Irizarry et al., 1997; Sturchler-Pierrat et 
al., 1997). In PDAPP mice AP plaques are present in the hippocampal formation, corpus 
callosum and cerebral cortex (Games et al., 1995; Masliah et al., 1996b; Reilly et al., 
I 
2003; Bussiere et al., 2004), while APP23 mice exhibit AP plaques in the hippocampus, 
cerebral cortex and cerebral vasculature and also in the thalamus, olfactory nucleus and 
caudate putamen in older mice (Sturchler-Pierrat et al., 1997; Calhoun et al., 1998; Kuo 
et al., 2001; Bondolfi et al., 2002). PDAPP and APP23 mice develop AP plaque-
associated DNs that are immunoreactive for a variety of epitopes including APP, 
synaptophysin, phosphorylated tau, PHF-tau and NF triplet protein (Games et al., 1995; 
Masliah et al., 1996b; Irizarry et al., 1997; Diez et al., 2003; Bussiere et al., 2004; 
Schwab et al., 2004). P-amyloid plaques are also associated with astrogliosis and 
microgliosis in both mouse models (Games et al., 1995; Masliah et al., 1996b; Irizarry et 
al., 1997; Sturchler-Pierrat et al., 1997; Bornemann et al., 2001; Schwab et al., 2004). 
As in Tg2576 mice, no neurofibrillary pathology is observed in PDAPP or APP23 mice 
(Games et al., 1995; Masliah et al., 2001; Schwab et al., 2004). Neuron loss is observed 
in the hippocampus and neocortex of APP23 mice, and is inversely correlated with AP 
plaque load (Calhoun et al., 1998; Bondolfi et al., 2002). In contrast, no overt neuronal 
loss is present in the entorhinal or cingulate cortex or the hippocampus in PDAPP mice 
up to 18 months of age (Irizarry et al., 1997). Both PDAPP and APP23 mice develop · 
memory deficits beginning at three months of age, prior to AP plaque deposition (Dodart 
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et al., 1999; Kelly et al., 2003; Van Dam et al., 2003; Hartman et al., 2005). However, 
the extent of navigation impairment in the Morris water maze does correlate with AP 
plaque load in APP23 mice (Sykova et al., 2005), and PDAPP mice show an age-
dependent decrease in spontaneous object-recognition that is more severe at ages when 
AP plaque deposition is known to occur (Dodart et al., 1999). 
1.8.1.3 TgCRND8 transgenic AD mice 
TgCRND8 AD mice accumulate AD-associated pathology much more rapidly than 
Tg2576, PDAPP and APP23 mice. P-amyloid plaques are present in TgCRND8 by 
three months of age, AP plaque deposition increases with age, and dense-cored AP 
plaques and neuritic pathology are evident at five months of age (Chishti et al., 2001; 
Dudal et al., 2004). TgCRND8 mice exhibit AP plaques in the amygdala, hippocampal 
formation and neocortex, then the thalamus, cerebral vasculature, striatum, cerebellum 
and brainstem, consecutively (Chishti et al., 2001; Dudal et al., 2004). Although the 
rapid accumulation of pathology in this AD mouse model does not necessarily resemble 
the slow increase of pathology of most human AD cases, it does provide researchers 
with an AD mouse model that develops pathology quickly, which is ideal to fast-track 
pilot studies or for testing potential therapeutics. P-amyloid plaques in TgCRND8 mice 
are also associated with NFH-, hyperphosphorylated-tau-, synaptophysin- and ubiquitin-
labelled DNs (Chishti et al., 2001), astrogliosis and microgliosis (Chishti et al., 2001; 
Dudal et al., 2004; Bellucci et al., 2007). Memory deficits are observed in TgCRND8 
mice beginning at three months of age, and are associated with high levels of AP42 
production and the onset of AP plaque deposition (Janus et al., 2000; Chishti et al., 2001, 
Hyde et al., 2005; Lovasic et al., 2005). 
1.8.1.4 Other widely used transgenic APP AD mice 
Other widely used APP-expressing AD mouse models include the APPLon, 
PDAPPSwe/Ind and APPSwe/Ind/ Arc models (Table 1.2). Pathology first appears in 
APPLon mice at 10-12 months of age, including AP plaques and AP plaque-associated 
DNs, astrogliosis and microgliosis in the hippocampus, cortex, thalamus, external 
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capsule, pontine nuclei and white matter (Moechars et al., 1999). PDAPPSwe/lnd mice 
develop Ap plaque pathology that begins at five to seven months of age in the dentate 
gyrus and neocortex, AP plaque pathology increases with aging, and AP plaque-
associated DNs are also observed in adult mice (Mucke et al., 2000; Descarries et al., 
2005). Finally, the relatively new APPSwe/lnd/Arc AD mouse model expresses APP 
harbouring the familial Swedish, Indiana and Arctic mutations (Cheng et al., 2004). The 
Arctic APP mutation results in AP more easily forming protofibrils in vitro (Lord et al., 
2006). Thus, AP plaque deposition in APPSwe/lnd/Arc mice occurs earlier, at two to 
three months of age, and is more extensive than in APPSwe/Ind mice (Cheng et al., 
2004). 
1.8.2 Double transgenic mouse models of AD 
Double transgenic AD mouse models generally entail mice expressing human APP 
harbouring mutations associated with familial AD in combination with mutant or non-
mutant human PS or tau. 
1.8.2.1 PS/APP double transgenic AD mice 
There are many APP and PS 1 or PS2 double transgenic mice, which generally develop 
AD-like pathology earlier and more extensively than APP transgenic mice (Holcomb et 
al., 1998; Chishti et al., 2001; Lee et al., 2001; Wirths et al., 2001; Blanchard et al., 
2003; Richards et al., 2003; Wang et al., 2003a; Savonenko et al., 2005). In comparison, 
mice overexpressing only human mutant PS 1, but not wild type PS 1, demonstrate 
increased AP42/43, do not develop AP plaques and exhibit no behavioural abnormalities 
(Duff et al., 1996; Guo et al., 1999; Sadowski et al., 2004). However, mice expressing 
human mutant or wild type PS2 exhibit behavioural dysfunction and immolabelling for 
APl-42 and human PS2 that is not present in age-matched non-transgenic control mice 
(Hwang et al., 2002). While other transgenic mice expressing wild type PS2 exhibit no 
increase in APl-42 and APl-40 production, but mice expressing familial AD mutant 
PS2 support robust production of APl-42 (Mastrangelo et al., 2005). 
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Perhaps the most commonly used APP/PS double transgenic mouse is the PSAPP AD 
mouse model (Table 1.2). P-amyloid plaque deposition initiates at 10 weeks of age in 
PSAPP mice compared to seven months of age in Tg2576 mice, probably due to 
increased levels of APl-40 and APl-42 in PSAPP mice compared to Tg2576 mice 
(Holcomb et al., 1998; McGowan et al., 1999; Takeuchi et al., 2000; Howlett et al., 
2004). Additionally, PSAPP mice develop larger numbers of fibrillar AP plaques than 
Tg2576 mice (Holcomb et al., 1998; Le et al., 2001). The localisation of AP plaques in 
PSAPP mice is similar to that of Tg2576 mice, with AP plaque deposition in the 
hippocampal formation, cerebral cortex, corpus callosum and cerebral vasculature 
(Holcomb et al., 1998; McGowan et al., 1999; Takeuchi et al., 2000; Kurt et al., 2003; 
Howlett et al., 2004). PSAPP mice also exhibit AP plaque-associated DNs (Lee et al., 
2001; Kurt et al., 2003) and astrogliosis (McGowan et al., 1999), but no NFTs or overt 
neuronal loss in the hippocampus and cortices (Takeuchi et al., 2000; Sadowski et al., 
2004). Although one study reports that PSAPP mice exhibit no impairments in spatial 
navigation at six to nine months of age (Holcomb et al., 1999), other studies detect 
memory deficits in six to 10 month old PSAPP mice (Howlett et al., 2004; Sadowski et 
al., 2004; Trinchese et al., 2004). These memory deficits do not match initiation of AP 
plaque deposition in PSAPP mice, but do correspond with increased AP plaque burden 
and the formation of DNs and gliosis (Howlett et al., 2004; Trinchese et al., 2004), 
suggesting that cognitive impairments in PSAPP mice are not simply related to AP 
deposition but may result from the disruption of neural connectivity (Howlett et al., 
2004). In addition, abnormal long-term potentiation is observed in PSAPP mice at three 
months of age, paralleling the appearance of AP plaques in this mouse model (Trinchese 
et al., 2004). 
1.8.2.2 Tau/APP double transgenic AD mice 
Transgenic tau mice have been developed that overexpress various isoforms of human 
tau with or without mutations associated with hereditary frontotemporal dementia and 
parkinsonism (Lewis et al., 2000; Gotz et al., 2001; Zhang et al., 2004a; Santacruz et al., 
2005; Terwel et al., 2005). Overexpression of non-mutant human tau results in axonal 
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dilations and spheroids and normal survival in transgenic mice (Terwel et al., 2005), but 
the overexpression of mutant tau, which potentially reduced the binding of tau to 
microtubules, results in the development of intra-neuronal NFTs and reduction in life 
span (Lewis et al., 2000; Gotz et al., 2001; Zhang et al., 2004a; Terwel et al., 2005). In 
addition, when the expression of mutant tau is repressed in two and a half month old 
transgenic tau mice (rTg(tauP301L) 4510; Table 1.2) pathological progression stops, but 
when expression of the transgene is suppressed in mice that are four and half months of 
age or older, NFTs continued to accumulate (Santacruz et al., 2005). Interestingly, in 
rTg(tauP301L) 4510 mice in which transgene expression is suppressed at two and half 
months of age, memory function improves despite ongoing accumulation of NFTs, 
suggesting that NFT formation does not disrupt cognitive function (Santacruz et al., 
2005). However, the cognitive deficits in rTg(tauP301L) 4510 mice are associated with 
the presence of oligomeric aggregates of tau, which are also present in JNPL3 mice and 
human AD (Berger et al., 2007). 
Two APP/tau double transgenic mouse models currently exist, namely APPSw/Tau/v/w 
and TAPP mice (Table 1.2). APPSw/Tau/v/w mice develop enhanced Ap plaque 
deposition in combination with neurofibrillary pathology and overt neuron loss in limbic 
areas (Ribe et al., 2005). Similarly, TAPP mice exhibit AP plaques at the same age as 
Tg2576 mice, but also produce enhanced NFT pathology and pre-NFTs in the limbic 
system and olfactory cortex, areas that rarely contain NFTs in JNPL3 mice (Lewis et al., 
2001). The data from these two transgenic mice suggest that reciprocal interactions 
occur in vivo between APP or AP and tau (Lewis et al., 2001; Ribe et al., 2005). 
1.8.3 Triple transgenic AD mice 
Finally, the 3xTg-AD mouse model combines the expression of mutated human APP, 
PS 1 and tau (Table 1.2). 3xTg-AD mice exhibit AP plaque and neurofibrillary 
pathology in a very similar regional and temporal pattern to human AD (Oddo et al., 
2003a). Tau pathology begins in the hippocampus of 3xTg-AD mice and progresses 
into the cortex, whereas AP plaques are first observed in the cortex and then in the 
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hippocampus (Oddo et al., 2003b ). A subset of AP plaques in 3xTg-AD mice are also 
associated with astrogliosis (Oddo et al., 2003b) and tau-labelled DNs (Oddo et al., 
2003a). Homozygous 3xTg-AD mice first develop AP plaques at six months of age, 
prior to the presence ofNFTs despite equivalent expression of both transgenes (Oddo et 
al., 2003a; Oddo et al., 2003b ). In addition, increasing the tau expression levels in 
3xTg-AD mice has no effect on the initiation or progression of AP expression or 
deposition in these mice (Oddo et al., 2007). Thus, 3xTg-AD mice provide further 
support for the amyloid cascade hypothesis (Oddo et al., 2003b; Oddo et al., 2007). A 
memory deficit can be detected in 3xTg-AD mice at four months of age, a time point at 
which AP plaques and NFTs are not observed, but intraneuronal AP is present in the 
hippocampus and amygdala (Billings et al., 2005). Furthermore, this cognitive deficit is 
rescued when intraneuronal AP is cleared by immunotherapy, suggesting that 
intraneuronal AP may also have a role in the inception of cognitive dysfunction (Billings 
et al., 2005). However, a further study found that immunisation protocols that reduce 
soluble AB and tau ameliorate cognitive deficits in 3xTg-AD mice, but immunisation 
that reduces soluble AB alone does not (Oddo et al., 2006). 
1.9 THERAPEUTIC INTERVENTIONS FOR AD 
There are presently no effective treatments to slow down the progression or to decrease 
the symptoms of AD (Parnetti et al., 1997). Currently, the therapies most commonly 
available for AD patients are cholinesterase inhibitors, which enhance cholinergic 
neurotransmission (Brion, 1996; Brodaty et al., 2001) and N-methyl-D-aspartate 
(NMDA) glutamate receptor antagonists (Livingston and Katona, 2004). However, 
current research suggests that some cholinesterase inhibitors may have other 
pharmacological modes of action. For example, Huperzine A is a potent acetyl-
cholinesterase inhibitor that is in Phase II clinical trials in China and the United States, 
which may also protect neurons by upregulating nerve growth factor (NGF), binding to 
NMDA receptors, interfering with APP processing to increase soluble APP levels, 
reducing glutamate-induced excitotoxicity and improving long-term potentiation, 
(Gordon et al., 2001; Jiang et al., 2003; Zhang et al., 2004b; Wang et al., 2006). 
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However, the currently available cholinesterase inhibitors and N.l\.IDA antagonist 
therapeutics for AD only decrease the clinical manifestation of AD in subset of patients, 
and this reprieve is usually only temporary, as these therapeutics do not affect disease 
progression (Parnetti et al., 1997). Thus, there is dire need for therapeutic interventions 
that either slow or stop the progression of AD. 
Assuming that AB plaques are the primary etiological agent of AD, two possible 
approaches to treating AD exist: to prevent AB plaque formation or to protect neurons 
against the damaging effects of AB (Vickers et al., 2000). Therapeutics that aim to 
protect neurons from the damaging effects of AD pathology include anti-inflammatory 
drugs, dietary supplements and antioxidants, growth factor therapy and cytoskeletal 
stabilising drugs. While therapeutic interventions with the goal of preventing or 
reducing AB levels and AB plaque formation include drugs that modulate APP 
processing, AB aggregation inhibitors, and therapeutics that increase AB clearance or 
degradation. The following part of this review highlights the many avenues of research 
into discovering and developing new therapeutics for AD that slow or halt disease 
progression. 
1.9.1 Anti-inflammatory drugs 
Anti-inflammatory drugs initially became the focus of AD research due to epidemiology 
studies, which suggest that the use of anti-inflammatory drugs reduced the risk of 
developing AD. Indeed, recent research does suggest that several nonsteroidal anti-
inflammatory medications (NSAIDs) lower AB levels in cultured cells and the brains of 
Tg2576 mice, by targeting the y-secretase complex that cleaves APP (Weggen et al., 
2001; Eriksen et al., 2003). However, studies assessing the effectiveness of anti-
inflammatory treatment of AD in humans, mostly concerning NSAIDs or NSAID related 
compounds, failed to show any benefit to the subjects in the study (as reviewed in 
Rozemuller et al., 2005). In addition, a large trail of NSAIDs (the AD anti-
inflammatory prevention trial) was undertaken by the United States National Institute on 
Aging, but was halted in 2004, as there was evidence of an increased risk of 
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cardiovascular events in the NSAID treatment group (Lyketsos et al., 2007). 
Furthermore, initial follow up studies of the AD anti-inflammatory prevention trial does 
not show that NSAIDs prevented AD (Lyketsos et al., 2007). 
1.9.2 Dietary supplements and antioxidants 
There is increasing evidence to suggest that diet may affect the risk of developing AD 
(Engelhart et al., 2002; Luchsinger et al., 2002; Morris et al., 2002; Luchsinger et al., 
2003; Luchsinger et al., 2007). In particular, foods high in antioxidants may slow the 
progression of AD by combating the effects of damaging free radicals (Markesbery and 
Carney, 1999; Engelhart et al., 2002). For example, there is evidence that the 
antioxidants Ginkgo biloba, curcumin, resveratrol, polyphenols and vitamin E all reduce 
AB pathology or AB plaque-associated oxidative stress in transgenic AD mouse models 
(Sung et al., 2004; Marambaud et al., 2005; Rezai-Zadeh et al., 2005; Garcia-Alloza et 
al., 2006; Hartman et al., 2006). Specifically, pomegranate juice, which contains high 
levels of polyphenols, significantly decreases soluble AB levels and AB plaque loads and 
improves behaviour in Tg2576 AD mice (Hartman et al., 2006). Similarly, green tea 
-
pholephenoic flavonoid (-)-epigallocatechin-3-gallate also decreases AB levels and AB -
plaque deposition in Tg2576 mice in association with the promotion of the a-secretase 
APP proteolytic pathway (Rezai-Zadeh et al., 2005). However, resveratrol, strongly 
requced AB levels in cell lines expressing wild type or Swedish mutant APP by 
promoting AB degradation via the proteasome (Marambaud et al., 2005). Both Ginkgo 
biloba and vitamin E also reduce the AB plaque-associated oxidative stress in vivo in 
double APP/PS 1 transgenic mice (Garcia-Alloza et al., 2006). Interestingly, AB plaque 
size is not significantly changed by Ginkgo biloba or vitamin E, but the curvature of AB 
plaque-associated DN s is significantly reduced in Ginkgo biloba treated transgenic AD 
mice and shows a similar, but not significant, trend in the vitamin E treated transgenic 
AD mice (Garcia-Alloza et al., 2006). Furthermore, chronic dietary supplementation 
with vitamin E reduces AB deposits in Tg2576 mice (Sung et al., 2004). In human 
epidemiology studies vitamin E from food and vitamin E supplements are both 
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correlated with lower incidence of Alzheimer's disease (Morris et al., 2002; Morris et 
al., 2005). 
In addition, supplementing diets with nutrients essential for efficient neuronal 
functioning are also being investigated. One such nutrient is docosahexaenoic acid 
(DHA), which is an omega-3 polyunsaturated fatty acid that is a major constituent of 
synaptic plasma membranes and has roles in membrane flexibility, signal transduction 
and neurotransmission (as reviewed in Horrocks and Farooqui, 2004; Marszalek and 
Lodish, 2005). Epidemiological studies have suggested that people with high plasma 
phosphatidylcholine DHA levels have a significantly reduced risk of developing 
dementia (Schaefer et al., 2006). Additionally, DHA supplementation in Tg2576 and 
3xTg-AD mice significantly reduces AP levels and AP pathology, and corrects synaptic 
deficits and cognitive function (Lim et al., 2005; Cole and Frautschy, 2006; Green et al., 
2007), which is attributed to decreases in presenilin 1 levels and not alterations in a- or 
P-secretase activity (Green et al., 2007). In addition, a clinical trial of omega-3 fatty 
acid in 174 mild to moderate AD subjects shows a significant reduction in cognitive 
decline in a subset of 32 subjects with very mild cognitive dysfunction, but no difference 
in the moderate AD subjects (Freund-Levi et al., 2006). 
1.9.3 Growth factor treatment 
The potential for NGF and brain derived neurotrophic factor (BDNF) to prevent or slow 
nerve cell loss in AD and other neurodegenerative diseases has been investigated for 
several decades. The therapeutic delivery of NGF and BDNF is problematic as neither 
crosses the blood brain barrier (BBB) and broad growth factor application to the brain 
has adverse effects, however, pharmacologically increasing endogenous growth factor 
expression, or administration of growth factors locally through autologous cells 
modified to produce growth factors, or by viral vectors are providing promising results 
(as reviewed in Fumgalli et al., 2006; Tuszynski, 2007). Although it should be noted 
that even if growth factors can be successfully administered to AD subjects it is unlikely 
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that growth factor therapy will "cure" AD, as so far there is no evidence that growth 
factors are able to slow the progression of AD (Tuszynski et al., 2005; Tuszynski, 2007). 
A recent Phase I trial of implanting autologous fibroblasts, genetically modified with a 
retroviral vector to express human NGF, into the forebrain of eight mild AD subjects 
shows that such therapy may be viable (Tuszynski et al., 2005). No long-term adverse 
reactions to the fibroblast implantation were present in the follow up of six subjects 
(Tuszynski et al., 2005). Cognitive function results are also promising, with three of the 
six subjects showing improved or stable cognitive function and two subjects showing 
decreased cognitive decline (Tuszynski et al., 2005). In addition, a robust cholinergic 
axonal sprouting response is observed into the site of NGF delivery, and the 
establishment of new connections may at least partially explain the positive changes 
observed in cognition (Tuszynski et al., 2005). 
Other therapeutics are also being investigated that induce the endogenous expression of 
growth factors (eg. Neotrofin, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor modulators), or mimic growth factor activities (eg. Cerebrolysin). For example, 
Neotrofin (AIT-082, NeoTherapeutics Inc.) activates a second messenger system that 
results in the production of mRNA for neurotrophins. Phase I trials with Neotrofin are 
complete (Grundman et al., 2003), and Neotrofin is now in Phase 11/111 clinical trials. 
The advantage of Neotrofin is that it is orally active, penetrates the blood-brain barrier 
and induces the production of multiple growth factors within the CNS. Furthermore, 
cerebrolysin (Ebewe Pharmaceutical) is an injectable neuroprotective, neurotrophic 
protein with NFG-like activity that has undergone human clinical trials (Ruther et al., 
2000; Panisset et al., 2002; Ruether et al., 2002; Alvarez et al., 2006). In addition to its 
neuroprotective and neurotrophic ability, cerebrolysin decreases the production of full 
length APP, and C terminal APP fragments probably by regulating the maturation of the 
APP and its transport to cellular sites where A~ is generated (Rockenstein et al., 2006). 
Thus, cerebrolysin treatment in transgenic AD mice results in decreased A~ plaque 
deposition and synaptic pathology, and ameliorates learning and memory deficits 
(Rockenstein et al., 2003; Rockenstein et al., 2006). Finally, human clinical trials show 
that cerebrolysin improves cognitive and behavioural outcomes in humans AD subjects, 
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which are still detectable up to six months after a four week treatment course of 
cerebrolysin (Ruther et al., 2000; Panisett et al., 2002; Ruether et al., 2002, Alvarez et 
al., 2006). 
1.9.4 Cytoskeletal stabilising drugs 
The hyperphosphorylated tau that is present in NFfs, pre-NFfs, DNs and neuropil 
threads in AD, is less able to bind to and stabilise microtubules. Thus, several 
microtubule stabilising drugs, aimed to substitute for the tau . sequestered into the 
inclusions in tauopathies (Zhang et al., 2004c), are being investigated for use as potential 
AD therapeutics. Paclitaxel (Taxol®, Bristol-Myers Squibb Company) is a pro-
apoptotic Bcl-2 binding and microtubule stabilising drug that is widely used to treat 
cancer that can protect neurons against various toxic stimuli including AB peptides and 
reactive oxygen species (Rodi et al., 1999; Michaelis et al., 1998; Sponne et al., 2003). 
However, Paclitaxel cannot cross the BBB so a search for novel microtubule stabilising 
drugs with neuroprotective properties that could also cross the BBB was undertaken 
(Michaelis, 2006). Thus, Taxotere, UK 100, GS164 and Tx67 were discovered, which 
all also significantly increase the percentage of surviving neurons following treatment 
with aggregated AB (Michaelis et al., 2002). The effects of two of these novel taxanes, 
namely Tx67 and KU-237, in transgenic tau mice are currently being investigated as 
potential therapeutics for AD (Michaelis, 2006). In addition, Paxceed™ (Angiotech 
Pharmaceuticals, Inc.), which is Paclitaxel in a micelle vehicle, was also developed. Tau 
transgenic mice treated with Paxceed™ exhibit ameliorated motor impairments 
compared to sham treated mice, which is associated with restored fast axonal transport 
and increased numbers of microtubules and stable tubulins (Zhang et al., 2004c). These 
results support a potential therapeutic role for microtubule stabilising drugs in the 
treatment of neurodegenerative tauopathies (Zhang et al., 2004c). 
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1.9.5 fl-amyloid precursor protein processing modifying drugs 
Therapy aimed to modify APP processing to produce less AP includes P-secretase and y-
secretase inhibitors, statins, heparins, and antibodies against the B-secretase cleavage site 
of APP, as well therapeutics that increase AB clearance through the upregulation of AB 
degrading enzymes. 
Inhibition of B-secretase and y-secretase reduces the production of AB, with the aim of 
stopping or slowing the progression of AB deposition and/or toxicity. Few human 
clinical trials have been undertaken for B-secretase and y-secretase inhibitors so far. 
However, experiments in which PDAPP mice are crossed with APP-cleaving B-secretase 
BACE-1 knock out mice provide proof of concept, as PDAPP/BACE-1-1- mice do not 
produce AB, AB plaques or have synaptic deficits (McConlogue et al., 2007). In 
addition, PDAPP/BACE-1 +i- mice initially exhibit only a 12% decrease in AB levels, but 
this is enough of a reduction to result in a dramatic decrease in AB plaque deposition, 
DN burden and synaptic deficits in the aged mice (McConlogue et al., 2007). 
GSK188909 is a relatively new selective peptide BACE-1 inhibitor, which inhibits B-
cleavage of APP and reduces secreted and intracellular AB in an APP expressing cell 
line (Hussain et al., 2007). Additionally, GSK188909 can lower brain AB levels 
following oral administration in APP/PSI transgenic AD mice (Hussain et al., 2007), but 
no clinical trials for GSK188909 are underway as yet. In contrast, Ly450139 dihydrate 
is a y-secretase inhibitor that is currently in Phase II clinical trials. Although initial 
results in transgenic PDAPP mice show a reduction of AB levels and AB plaque burden 
(Ness et al., 2004 presented at the 8th International Montreal/Springfield Symposium on 
Advances in Alzheimer Therapy), human clinical trials report that plasma AB is only 
lowered for six hours following Ly450139 dihydrate administration in human subjects, 
and that cerebrospinal fluid AB is unchanged (Siemers et al., 2005; Siemers et al., 2006). 
Another y-secretase inhibitor that is in human clinical trials is Flurizan™ (r-
flurbiprofen). Flurizan™ does not inhibit cyclooxygenase, but does lower ABl-42 levels 
and AB plaque deposition by selectively modulating y-secretase activity (Eriksen et al., 
2003). In transgenic AD mice Flurizan™ reduces AB levels, and AB plaque load and 
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results in decreased memory and learning deficits (Kukar et _al., 2007), and in human 
trials Flurizan TM significantly improves cognitive function in mild AD subjects (Wilcock 
et al., 2005 presented at Alzheimer's Association International Conference on Prevention 
of Dementia). Two Ppase III clinical trials for Flurizan™ are now underway. Finally, 
ongoing research aimed at discovering or designing new more efficient secretase 
inhibitors is also providing some promising results in transgenic AD mice (Best et al., 
2007; Prasad et al., 2007). 
Statins are HMG Co-A reductase inhibitors that decrease de novo cholesterol synthesis, 
and are currently used to lower elevated low-density lipoprotein cholesterol levels. 
Epidemiology studies suggest that statins may also reduce the risk of dementia (Jick et 
al., 2000). Thus, several statins are currently in Phase II/III clinical trials for AD 
including atorvastatin, verivastatin, fluvastatin, lovastatin, pravastatin and simvastatin, 
and are thought to act by altering APP metabolism to reduce the production of A~ 
(Simons et al., 2002; Hoglund et al. 2005; Sparks et al., 2005). For example, simvastatin 
is hydrolysed in vivo to produce a metabolite that competes with HMG-CoA, which is a 
rate limiting enzyme for cholesterol synthesis, and simvastatin also inhibits both a- and 
~-secretase in the brain (Simons et al., 2002; Sjogren et al., 2003). However, Tg2576 
mice treated with simvastatin exhibit improvements in learning and memory, but no 
changes in the level of A~, or A~ plaques within their brains (Li et al., 2006). In 
addition, treating 19 human AD subjects with doses of simvastatin, which affects 
cholesterol metabolism in the CNS, for 12 months, did not significantly change 
cerebrospinal fluid A~ levels or cognition compared to untreated controls subjects 
(Hoglund et al. 2005). While a shorter term simvastatin treatment trial in human AD 
patients found no significant decrease in cerebrospinal fluid A~ levels overall, a subset 
of subjects with mild AD demonstrate a significant reduction in cerebrospinal fluid A~ 1-
40 levels (Simons et al., 2002). Similarly, heparins are generally utilised as anti-
coagulant agents, but heparins and related heparin oligosaccharides also inhibit 
proteoglycan assembly and have anti-inflammatory properties that may have beneficial 
effects in AD subjects (Ma et al., 2007b). For example, enozaparin, a low molecular 
weight heparin, significantly reduces A~ plaque load, and A~ 1-40 levels and the number 
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of activated astrocytes adjacent to AB plaques in transgenic AD mice (Bergamaschini et 
al., 2004). Finally, lithium is another therapeutic agent, commonly used for treatment of 
bipolar disorder, which is also currently under investigation for use as an AD 
therapeutic. Lithium reduces the activity of GSK3, which plays a role in tau 
phosphorylation and the regulation of APP processing (Engel et al., 2006; Caccamo et 
al., 2007; Rockenstein et al., 2007). Transgenic AD mice expressing mutated APP 
treated with lithium chloride display reduced GSK3B activity, APP phosphorylation and 
AB production, improved learning and memory, preserved dendritic structure and 
decreased tau hyperphosphorylation (Rockenstein et al., 2007). This study also suggests 
that lithium chloride may exert some of these positive effects by reducing GSK3B 
activity, which in turn modulates the processing of APP (Rockenstein et al., 2007). 
However, lithium administration to 3xTg-AD mice reduces tau phosphorylation, but 
does not reduce A~ plaque loads or improve memory function (Caccamo et al., 2007). 
In addition, early lithium administration to a tau-only transgenic mouse model can 
prevent NFT formation, but lithium treatment cannot alter existing NFTs (Engel et al., 
2006). 
1.9.6 Aggregation inhibitors 
Many approaches to A~ plaque prevention or removal are under investigation (Vickers 
et al., 2000; Ono et al., 2006). In fact, two AB aggregation inhibitors, AZD-103 
(Transition Therapeutics) and Alzhemed™ (Neurochem Inc.), are currently in Phase 1 
and Phase 3 human trials, respectively. Alzhemed™ is an orally bioavailable organic 
molecule that interferes with the association between glycosaminoglycans and Ap, can 
prevent the formation and deposition of fibrillar AP and also binds to soluble Ap. 
Other AP aggregation inhibitors are copper and zinc chelators. P-amyloid has both high 
and low affinity copper and zinc binding sites that affect its reversible precipitation into 
insoluble masses (Bush et al., 1994; Huang et al., 1997; Atwood et al., 1998) and the 
production of hydrogen peroxide that is mediated by redox-active metal ion and AP 
interactions (Cherny et al., 1999; Huang et al., ~999; Opazo et al., 2002). Two copper 
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and zinc chelators that inhibit zinc and copper induced Ap aggregation are now in 
clinical trails (Ritchie et al., 2003; PranaBiotechnology Limited). One such metal 
chelator is clioquinol (5-chloro-7-iodo-8-hydroxyquinoline), which significantly 
decreases AP plaque deposition in Tg2576 mice (Cherny et al., 2001). In addition, a 
small pilot Phase II clinical trial of clioquinol showed decreases in plasma AP 1-42 levels 
in the clioquinol treatment group compared to the placebo treated group, but a 
significant improvement in cognitive decline was only detected in severe AD subjects 
treated with clioquinol compared to severe AD placebo treated subjects (Ritchie et al., 
2003). Another metal chelator that is also currently in Phase II clinical trials is PBT2 
(Prana Biotechnology Ltd.). PBT2 is a small orally effective molecule that was 
designed to inhibit catalytic redox reactions by preventing AP from abnormally binding 
to copper, and the subsequent generation of hydrogen peroxide. Thus, PBT2 inhibits the 
redox-dependent formation of oligomeric Ap, prevents AP plaque deposition, improves 
cognitive performance in Tg2576 and APP/PS 1 mice and may promote normal copper 
and zinc homeostasis within the brain (Adlard et al., 2007 presented at the International 
Brain Research Organisation World Congress of Neuroscience; Finkelstein et al., 2007 
presented at the International Brain Research Organisation World Congress of 
Neuroscience). 
However, as other in vitro and in viva studies (Lambert et al., 1998; Hartley et al., 1999; 
Huang et al., 2006; Chauhan, 2007; Lacor et al., 2007; Matsayama et al., 2007) suggest 
that it is soluble AP assemblies that are toxic and cause behavioural deficits in AD, 
accelerating AP fibrilisation may be an alternative therapeutic intervention. Recent 
research suggests that increasing Ap fibrilisation reduces soluble AP levels and 
behavioural impairments in transgenic mice expressing human APP harbouring the 
Arctic mutation (Cheng et al., 2007). Additionally, if soluble AP is the toxic species of 
Ap, therapeutics that disaggregate and solubilise AP plaques on a large scale may have 
detrimental effects. For example, AD subjects in the clinical AN-1792 immunisation 
trial exhibit decreased parenchymal Ap plaques, but increases in soluble AP levels and 
vascular AP deposits compared to non-immunised AD subjects, suggesting that 
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immunisation disrupts AP plaques but vascular capture of AP prevented large scale 
removal of soluble AP from the brain (Patton et al., 2006). 
1.9. 7 Therapeutics that increase the clearance of AP 
Interest in immunotherapy for AD was ignited in 1999 when a paper by Schenk and 
colleagues was published, reporting the success of an active immunisation protocol in a 
mouse model of AD. In this study PD APP mice were immunised with A~ 1-42 and 
adjuvant at 11 months of age, when neuropathology is well established, resulting in a 
significant reduction in A~ burden, astrogliosis and neuritic pathology (Schenk et al., 
1999). A reduction of A~ levels, clearance or prevention of A~ plaques and associated 
neuritic dystrophy, astrogliosis and microgliosis have been replicated with varying 
degrees of success in many different AD mouse models (Table 1.2) using both active 
(Schenk et al., 1999; Janus et al., 2000; Sigurdsson et al., 2001; Bard et al., 2003; Das et 
al., 2003; Lemere et al., 2003; Zhang et al., 2003; Hara et al., 2004; Kim et al., 2004; 
Schultz et al., 2004; Bowers et al., 2005; Buttini et al., 2005; Frenkel et al., 2005) and 
passive (Bard et al., 2000; Bacskai et al., 2002; Chauhan and Siegel, 2003; Lombardo et 
al., 2003; Wilcock et al., 2003; Bussiere et al., 2004; Horikoshi et al., 2004; Oddo et al., 
2004; Wilcock et al., 2004; Brendza et al., 2005; Chauhan and Siegel, 2005; Hartman et 
al., 2005; Yamamoto et al., 2005; Levites et al., 2006) immunisation protocols. The 
memory and learning deficits associated with many transgenic mouse models of AD are 
also ameliorated by immunotherapy (Janus et al., 2000; Morgan et al., 2001; Dodart et 
al., 2002; Kotilinek et al., 2002; Wilcock et al., 2004; Billings et al., 2005; Hartman et 
al., 2005; Jensen et al., 2005; Lee et al., 2006). Interestingly, these documented 
improvements in functional memory may be due to the recovery of cellular dynamics 
and normal morphology in DNs following A~ plaque clearance (Lombardo et al., 2003; 
Oddo et al., 2004; Bussiere et al., 2004; Brendza et al., 2005). 
The success of A~ immunisation in terms of reduced A~ plaque burden, neurite 
dystrophism, reactive astrogliosis and microgliosis and positive functional outcomes in 
many different mouse models of AD captured corporate interest and Elan Corporation 
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and collaborators Wyeth-Ayerst initiated human trials with AN 1792, an aggregated 
human ABl-42 peptide, with QS-21 adjuvant. Although Phase 1 trials reported no ill 
effects of active immunisation with AN1792 (ABl-42 and QS-21 adjuvant) (Check, 
2002), the Phase 2A trial for therapy effectiveness was terminated when six percent of 
patients (18 of 298 treated with AN1792) developed aseptic meningoencephalitis 
(Orgogozo et al., 2003; Gilman et al., 2005). 
Despite this adverse reaction to active immunisation with AB in the human population, 
post-mortem analysis of three subjects from the AN1792 trial (two suffered 
meningoencephalitis) reveals widespread clearance of AB plaques and astrocyte clusters, 
variable clearance of tau-labelled DNs and amyloid angiopathy, but no reduction of 
NFfs or neuropil threads (Nicoll et al., 2003; Ferrer et al., 2004; Nicoll et al., 2006 
Bombois et al., 2007). Long-term follow-up studies on the AN1792 trial also show 
significantly lower cognitive decline and significantly higher quality of life scores in 
antibody responders (Hock et al., 2003; Gilman et al., 2005). Thus, interest in alternate 
active and passive immunisation regimes continues. 
The time-course of immunisation, route of administration and the antigen or antibody 
used for immunisation will all affect the immunological outcome. Interest in passive 
immunisation regimes continue with clinical trials currently in progress for several new 
therapeutic protocols including a 3D6-based antibody (Elan Pharmaceuticals/Wyeth), 
LY206430 the humanised version of m266 antibody that recognises AB16-23 (Eli Lilly 
and Co.) and !Vig, a mixture of purified polyclonal antibodies from blood donors 
(Baxter Bioscience; Dodel et al., 2004). Investigations into utilising shorter AB peptide 
immunogens or DNA encoding AB as an active immunogen are already underway and 
show promising results (Qu et al., 2004; Schultz et al., 2004; He et al., 2005; Maier et 
al., 2006; Okura et al., 2006). Additionally, immunising transgenic AD mice with viral 
vectors expressing AB peptides successfully decreases levels of AB plaque deposition in 
the brain and improves cognition function (Zhang et al., 2003; Hara et al., 2004; Kim et 
al., 2004; Bowers et al., 2005). Active immunotherapies including CAD106 
(Novartis/Cytos Biotechnology) and ACC-001 (Elan Pharmaceuticals/Wyeth) are also 
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currently undergoing human trials. CAD106 consists of the first six N-terminal amino 
acids of AB attached to a virus-like particle. Similarly, ACC-001 consists of an AB 
fragment attached to a conjugate carrier protein to aid the induction of an antibody 
response to AB. Immunotherapy undoubtedly results in the clearance of cerebral AB 
plaques and reductions in the AB plaque-associated neuritic dystrophy, astrogliosis, 
microgliosis and improved cognitive performance in transgenic mouse models of AD. 
However, the conversion of immunotherapy protocols that are effective in mice for 
human use may not be as simple as initially hoped. Therefore, it is important to keep 
exploring alternative interventions as AD therapeutics. 
Finally, therapeutics other than immunisation protocols that increase the clearance of AB 
are also being investigated (Leissring et al., 2003; Risner et al., 2006; Riddell et al., 
2007). Transgenic APP mice that also overexpress insulin-degrading enzyme or 
neprilysin, both of which degrade AB, exhibit reduced AB levels and AB plaque 
deposition (Leissring et al., 2003), providing proof of concept for therapeutics aimed at 
increasing endogenous enzymatic AB degradation. One such agent is T09013 l 7 is a 
liver X receptor agonist that is being investigated for its potential to increase AB 
clearance through the induction of genes involved in intracellular lipid transport and 
efflux (Riddell et al., 2007). T0901317 treatment decreases ABl-42 levels and memory 
deficits in Tg2576 mice, with no effects on the levels of full length APP, ABl-40 or 
other APP processing products, suggesting that T0901317 specifically increases AB 1-42 
clearance (Riddell et al., 2007). Finally, as there is an increased risk of developing AD 
in type 2 diabetes patients (Arvanitakis et al., 2004), and diet-induced insulin resistance 
in Tg2576 mice decreases insulin-degrading enzyme activity, increases y-secretase 
activity, memory deficits, AB levels and plaque load (Ho et al., 2004), rosiglitazone 
maleate, a nuclear hormone receptor peroxisome proliferator-activated receptor gamma 
agonist that is usually used to reduce blood glucose levels and hyperinsulineamia in 
diabetics, is currently in Phase III trails for use in AD subjects (GlaxoSmithKline). 
Rosaglitazone treatment in Tg2576 mice improves learning and memory, ameliorates 
reduced insulin-degrading enzyme activity, and decreases brain A~ levels without 
affecting AB plaque load (Pedersen et al., 2006). In humans rosaglitazone improves 
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cognition in a subset of human mild-moderate AD subjects that are apoe4 allele carriers 
(Risner et al., 2006). 
A better understanding of the link between A~ deposition and the neuronal pathology 
apparent in AD will lead to more effective treatment of the disease. Reducing the classic 
reactive changes of injured neurons, or inhibiting or encouraging the resolution of the 
regenerative responses exhibited by injured neurons may also be an approach that will 
reduce neurodegeneration in AD. However, successful application of such therapeutics 
in clinical settings would need to occur early in the disease process before substantial 
neuronal degeneration has occurred. The accurate diagnosis of preclinical AD cases 
prior to the clinical diagnosis of AD utilising a combined biomarker/imaging approach 
may soon be possible (as reviewed in Borroni et al., 2007; de Leon et al., 2007), due to 
improved technology, imaging techniques, the discovery of biomarkers, and the 
development of new labels for A~ and tau that can be used in vivo (Shoghi-Jadid et al., 
2002; Klunk et al., 2004; Mintun et al., 2006; Small et al., 2006; Klunk et al., 2007; 
Wierenga and Bondi, 2007). 
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1.10 PROJECT AIMS 
While the pathological hallmarks of AD and cellular pathways involved in the 
production, processing and functions of A~ and tau have been extensively investigated, 
the primary causative agent or mechanisms of AD are still unknown. In addition, the 
exact cellular pathways that link the development of A~ plaques, DNs, NFTs and 
neuropil threads to one another and to the neurodegeneration and neuronal loss 
characteristic of AD have not yet been elucidated. Examining the cellular and 
biochemical mechanisms that underlie the initiation and progression of AD is vital, not 
only for a complete understanding of the disease process, but also for the identification 
of targets for the development of effective treatments to stop or slow AD progression. 
Therefore, this thesis will investigate several aspects of the pathological changes leading 
to neuronal degep.eration in AD. 
Aiml 
To investigate the role of apoptosis in AD 
To date, the literature regarding the role of apoptosis in AD provides evidence both for 
and against apoptosis playing a major role in the progression and neurodegeneration that 
occurs in AD. Therefore, to clarify this contentious area of AD research, apoptotic 
nuclear morphology and a comprehensive set of apoptotic-related proteins will be 
examined via immunohistochemistry in human AD, preclinical AD and control cases. 
In addition, the levels of mRNA for apoptosis-related proteins will also be quantified in 
the same cohorts of cases. 
Aim2 
To examine the relationship between cytochrome c release and the pathological 
hallmarks of AD 
The release of cyto c from the mitochondria into the cytoplasm is indicative of the 
activation of apoptosis and/or mitochondrial damage or dysfunction. Although, cyto c 
has been previously reported to be present in a subset of DNs, the association of cyto c 
with the pathological hallmarks of AD, and its cellular localisation in this regard, 
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remains to be determined. Utilising immunohistochemical techniques the relationship 
between cyto c, including its cellular localisation, with AP plaques, DNs and NFTs will 
be assessed. In addition, cyto c localisation in relation to the staging of AD pathology 
will also be investigated. 
Aim3 
To determine whether the AP plaque-associated neuronal pathology in two transgenic 
AD mouse models more closely resembles that of human preclinical AD or AD cases 
The AP plaque-associated neuronal pathology in human preclinical AD cases differs 
from that in AD cases, suggesting that this neuronal pathology matures or develops as 
AD progresses. These experiments will seek to assess whether the AP plaque-associated 
neuronal pathology in two widely utilised transgenic AD mouse models, namely 
TgCRND8 and Tg2576 mice, mimic the pathology present in human preclinical AD or 
AD cases. Utilising immunohistochemistry, the percentage of neuritic AP plaques, the 
morphology of AP plaque-associated dendrites and the morphology and neurochemistry 
of DNs will be compared to that present in human preclinical AD and AD cases. 
Aim4 
To assess metallothionein isoform IIA as a potential therapeutic agent/or AD 
utilising a mouse model of AD 
The final aim of this thesis is to investigate the potential of metallothionein isoform IIA 
(MTIIA) as a therapeutic intervention of AD. Currently available therapeutics for the 
treatment of AD only address the disease's symptoms and do not affect disease 
progression. Thus, research into new therapeutic agents with potential modes of action 
that will inhibit or halt AD pathology is imperative. Metallothionein IIA is a small 
protein with neuroprotective, metal chelating and antioxidant properties that has 
previously improved outcomes in experimental models of CNS injury, multiple sclerosis 
and Parkinson' s disease. In these experiments MTIIA or saline solution will be 
administered to Tg2576 mice and the AP-labelled and thioflavine s-stained plaque loads 
and AP plaque-associated neuronal pathology will subsequently be assessed. 
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2 MATERIALS AND METHODS 
2.1 HUMAN BRAIN TISSUE SOURCES AND PROCESSING 
Human brain tissue was obtained from multiple sources: National Tissue Resource 
Centre, University of Melbourne (Australia), Sun Health Research Institute (Arizona, 
USA), National Health and Medical Research Council Brain Bank (Adelaide, Australia) 
and the Department of Pathology, University of Sydney (Australia), as previously 
described (Saunders et al., 1998; Dickson et al., 1999). Permission for brain autopsy and 
use for research were obtained by the original tissue sources, and the Tasmanian Human 
Research Ethics Committee approved all research. Blocks of cerebral cortex were 
immersion-fixed in paraformaldehyde or 10% buffered formalin or the brains were 
perfusion-fixed with either 2% picric acid or 4% paraformaldehyde. Blocks of cerebral 
cortex were cryoprotected in 18.0%, then 30.0% sucrose solution, embedded in Shandon 
cryomatrix tissue compound (Thermo Scientific, Runcorn, UK) and 40 micron sections 
of SFG and ITG were sectioned on a cryostat. 
Throughout this thesis a total of 20 AD cases, 11 preclinical AD cases and nine control 
cases were analysed (Table 2.1 ). No AD associated pathology was present in the control 
cases, which were of similar ages to AD and preclinical AD cases. The AD cases 
conform to the CERAD criteria, and demonstrate Braak stages V and VI pathology 
(Braak and Braak, 1991; Mirra et al., 1991). A subset of non-demented cases exist that 
exhibit signs of pathological aging that include widespread neocortical A~ plaques, but 
no 'classical' neurofibrillary pathology or overt nerve cell degeneration (Price and 
Morris, 1999; Vickers et al., 2000). Such pathologically aged cases correspond to Braak 
stage III pathology, and may represent a preclinical stage of AD. The preclinical AD 
cases do not conform to the CERAD criteria for the diagnosis of clinical AD, but exhibit 
Braak stage III pathology including widespread non-neuritic (based on thioflavin S or 
PHF-tau-labelling) A~ immunolabelled plaques in the neocortex and neurofibrillary 
pathology in the entorhinal formation and hippocampus (Braak and Braak, 1991; 
Vickers et al., 1996; Saunders et al., 1998). 
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Table 2.1 Human brain cases utilised for immunohistochemistry and analysis. 
Type Age Gender Postmortem Conical Pathological Source F1xat10n 
(~ears) mterval (h) re!l1on diall!!OSIS 
AD 60 M 64 5 ITG COAD NTRC 4%Para• 
AD 65 M 3 SFG,ITG AD NHMRC bram bank 2% p1cnc acid* 
AD 67 M 31 ITG Respiratory failure NTRC 4%Para* 
AD 67 M 61 ITG AD NHMRC bram bank 2% p1cnc acid• 
AD 71 F 13 SFG,ITG AD NHMRCbrambank 2% p1cnc acid* 
AD 72 F 4 SFG, ITG AD SHRI 4% Para• 
AD 73 M 65 SFG,ITG AD NHMRC bram bank 2%p1cnc acid* 
AD 73 M 35 ITG Pneumoma NHMRC bram bank 2% p1cnc acid* 
AD 74 F 2 SFG, ITG Pneumoma SHRI 4% Para* 
AD 74 M 2 75 SFG Respiratory failure, AD SHRI 4% Para* 
AD 76 F 26 SFG,ITG AD NHMRC bram bank 2% p1cnc acid* 
AD 79 M 24 ITG Respiratory failure NTRC 4% Para* 
AD 81 M 23 5 ITG Cardiac fatlure NTRC 4% Para• 
AD 83 M 2 83 SFG,ITG Dementia SHRI 4% Para* 
AD 83 F 5 ITG AD NHMRC bram bank 2% p1cnc acid* 
AD 84 F 3 SFG,ITG AD SHRI 4%Para• 
AD 84 F 16 5 lTG Cardiac failure NHMRC bram bank 2% p1cnc acid• 
AD 88 M 7 SFG,ITG Dementia SHRI 4%Para* 
AD 91 F 64 ITG Mahgnant mesothehoma NTRC 4%Para* 
AD 92 F 2 25 ITG Pneumoma SHRI 4%Para• 
Prechmcal AD 71 M 32 5 SFG Cardiac arrhythmia Um of Sydney 15% fonnalm* 
Prechmcal AD 74 M 31 5 ITG Cardiac fatlure NTRC 4%Para• 
Prechmcal AD 74 M 68 ITG Cardiac failure NTRC 4%Para* 
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Type Age Gender Postmortem Contcal Pathological Source F1xat10n 
{years) mterval (h) region dla!l!!OSIS 
Prechmcal AD 78 M 2 25 SFG Postoperative SHRI 4%Para• 
Prechmcal AD 81 F 3 SFG Cardiac arrest SHRI 4%Para• 
Prechmcal AD 82 M 48 5 ITG Cardiac mfarc!lon NTRC 4% Para• 
Prechmcal AD 82 M 50 ITG Cardiac fallure NTRC 4% Para• 
Prechmcal AD 84 M 3 SFG Card10puhnonary arrest SHRI 4% Para* 
Prechmcal AD 90 M 2 16 SFG Respiratory arrest SHRI 4%Para• 
Prechmcal AD 91 M 3 SFG Cardiac failure SHRI 4%Para• 
Prechmcal AD 91 M 48 ITG Renal fallure NTRC 4%Para• 
Control 47 M 27 5 SFG Cardiac mfarctton Um of Sydney 15% fonnalm* 
Control 51 M 23 3 SFG Pulmonary embolus Um of Sydney 15% fonnalm* 
Control 58 M 27 SFG Coronal}' disease Um of Sydney 15% fonnahn* 
Control 58 F 30 ITG Asthma NTRC 4% Para• 
Control 65 M 16 SFG Cardiac mfarctton Um of Sydney 15%fonnalm* 
Control 73 F 26 5 ITG Pulmonary Embohsm NTRC 4%Para* 
Control 77 M 53 5 ITG Cardiac fatlure NTRC 4%Para• 
Control 79 M 57 ITG Respiratory fallure NTRC 4%Para* 
Control 84 M 55 Cardiac mfarction NTRC 4%Para* 
NTRC, National Tissue Resource Centre, SHRI, Sun Health Research Instttute, Um of Sydney, Umvers1ty of Sydney, 4% para*, Immers10n fixed m 
4% parafonnaldehyde, 2% p1cnc acid, perfus10n fixed m 2% p1cnc acid, 10% fonnahn*, Immers10n fixed in 10% fonnahn 
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2.2 HISTOLOGICAL STAINS 
2.2.1 Thioflavine s-staining 
The tissue sections were placed in 0.0125% thioflavine s (Sigma, St Louis, MO) 
dissolved in 60% O.OlM phosphate buffered saline (PBS) and 40% ethanol for three 
minutes in the dark on an orbital shaker at room temperature (RT). Following 
differentiation: in two one minute incubations in 50:50 PBS:ethanol at RT in the dark, the 
tissue sections were washed three times with O.OIM PBS at RT in the dark on an orbital 
shaker. Thioflavine s stains a subset of plaques that contain fibrillar aggregates. 
2.2.2 Nuclear yellow-staining 
Tissue sections were incubated in 0.001% Nuclear Yellow (Sigma) in PBS for 30 
minutes in the dark at RT, on an orbital shaker. Tissue sections were then washed three 
times with O.OIM PBS for 10 minutes each, at RT on an orbital shaker. 
2.3 IMMUNOIDSTOCHEMISTRY 
2.3.1 Formic acid epitope exposure 
Tissue sections were incubated in 90% formic acid (Sigma) for 20 minutes at RT on an 
orbital shaker. Brain sections were then washed seven times with O.OIM PBS for 10 
minutes each, at RT on an orbital shaker. 
2.3.2 Autofluorescence quenching 
Brain sections were destained in 0.25% potassium permanganate for 20 minutes at RT 
on an orbital shaker and washed twice in O.OlM PBS for two minutes at RT. Brain 
sections were then de-labelled in 1.0% pot-metabisulphite and oxalic acid for one to two 
minutes. Tissue sections were then washed three times with O.OlM PBS for 10 minutes 
each, at RT on an orbital shaker. 
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2.3.3 Indirect fluorescent immunohistochemistry 
Brain tissue sections were incubated in primary antibody solutions for 16-72 hours at RT 
or at 4 °C (Table 2.2). Optimal antibody concentrations were individually determined for 
each antibody, and omitting primary antibodies eliminated all immunoreactivity. After 
three washes with O.OlM PBS for 10 minutes, each at RT on an orbital shaker, primary 
antibodies were exposed to Alexa Fluor goat anti-mouse/rabbit secondary antibodies for 
two hours at RT, on an orbital shaker in the dark (Table 2.3). All antibodies were 
diluted in 3.0% triton-X (Sigma) in O.OlM PBS to permeabilise the cell membranes. 
Tissue sections were then washed three times with O.OlM PBS for 10 minutes each at 
RT on an orbital shaker, and mounted onto microscope slides and coverslipped with 
permafluor aqueous mounting medium (Immunotech, Marseille, France). 
2.3.4 Antigen retrieval 
Brain sections were loaded into tissue cassettes, placed in O. lM citrate buffer (pH 6.0) 
and heated on high for 10 minutes in a conventional microwave oven (LG MS-314SCE, 
1000 watts). The tissue sections were then heated on high power for a further two and a 
half minutes and six minutes on medium power under pressure in a microwave tender 
cooker (Nordic ware, Minneapolis). The specimens were cooled to RT in citrate buffer 
before being transferred back into O.OlM PBS. Tissue sections were then removed from 
the tissue cassettes and washed three times with O.OlM PBS for 10 minutes each at RT 
on an orbital shaker. 
2.3.5 Indirect immunoperoxidase immunohistochemistry 
Brain sections were incubated in 1.0% hydrogen peroxide diluted in methanol for 15 
minutes at RT on an orbital shaker, washed three times with O.OlM PBS for 10 minutes 
each, at RT on an orbital shaker, then incubated in primary antibody solutions for two 
hours at RT on an orbital shaker, and then overnight at 4°C. The sections were then 
washed three times with O.OlM PBS for 10 minutes each, at RT on an orbital shaker, and 
incubated in goat anti-mouse/rabbit immunoglobulin horse-radish peroxidase 
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Table 2.2 Primary antibodies used for immunohistochemistry. 
Antibody name Type Immunoreactivity Dilution Sonrce 
anll-acltve caspase-3 R Pepllde from the p 18 fragment of I 250/ Promega (Madison, WI) 
of cleaved procaspase-3 I 500 
an11-act1ve caspase-8 M N-termmal region ofplO subumt I 100 Oncogene Research Products (San Diego, CA) 
of cleaved procaspase-8 
ant1-acllve caspase-9 R N-termmal reg10n of I OkDa I 200 B1osource Jnt (Camanllo, CA) 
fragment of autoacavated procaspase-9 
antt-a-mternexm M C-termmal of a-mternexm I 500 Chem1con (Temecula, CA) 
antt-a-mternexm R Whole a-mternexm protem I 500 Novus B1olog1cals (L11tleton, CO) 
anll-Bax R N-termmus of Bax I 200 Santa Cruz B1otechnology (Santa Cruz, CA) 
anti-Bcl-2 R N-termmus ofBcl-2 I 200 Santa Cruz B1otechnology (Santa Cruz, CA) 
an1t-NCL-p-arnyl01d M A site on P-arnylo1d peptlde I 500 Novocastra (Newcastle, UK) 
an1t-pan-P-arnyl01d R All P-amyl01d pepttdes I 1000 B1osource Int (Camanllo, CA) 
anll-calretnm R Calcmm-bound and unbound I 1000 Biosource lnt (Camartllo, CA) 
conformattons of calretnm 
ant1-chromogranm A R Large synapttc vesicles I 500 DAKO (Carpmtena, CA) 
antt-cytochrome c M CYtochrome c I 500 BD B10sc1ences Pharm1gen (Franklin Lakes, NJ) 
antl-femtm R Humanfemlln 1 2000 DAKO (Carpmtena, CA) 
anti-GFAP M Gita! fibnllary ac1d1c protem I 500 Chem1con lnt (Temecula, CA) 
ant1-MTI/JJ M MTiandMTII I 500 DAKO (Carpmtena, CA) 
ant1-MAP2 M M1crotubule associated protem 2 I 250 Chem1con Int (Temecula, CA) 
anti-ohgodendrocyte M Myelm/Ohgodendrocyte specific protein I 500 Chemicon Int (Temecula, CA) 
antt-SMI32 M Dephosphorylated NFM and NFH I 2000 Sternberger Monoclonals Inc (Lutherv1Jle, MD) 
anti-SMI312 M Phosphorylated NFM and NFH I 3000 Sternberger Monoclonals Inc (Lutherv1Jle, MD) 
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antt-hyperphosphorylated 
-tau 
anu-hwnan tau 
ant1-TRADD 
Type Immunoreactivity 
M Phosphorylated Ser202fThr205, S~r202/ 
Ser205 or Ser205/Ser208 of PHF-tau (ATS) 
R Phosphorylauon mdependent tau 
M C-termmal half ofTRADD 
M, mouse monoclonal anttbody, R, rabbit polyclonal anubody, MT, metallotluonem 
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Dilution Source 
I 500 Endogen (Wobum, MA) 
I 4000 DAKO (Carpmtena, CA) 
I 250 BD B10sc1ences Pharm1gen (Franklm Lakes, NJ) 
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Table 2.3 Fluorescent secondary antibodies utilised for indirect fluorescent 
immunohistochemistry. 
Emission (nm) Reactivity Species Dilution Supplier 
488 mouse lgG goat 1:500 Molecular Probes (Eugene, OR) 
594 mouse lgG goat 1:500 Molecular Probes (Eugene, OR) 
488 rabbit goat 1:500 Molecular Probes (Eugene, OR) 
594 rabbit goat 1:500 Molecular Probes (Eugene, OR) 
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(1 :200, DAKO) for one and a half hours at RT on an orbital shaker, followed by three 
washes with O.OlM PBS for 10 minutes each, at RT on an orbital shaker. All antibodies 
were diluted in 3.0% triton-X in O.OlM PBS to permeabilise the cell membranes. The 
Vectastain ABC Kit (Vector Laboratories, Burlingame, CA) was used for amplification 
via avidin/biotin according to manufacturers instructions. The primary antibody 
complex was visualised by a two to three minute incubation in Sigma Fast™ 3,3'-
Diaminobenzidine tablet set (Sigma) diluted in Milli-Q® water. The tissue sections were 
washed three times with O.OlM PBS for 10 minutes each, at RT on an orbital shaker 
mounted and left to dry overnight at RT. The mounted sections were then incubated in 
Milli-Q® water for 20 minutes at RT followed by three minute incubations in 70%, 90% 
and 100% ethanol. After 30 minutes in xylene at RT the tissue sections were 
coverslipped with pertex (Medite, Burgdorf, Germany). 
2.4 MICROSCOPY AND ANALYSIS 
Immunolabelled specimens were examined using a Leica DM LB2 immunofluorescence 
microscope or a Leica DMB IRB inverted fluorescence microscope. Images were 
acquired using a cooled CCD Magnafire (Optronics) digital camera and Magnafire 
(version 1.0) software. Image analysis, such as area quantitation, was performed using 
NIH ImageJ (version l.34s) software. Statistical analysis was performed in Microsoft 
Excel (Mac Os X) and Graphpad Prism4® software, with p values less than 0.05 (Cl 
95%) being considered statistically significant. Means were reported ± standard error of 
the mean (SEM). Graphs were prepared in Microsoft Excel or Prism (version 4.0c). 
Images for figures were prepared using Adobe Photoshop (version 9.0). 
All solutions are provided in full in Appendix 1. , 
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3 NO DIFFERENCE IN EXPRESSION OF APOPTOSIS-RELATED 
PROTEINS AND APOPTOTIC MORPHOLOGY IN CONTROL, 
PRECLINICAL ALZHEIMER'S DISEASE AND ALZHEIMER'S 
DISEASE CASES 
3.1 INTRODUCTION 
Apoptosis is a form of programmed cell death, which involves several pathways that 
result in the activation of caspases, and eventually cell death characterised by chromatin 
condensation, nuclear shrinkage, DNA fragmentation, cytoplasm condensation and 
disintegration. The search for signs of apoptosis including DNA fragmentation, frank 
apoptotic morphology, activated caspases, caspase cleavage products and changed levels 
of pro- and anti-apoptotic molecules in AD brains has produced contrasting and often 
conflicting results. The frequency of DNA fragmentation has been assessed in AD and 
control brains with reports of similar levels of DNA fragmentation in AD and control 
brains (Lucassen et al., 1997) or increased DNA fragmentation in AD brains (Smale et 
al., 1995; Cotman and Su, 1996; Lassmann, 1996; Troncoso et al., 1996; Lucassen et al., 
1997; Sugaya et al., 1997; Masliah et al., 1998; Stadelmann et al., 1998). Despite these 
reports of increased DNA fragmentation in AD brains, classical apoptotic morphology is 
seldom observed or not observed at all in AD (Lassmann et al., 1995; Troncoso et al., 
1996; Lucassen et al., 1997; Stadelmann et al., 1998; Jellinger and Stadelmann, 2000; 
Nunomura and Chiba, 2000; Raina et al., 2001; Raina et al., 2003). Such studies are 
further complicated by the fact that both DNA fragmentation and classical apoptotic 
morphology can occur independently of apoptosis (Raina et al., 2003; Tatton et al., 
2003). Additionally, many studies have reported an increase in the levels and/or 
numbers of cells containing anti-apoptotic Bcl-2 (Satou et al., 1995; Su et al., 1996b; 
Kitamura et al., 1998), pro-apoptotic Bax (Nagy and Esiri, 1997? Su et al., 1997; 
Giannakopolous et al., 1999), active caspase-3 (Stadelmann et al., 1999; Zhao et al., 
2003b), inactive and active caspase-8 (aC8, Rohn et al., 2001a; Pompl et al., 2003) and 
inactive and active caspase-9 (aC9, Rohn et al., 2002; Pompl et al., 2003) in AD brains 
compared to control brains, while others have not found increases in these proteins in 
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AD brains (MacGibbon et al., 1997; Nagy and Esiri, 1997; Kitamura et al., 1998; 
Stadelmann et al., 1998; Engidawork et al., 2001). 
To investigate whether apoptosis plays a major role in the pathological process of AD 
the presence of apoptotic-like nuclei and a comprehensive array of apoptosis-related 
proteins from both the death receptor and mitochondrial apoptotic pathways were 
assessed. Using immunohistochemistry and real time reverse transcriptase polymerase 
chain reaction (RT-PCR), both the SFG and ITG of AD and control brains were 
analysed. In addition to control and AD cases, apoptosis-related changes were also 
investigated in preclinical AD cases, as such preclinical cases may provide important 
clues to the initiation and progression of neuronal pathology (Benzing et al., 1993; Lue 
et al., 1996; Vickers et al., 1996). So far, few studies have investigated apoptosis in such 
preclinical and early AD cases (Su et al., 1997; Gastard et al., 2003; Zhao et al., 2003a; 
Zhao et al., 2003b; Albrecht et al., 2007; Christie et al., 2007). 
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3.2 MATERIALS AND METHODS 
3.2.1 Human brain tissue source and processing 
Human brain tissue was obtained from multiple sources: National Tissue Resource 
Centre, Sun Health Research Institute, National Health and Medical Research Council 
Brain Bank and the Department of Pathology, University of Sydney, as previously 
described (Section 2.1 ). 
3.2.2 Immunohistochemistry and analysis of apoptotic-like nuclei 
Fourteen AD cases (average age, age range; average postmortem interval, postmortem 
interval range 76.8, 65-92 years; 10.7, 2-61 hours; Table 3.1), six preclinical AD cases 
(82.5, 71-91 years; 7.7; 2.25-32.5 hours; Table 3.1) and four control cases (55.3, 47-65 
years; 23.5, 16-27.5 hours; Table 3.1) were stained with thioflavine s (Section 2.2.1) and 
Nuclear Yellow (Section 2.2.2). Cases were age and PMI matched as closely as 
possible, however, the age and PMI of control cases was significantly different when 
compared to AD cases, and the age of the control cases ~as also significantly different 
lower than preclinical cases (p <0.05). It was not possible to gender match between 
case types· due to the difficulty in obtaining appropriately fixed human brain tissue. 
Although there was no robust association between sex and the percentage of apoptotic 
nuclei, an interaction between these two factors cannot be discounted nor could it be 
statistically analysed with this sample of cases. Thioflavine s stains plaques that contain 
fibrillar aggregates. Additionally, the SFG neocortex of five AD, five preclinical AD 
and four control cases and the ITG of five AD cases were quenched (as per Section 
2.3.2), stained with thioflavine s (Section 2.2.1) and Nuclear Yellow (Section 2.2.2) and 
then immunolabelling for astrocytes ( anti-glial fibrillary acidic protein, GF AP), 
oligodendrocytes (anti-oligodendrocyte/myelin specific protein), microglia (anti-
ferritin), calretinin-labelled neurons or dephosphorylated NF triplet protein-labelled 
neurons (a pyramidal cell marker, see Kirkcaldie et al., 2002) and tau (Table 2.2) was 
performed as previously described (Section 2.3.3). Several AD brain tissue sections 
were also treated with 90% formic acid (Section 2.3.1) and labelled with rabbit anti-Af3 
(Table 2.2) instead of thioflavine s-staining to more clearly assess the association of 
nuclei with Af3 plaques. 
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Table 3.1 Human cases used for cell type specific apoptotic-like nuclei analysis 
Type Age Gender Postmortem Cortical Pathological 
(years) interval (h) region diagnosis 
AD 65 M 3 SFG, ITG AD 
AD 67 M 61 ITG AD 
AD 71 F 13 SFG, ITG AD 
AD 72 F 4 SFG, ITG AD 
AD 73 M 6.5 SFG, ITG AD 
AD 73 M 35 ITG Pneumonia 
AD 74 F 2 SFG, ITG Pneumonia 
AD 74 M 2.75 SFG Respiratory failure, AD 
AD 76 F 2.6 SFG, ITG AD 
AD 83 M 2.83 SFG, ITG Dementia 
AD 83 F 5 ITG AD 
AD 84 F 3 SFG, ITG AD 
AD 88 M 7 SFG, ITG Dementia 
AD 92 F 2.25 ITG Pneumonia 
Preclinical AD 71 M 32.5 SFG Cardiac arrhythmia 
Preclinical AD 78 M 2.25 SFG Postoperative 
Preclinical AD 81 F 3 SFG Cardiac arrest 
Preclinical AD 84 M 3 SFG Cardiopulmonary arrest 
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Type Age Gender Postmortem Cortical Pathological 
(years) interval (h) region diagnosis 
Preclinical AD 90 M 2.16 SFG Respiratory arrest 
Preclinical AD 91 M 3 SFG Cardiac failure 
Control 51 M 23.3 SFG Pulmonary embolus 
Control 58 M 27 SFG Coronary disease 
Control 65 M 16 SFG Cardiac infarction 
Control 47 M 27.5 SFG Cardiac infarction 
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To determine the percentage of abnormal nuclei present in pathology-rich cortical areas, 
images of five random fields of view in cortical layer III were captured at 40x in the 
SFG of six preclinical AD, six AD and four control cases and in the ITG of six AD, five 
preclinical AD and three control cases. Cases were selected based on optimal fixation 
conditions for Nuclear Yellow-staining. Normal and abnormal nuclei were counted, with 
apoptotic-like nuclei being defined as brightly fluorescent (indicating condensed 
chromatin), rounded, shrunken and/or fragmented nuclei (Tompkins et al., 1997; 
Verdageur et al., 2002; Conti et al., 2003; Roy and Sapolsky, 2003). To provide an 
indication of the severity of AD pathology, NFTs were counted in 10 randomly chosen 
fields of view in neocortical layer III of each case. Linear regression analysis was 
performed on the apoptotic nuclei, NFT load and postmortem interval data sets and no 
significant correlations were present. The nuclei of all tau-immunoreactive intracellular 
NFTs co-localised with dephosphorylated NF triplet protein-labelled neurons were also 
examined in the SFG and ITG of five AD cases. 
Additionally, blinded to case type, 100 astrocytes, microglia, calretinin- and 
dephosphorylated NF triplet protein-labelled neurons were counted in each case and any 
co-localisation with apoptotic nuclei was recorded. As oligodendrocyte-specific-
protein-labelling was often very dense in the outer neocortical layers quantitation of this 
cell type was not possible. 
3.2.3 Immunohistochemistry and analysis of apoptosis-related proteins 
To ascertain whether apoptotic pathways were activated in AD, sections from five AD 
(average age, age range, average postmortem interval, postmortem interval range; 76, 
60-91 years; 41, 23.5-64.5 hours), five preclinical AD (81, 74-91 years; 49, 31.5-68 
hours) and five control cases (74, 58-84 years; 44, 26.5-57 hours) underwent antigen 
retrieval (Section 2.3.4) and then immunohistochemistry for aC3, aC8, aC9, Bcl-2, Bax 
or TRADD (Table 2.2) using standard immunoperoxidase labelling techniques (Section 
2.3.5). The ages and PMis of control, preclinical AD and AD cases were not 
significantly different. It was not possible to gender match between case types due to 
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the difficulty in obtaining human brain tissue. Although there was no robust association 
between sex and the percentage of the levels of apoptotic-related proteins and real time 
RT-PCR analysis, an interaction between these two factors cannot be discounted. 
However, such an interaction could not be statistically analysed with the sample of cases 
used in the current study. To determine the identity of the aC3-labelled cells the SFG 
neocortex of five AD, five preclinical AD and four control cases and the ITG of five AD 
cases were also double labelled with aC3 and GF AP, using standard immunofluorescent 
labelling techniques (Section 2.3.2) and stained with Nuclear Yellow (Section 2.2.2). 
Whilst blinded to case type, each case was given a rating of 1-3 according to the amount 
of aC3-, aC8-, aC9-, Bcl-2-, Bax- or TRADD-labelling that was present in the neocortex 
in a similar way to previous studies (Lucassen et al., 1997; Stadelmann et al., 1998; Su 
et al., 2003). The tissue sections were then grouped into control, preclinical AD and AD 
cases and analysed by a one-way ANOV A with a Bonferroni post-hoe analysis. 
Following this, the brain sections were analysed for any change in the distribution of 
labelling for each apoptotic marker. 
3.2.4 RNA extraction and purification 
RNA was extracted from the frozen unfixed ITG neocortex of the same five AD 
(average age, age range, average postmortem interval, postmortem interval range; 76, 
60-91 years; 41, 23.5-64.5 hours), five preclinical AD (81, 74-91 years; 49, 31.5-68 
hours) and five control cases (74, 58-84 years; 44, 26.5-57 hours) that were 
immunolabelled for apoptotic related-proteins (Section 3.1.3). A thin slice of neocortex 
(0.04-0. lg) was taken from each case and the white matter and meninges were removed. 
RNA was extracted from the tissue samples using TRizol® reagent (lnvitrogen, Calsbad, 
CA) and then DNase treated with the DNA-free™ Kit (Ambicon, Austin, Texis) 
according to manufacturers instructions and stored at -80°C. The concentration and 
purity of the RNA solutions were determined by reading the optical density at 260 and 
280nm of each sample diluted in TE buffer (pH 8.0). When RNA was extracted twice 
from the same cerebellum sample and analysed by RT-PCR less than five percent 
variation was present in the Cr value. 
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3.2.5 Oligonucleotide primers 
The primer sequences used were as follows: Bax forward 5'-
ATCCAGGATCGAGCAGGGCG-3' and reverse 5'-ACTCGCTCAGCTTCTTGGTG-
3' (Billbault et al., 2004); Bcl-2 forward 5'-TGTGGCCTTCTTTGAGTTCG-3' and 
reverse 5'-GAAATCAAACAGAGGCCGCATG-3' (Sawa et al., 1997), TRADD 
forward 5'-CGGCTCCGGGATGAAGA-3'and reverse 5'-
GAGCCGCACTTCAGATTTCG- 3' (Lund et al., 2003); GAPDH forward 5'-
TTCATTGACCTCAACTAC-3 'and reverse 5' -GTGGCAGTGATGGCATGGAC-3' 
(designed on Primer Express Software; Applied Biosystems Inc. Foster City, CA) 
3.2.6 Real time RT-PCR 
Real time quantitative RT-PCR reactions were carried out using the Quantitect® SYBR® 
Green RT-PCR kit (Qiagen; Applied Biosystems Inc. Foster City, CA) in a 1 Oµl volume 
on a Rotor-gene 2000 (Corbett Research, Mortlake, NSW, Australia). All reactions were 
performed in duplicate with a no template control. The RT-PCR conditions for GAPDH 
and TRADD were 50°C for 30 min, 95°C for 15 min, followed by 40 cycles of 94°C for 
15s, 55°C for 20s and 72°C for 20s. Whereas, the RT-PCR conditions for Bcl-2 and 
Bax were 50°C for 30 min, 95°C for 15 min followed by 40 cycles of 94°C for 15s, 
50°C for 20s and 72°C for 20s. The fluorescence was recorded during the elongation 
phase of each PCR cycle. A melt curve from 65-95°C was also performed at the end of 
each RT-PCR run to ensure that no primer dimers were present in the reaction products. 
A standard curve was prepared using real time RT-PCR products derived from cDNA 
for each primer set to ensure that the reaction was efficient over the range of 
concentrations present in the RNA samples. Briefly, real time RT-PCR products were 
run on a 2.5% agarose gel with a lOObp DNA Ladder (New England Biolabs, Herts, 
UK). The bands were photographed and excised under a UV transilluminator and 
cDNA was extracted with a QIAquick® gel extraction kit (Qiagen, Clifford Hill, 
Victoria, Australia) according to the manufacturer's protocol. A serial dilution of the 
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extracted cDNA was prepared for each primer set to create a RT-PCR cDNA standard 
curve. A standard curve was also prepared for each primer set using serial dilutions of 
brain RNA to ensure that the amount of RNA added to each RT-PCR reaction was not 
inhibiting the efficiency of the RT-PCR reaction. 
The CT values of all samples for the Bax, Bcl-2 and TRADD primer sets were 
normalised to GAPDH by dividing the CT value of the gene of interest by the CT value 
of GAPDH for each sample. GAPDH was used as the housekeeping gene as it was 
similarly expressed in control and AD brains (Gutala and Reddy, 2004). The GAPDH 
normalised CT values for each gene of interest in preclinical AD- and AD-samples were 
then divided by the average CT value of the control samples and expressed as a 
percentage of the average control value. The data was analysed using a one-way 
ANOV A with a Bonferroni post-hoe analysis. When linear regression analysis was 
performed no significant correlation was present between postmortem interval and Bax, 
Bcl-2 and TRADD mRNA levels. In addition, no real time RT-PCR for caspases-3, -8 
and -9 was performed as they are constitutively present as zymogens within cells, and as 
there was no qualitative correlation with amount of active caspase-3, -8 and -9 
immunolabelling with case types, the unfixed frozen human brain tissue, which was a 
highly limited resource, was not utilised to determine caspase activity levels. 
77 
Chapter 3 - Results 
3.3 RESULTS 
3.3.1 Apoptotic-like nuclei and cell type in AD, preclinical AD and control 
brains 
To assess the rate of apoptosis in AD, preclinical AD and control brains the percentage 
of apoptotic-like nuclei in neocortical layer III was investigated (Figure 3.lA). 
Statistical analysis demonstrated similar levels of apoptotic-like nuclei in neocortical 
layer III of the ITG in control and preclinical AD brains with significantly more 
abnormal nuclei in control cases than AD cases (p = < 0.05; Figure 3.lA). Additionally, 
the AD and preclinical AD cases had a significantly higher percentage of abnormal 
nuclei in cortical layer III in the SFG than in the ITG (p = < 0.05). In layer III of the 
ITG the percentages of cells with apoptotic-like nuclei in AD, preclinical AD and 
control cases were 4.72% ± 0.28, 5.20% ± 0.69 and 6.72% ± 0.59, respectively (Figure 
3.lA). In layer III of the SFG 7.35% ± 0.69, 8.02% ± 0.49 and 8.13% ± 0.69 of cells 
were apoptotic-like in AD, preclinical AD and control cases, respectively (Figure 3. lA). 
The percentages of apoptotic nuclei in neocortical areas did not correlate with the 
postmortem intervals or age of the analysed cases (p > 0.05), and was not associated 
with particular modes or causes of death. 
With specific reference to the hallmarks of AD, there was a significant negative 
correlation between the average number of NFTs in neocortical layer III and the 
percentage of apoptotic-like nuclei present (p = < 0.05, Figure 3.lB). In addition none 
of the dephosphorylated NF triplet protein-labelled NFT-bearing neurons (n=142) 
observed in the SFG and ITG of five AD cases had apoptotic-like nuclei, indicating that 
NFT-bearing neurons do not account for a high proportion of cells with apoptotic-like 
nuclei (Figure 3.lC-H). Nuclei observed adjacent to AP plaques and nuclei enveloped 
within AP plaque's fibrils were almost always non-apoptotic (Figure 3.11-J). 
To determine what type of cell exhibited apoptotic-like nuclei, GF AP, ferritin, calretinin, 
dephosphorylated NF triplet protein, and oligodendrocyte/myelin specific protein-
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Figure 3.1 
The percentage of apoptotic-like nuclei were not significantly different in neocortical 
layer III of the SFG in AD, preclinical AD and control cases or in the ITG of control and 
preclinical AD cases. Bar graph showing the percentage of apoptotic-like nuclei in 
neocortical layer III of the ITG and SFG of control, preclinical AD and AD cases (A:* p 
<0.001 ** p <0.01; error bars indicate SEM). Line graph demonstrating the significant 
negative correlation that was present when the average number of NFTs present per field 
of view in neocortical layer III of the SFG and ITG of each AD case were plotted against 
the average percentage of apoptotic-like nuclei present in neocortical layer III of each 
AD case (B p = <0.001; R2 = 0.7058). Panels C-H show typical NFT-bearing neurons. 
None of the Nuclear Yellow-stained nuclei (arrows, C, F) of dephosphorylated NF 
triplet protein-labelled neurons (D, G) bearing tau-labelled intracellular NFTs (E, H) 
were apoptotic-like. I and J show Nuclear Yellow-stained nuclei (arrows, I) relative to a 
A~-labelled plaque (J), such nuclei almost always had normal morphology. Scale bar: 
C-H = 20µm; I-J = lOµm. 
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labelling was undertaken in conjunction with Nuclear Yellow-staining to identify 
astrocytes, microglia, calretinin-labelled neurons, dephosphorylated NF triplet protein-
labelled neurons and oligodendrocytes, respectively (Figure 3.2). Frank nuclear 
apoptotic changes were largely restricted to astrocytes and microglia rather than 
calretinin- and dephosphorylated NF triplet protein-labelled neurons in AD, preclinical 
AD and control cases (Table 3.2). Apoptotic-like nuclei were consistently associated 
with abnormal cellular morphology (Figure 3.2). 
3.3.2 Active-caspase-3-, active caspase-8-, active caspase-9-, Bax-, Bcl-2- and 
TRADD-labelling in AD, preclinical AD and control brains 
The labelling of several apoptotic markers across AD, preclinical AD and control cases 
was also investigated. No increased labelling of any marker or different cortical or 
cellular labelling pattern that distinguished between case categories was present. When 
analysed blind to case type, there was no difference in the frequency of TRADD-, pro-
apoptotic aC3-, aC8-, aC9- and Bax- and anti-apoptotic Bcl-2-labelling between control, 
preclinical AD or AD cases (Table 3.3). There was also no association between 
increased labelling of these apoptotic markers and the postmortem interval of each case 
(Table 3.3). Bax, Bcl-2, aC8, aC9 and TRADD immunohistochemical labelling were 
present in the soma of both pyramidal and non-pyramidal cells and were cytoplasmic 
apart from the granular labelling of TRADD (Figure 3.3). Bax, Bcl-2 aC8, aC9 and 
TRADD immunostaining was present in the proximal region of the apical dendrites of 
some pyramidal cells and aC9-, Bax- and TRADD-labelling also extended into the basal 
dendrites of some pyramidal cells (Figure 3.3). Active caspase-3-labelling was also 
cytoplasmic, but in contrast to the other apoptotic-related proteins, aC3-labelled the 
soma of glial cells (Figure 3.4). Active caspase-3-labelling co-localised with GFAP 
(Figure 3.4). Additionally, co-staining with Nuclear Yellow demonstrated that the 
nuclei of> 95% of aC3-labelled cells were not apoptotic-like. 
Active caspase-9-labelling was observed throughout neocortical layers II-VI with an 
increased number of labelled cells in layers III and V in all cases. Similarly, Bcl-2 
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Figure 3.2 
There was no significant difference in the percentage of astrocytes, microglia and 
neuronal subsets with apoptotic-like nuclei in the neocortex of control, preclinical AD 
and AD cases. Apoptotic-like nuclei were defined as brightly fluorescent, rounded, 
shrunken (arrow, C) and/or fragmented (arrow, D) nuclei. All of the dephosphorylated 
NF triplet protein-labelled neurons (A) and most of the ferritin-labelled microglia (E), 
GF AP-labelled astrocytes (I), oligodendrocytes (M) and calretinin-labelled neurons (Q) 
had normal nuclei (arrows, B, F, J, N, R, respectively) and cellular morphology (A, E, I, 
M, Q, respectively) in the neocortex. The small percentage of microglia, astrocytes, 
oligodendrocytes and calretinin-labelled neurons with apoptotic-like nuclei (arrows, H, 
L, P, T, respectively) also exhibited abnormal cellular morphology (G, K, O, S, 
respectively) characterised by cytoplasmic shrinkage. Scale bar: A-B = 5µm; C-T = 
lOµm. 

Figure 3.3 
No robust changes in the labelling of apoptotic-markers were present in the neocortex of 
control, preclinical AD and AD cases. Labelling for TRADD (A), aC8 (B), aC9 (C), 
Bax (D) and Bcl-2 (E) in neocortical layer III of all case types was somatic and present 
in both pyramidal and non-pyramidal cells. Labelling of all the apoptotic markers often 
extended into the proximal apical dendrites (arrows) of pyramidal cells. While TRADD-, 
aC9- and Bax-labelling was also observed to extend into the basal dendrites (arrow 
heads) of pyramidal cells. The laminar distribution of TRADD (F), aC9, Bax and Bcl-2 
were similar in most of the cases examined, and exhibited an increased density of 
labelling in neocortical layers III and V. Scale bar: A-E = 45µm; F = lOOµm. 

Figure 3.4 
Labelling for aC3 in neocortical layer III of all case types was cytoplasmic (A) and 
present in glial cells (arrows). Active caspase-3-labelling (B) co-localised with GFAP 
(C) and extended into the processes (arrows) of most aC3-labelled cells. The laminar 
distribution of aC3-labelling was homologous (D) throughout neocortical layers I-VI in 
most cases. WM= white matter Scale bar: A= l 70µm; B-C = 25µm; D = 330µm. 
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Table 3.2 The percentage of astrocytes, microglia and neurons labelled with calretinin 
or dephosphorylated NF triplet proteins with apoptotic like-nuclei in layer III of the 
neocortex. 
Astrocytes Microglia Neurons Neurons 
(GFAP-labelled) (ferritin-Iabelled) (calretinin-labelled) (dephosphorylated NF 
tri(!let (!rotein-labelled} 
ADSFG 0.6 ± 0.4 0.8±0.6 0.0±0.0 0.0±0.0 
Preclinical AD SFG 1.2 ±0.7 0.2±0.2 0.0±0.0 0.0±0.0 
Control SFG 0.75 ± 0.5 0.5 ± 0.3 0.3 ±0.2 0.0±0.0 
ADITG 1.0 ±0.3 1.4±0.6 0.0±0.0 0.0±0.0 
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Table 3.3 
extraction. 
Human brain cases used for analysis of apoptotic markers and RNA 
Type Age Gender PMI Pathological Immunohistochemical staining for: 
(years) (h) Diagnosis Active caspase-8 Active caspase-9 Active caspase-3 Bax Bcl-2 TRADD 
AD 60 M 645 COAD + + ++ + ++ +++ 
AD 67 M 31 Resptrat01y failure +++ ++ +++ + + + 
AD 79 M 24 Resptratory fatlure ++ +++ +++ +++ + + 
AD 81 M 235 Cardrnc failure +++ ++ + +++ ++ +++ 
AD 91 F 64 Malignant mesothehoma + +++ +++ + +++ + 
Prechrucal AD 74 M 31 5 Cardiac fatlure + ++ ++ + +++ ++ 
Prechrucal AD 74 M 68 Cardiac failure ++ + ++ ++ ++ ++ 
Prechmcal AD 82 M 485 Cardiac mfarctton +++ +++ + + + +++ 
Prechrucal AD 82 M 50 Cardiac frulure + +++ +++ ++ + +++ 
Prechruca! AD 91 M 48 Renal fatlure ++ ++ + +++ + + 
Control 58 F 30 Asthma +++ ++ ++ ++ + ++ 
Control 73 F 265 Pulmonary Embolism +++ + ++ + ++ +++ 
Control 77 M 53 5 Cardiac failure +++ ++ + +++ +++ +++ 
Control 79 M 57 Resptratory fatlure + + +++ ++ +++ ++ 
Control 84 M 55 Cardiac mfarct1on ++ +++ + ++ ++ + 
PM!, postmortem mterval 
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labelling was present in neocortical layers I-VI and the density of labelled cells was 
increased in layers III and V in most cases. Bax immunoreactivity was distributed 
throughout neocortical layers II-VI with an increased density of labelled cells in 
neocortical layer III in most cases. TRADD immunoreactivity was also observed in 
neocortical layers II-VI and an increase in the number of TRADD-labelled cells was 
present in layers III and V in some cases (Figure 3.3F). In contrast, aC8-labelling was 
homologous throughout neocortical layers III-VI in all cases, while aC3-labelling was 
homologous throughout layers I-VI in most cases. The density of Bcl-2, aC9 and 
TRADD-labelling in neocortical layers III and V was variable, being higher in layer III 
than in layer V in some cases and higher in layer V than in layer III in others .. 
3.3.3 Real time RT-PCR analysis of Bax, Bcl-2 and TRADD in AD, preclinical 
AD, and control cases 
To confirm the immunohistochemical observations of apoptotic markers in the 
preclinical AD, AD and control brains, the mRNA levels of Bax, Bcl-2 and TRADD 
were analysed in the same set of cases. No dramatic changes in the expression of these 
three genes were found, although there was a trend of reduced expression of each gene 
(relative to GAPDH) in AD brains compared to control brains that attained statistical 
significance in the case of Bcl-2 (Figure 3.5). No difference in Bcl-2 mRNA levels were 
present between control and preclinical AD cases, but there was a small but significant 
decrease in Bcl-2 mRNA in AD cases to 92.4% of control levels when control and 
preclinical AD cases were compared to AD cases (Figure 3.5, p = < 0.05). 
When analysed by real time RT-PCR, the mRNA levels of Bax were decreased to 98.4 ± 
2.6% and 94.9 ± 1.3% of control Bax levels in preclinical AD and AD cases, 
respectively (Figure 3.5). The levels of Bcl-2 mRNA was decreased to 92.4 ± 1.8% of 
control levels in AD cases, while the level of Bcl-2 mRNA in preclinical AD cases was 
increased to 100.1 ± 1. 7% of control Bcl-2 levels. TRADD mR_NA levels were 
decreased to 98.0 ± 3.0% and 93.3 ± 2.3% of control TRADD levels in preclinical AD 
and AD cases, respectively (Figure 3.5). 
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Figure 3.5 
There was little difference between Bax, Blc-2 and TRADD mRNA levels in control, 
preclinical AD and AD cases. Bar graph showing the percentage change of Bax, Bcl-2 
and TRADD mRNA extracted from the ITG neocortex in preclinical AD and AD cases 
compared to the control cases.* p<0.05. Error bars indicate SEM. 
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3.4 DISCUSSION 
Using a combination of immunohistochemical and molecular techniques, the degree of 
apoptosis in AD, preclinical AD, and contra.I brains was investigated. Overall there were 
no robust changes in the presence of apoptotic-related proteins or in the percentage of 
apoptotic nuclei between control and AD cases. Analysis of the preclinical cohort of 
cases also showed no obvious increases or decreases in apoptotic markers or apoptotic-
like nuclei. These results suggest that there is no staging of apoptotic changes in AD 
and that apoptosis does not play a major role in AD pathogenesis, although apoptosis 
may still be involved in AD-associated neurodegeneration. 
Unlike previous studies (Satou et al., 1995; MacGibbon et al., 1997; Nagy and Esiri, 
1997; Su et al., 1997; Kitamura et al., 1998; Giannakopolous et al., 1999; Rohn et al., 
2001a; Rohn et al., 2002; Zhao et al., 2003b; Del Villar and Miller, 2004), the current 
investigation assessed a wide range of apoptotic-markers including aC3, aC8, aC9, Bax, 
Bcl-2 and TRADD in the same set of control, AD and preclinical AD cases and 
observed no consistent alterations in the frequency, or cortical and cellular localisation 
of labelling between case types. Although, a few research groups have reported similar 
levels of Bax (Kitamura et al., 1998) and Bcl-2 (Nagy and Esiri, 1997; Stadelmann et al., 
1998) in AD and control brains. Additionally, the unique ability to analyse the same 
cohort of control, preclinical AD and AD cases by real time RT-PCR provided data that 
supported the immunohistochemical results. No major change in the expression of Bax, 
Bcl-2 and TRADD mRNA levels were detected apart from significant small decrease of 
Bcl-2 mRNA to 92.4% of control levels. The importance of the small decrease in Bcl-2 
mRNA is difficult to assess as these results represent a contribution from all expressing 
cells in the neocortex and are influenced by the progressive neuronal loss and increasing 
numbers of reactive astrocytes and activated microglia in the cortex in AD (Schechter et 
al., 1981; Hof et al., 1990; Szpak et al., 2001). 
Abnormal nuclei were distributed amongst glial cell types and the calretinin-labelled 
subset of neurons (Sampson et al., 1997), and labelling for aC8, aC9, Bax, Bcl-2 and 
TRADD were also present in glia and neurons in all case types. However, there were no 
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significant differences in apoptotic marker labelling or the rate of apoptosis of 
astrocytes, microglia and calretinin- and dephosphorylated NF triplet protein-labelled 
neurons between AD, preclinical AD and control cases. These results elaborate on 
previous reports of DNA fragmentation (Smale et al., 1995; Troncoso et al., 1996; 
Lucassen et al., 1997; Sugaya et al., 1997; Masliah et al., 1998; Jellinger and 
Stadelmann, 2001; Kobayashi et al., 2002; Kobayashi et al., 2004) and apoptotic-related 
proteins (MacGibbon et al., 1997; Nagy and Esiri, 1997; Su et al., 1997; Kitamura et al., 
1998; Masliah et al., 1998; Stadelmann et al., 1999; Su et al., 2002; Zhao et al., 2003a; 
Zhao et al., 2003b) localised in glia and neurons in control and AD cases. The cellular 
and cortical localisation and clear labelling of pyramidal cells in neocortical layers III 
and V observed for Bax, Bcl-2, aC8, aC9 and TRADD was similar to reports in previous 
studies (MacGibbon et al., 1997; Su et al., 1997; Masliah et al., 1998; Rohn et al., 
200la; Rohn et al., 2002; Su et al., 2002; Zhao et al., 2003a), and may indicate that the 
pyramidal subset of neurons are especially vulnerable to molecular and mechanical 
insults. However, despite pyramidal neurons being selectively vulnerable to 
degeneration in AD (Hof et al., 1990; Hof, 1997) and clearly immunolabelled for 
apoptotic-related proteins, both dephosphorylated NF triplet protein-labelled pyramidal 
cells and calretinin-labelled intemeurons rarely co-localised with apoptotic-like nuclei in 
any case type. Stadelmann et al. (1999) have previously documented aC3-labelling in 
' 
approximately 1 in 1100 to 5000 neurons in the hippocampal formation of AD cases but 
not controls cases. Similarly, using the same antibody as the present study, Gastard et 
al. (2003) described aC3-labelling in the entorhinal cortex and the hippocampus. In 
contrast, the current study determined that aC3-labelling in two neocortical areas was 
associated with glial cells and not neurons, with glial cells similarly demonstrating a 
higher percentage of apoptotic-like nuclei than the calretinin- and dephosphorylated NF 
triplet protein-labelled neurons in all case types. Indeed, no pyramidal or non-pyramidal 
neurons were detected in the neocortex labelled with these markers with frank nuclear 
changes indicative of apoptosis in any AD or preclinical AD cases, indicating a 
frequency of apoptosis much less in the neocortex than in the hippocampal formation 
(Stadelmann et al., 1999). This may reflect a differential staging of the disease between 
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these brain regions, with the hippocampal formation and entorhinal cortex demonstrating 
substantial pathology much earlier than the neocortex (reviewed in Vickers et al. 2000). 
The low percentage of apoptotic nuclei present in neocortical layer III of the ITG and 
SFG in control, preclinical AD and AD cases confirms previous qualitative reports of 
classic apoptotic morphology being seldom observed in AD brains (Lassmann et al., 
1995; Troncoso et al., 1996; Lucassen et al., 1997; Stadelmann et al., 1998; Jellinger and 
Stadelmann, 2000; Nunomura and Chiba, 2000; Raina et al., 2003). The percentage of 
apoptotic nuclei in each case demonstrated no relationship with postmortem intervals. 
Unexpectedly, the percentage of apoptotic-like nuclei was significantly increased by 
2.0% in control cases compared to AD cases in the ITG. Statistical analysis also showed 
that the SFG of AD and preclinical AD cases had a significantly higher percentage of 
abnormal nuclei in cortical layer III than the ITG. Additionally, there was also an 
inverse correlation between NFT quantity and apoptotic nuclei. This result was 
unanticipated as the ITG typically has more NFT-bearing neurons than the SFG (Braak 
and Braak, 1991; Vickers et al., 2003). Finally, there was no clear association between 
the apoptotic profile of cases relative to the mode or cause of death. However, it cannot 
be ruled out definitively as to whether variance in premortem illness or agonal state may 
underlie the small differences between control brains and cases showing AD-related 
pathology. Cardiac and respiratory failures were relatively more common in the control 
cases, raising the possibility of brain ischemia contributing to these differences. 
Conversely, given that the frank apoptotic pathology is restricted to glial cell types, these 
data may indicate a lower degree of normal turnover of these cells in response to active 
neurodegeneration in AD cases. 
The lack of any specific co-localisation of apoptotic-like nuclei with pathological 
hallmarks of AD such as NFTs or AP plaques is a striking finding (Troncoso et al., 
1996; Lucassen et al., 1997; Sugaya et al., 1997; Broe et al., 2001). The paucity of 
apoptotic-like nuclei within or adjacent to AP plaques provides some in vivo evidence 
against the proposition that AP plaques are toxic to surrounding neurons. Surprisingly 
early- (Figure 3.lC-E) and late-stage (Figure 3.lF-H) NFTs were not co-localised with 
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apoptotic-like nuclei. In conjunction with reports that most neocortical NFTs in AD are 
intracellular (Sampson et al., 1997; Vickers et al., 2003) and recent evidence that NFTs 
in experimental models do not directly correlate with neuronal loss (Andorfer et al., 
2005; Santacruz et al., 2005), these findings suggest that affected neurons may be able 
to withstand NFT formation for long periods of time before frank degeneration occurs 
(as reviewed by Jellinger and Stadelmann, 2001). However, one apoptosis related 
protein, cyto c, has been observed in a subset of neurons that exhibit pre-NFTs and a 
subset of AP plaque-associated DNs in AD cases (Blanchard et al., 2003). 
The variability, discrepancies and contradictions present in the literature, including the 
data generated in the current study, regarding apoptotic nuclear morphology, DNA 
fragmentation and the level of apoptotic markers in AD and healthy control brains may 
be the result of different cerebral areas and cell populations being analysed, the different 
molecular and immunohistochemical techniques and/or antibodies used and even 
differences between fixation methods or the exact cohort of brain cases analysed ( eg. 
Table 1.3). Thus, this comprehensive analysis of several apoptotic-related proteins via 
immunohistochemistry and real time RT-PCR, apoptotic morphology and the 
association of apoptotic morphology with the pathological hallmarks of AD in a 
substantial sample of control, preclinical AD aild AD cases has notably contributed to 
this contentious area of AD research. 
In summary, there were no significant differences in the incidence of apoptotic nuclear 
morphology and apoptotic markers at the cellular and gene expression level, present in 
control, preclinical AD and AD brains. These data suggest apoptosis may not play a 
major role in the pathogenesis or widespread neuronal loss that occurs in AD. 
c Furthermore, as the underlying cause of neuronal loss and the final pathway to cell death 
in AD are yet to be fully elucidated, expanding our knowledge of the cellular processes 
involved in AD progression that ultimately lead to the dysfunction and loss of nerve 
cells may be vital for the discovery or design of effective therapeutic agents for AD and 
other neurodegenerative diseases. 
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4 CYTOPLASMIC CYTOCHROME C IMMUNOLABELLING IN 
DYSTROPHIC NEURITES IN ALZHEIMER'S DISEASE 
4.1 INTRODUCTION 
Cytochrome c has a well-established role in electron transfer and as a mediator of 
apoptotic cell death. The release of cyto c occurs upon activation of the intrinsic 
apoptotic pathway, which is regulated by cytokines and other death-survival signals (as 
reviewed in Adams and Cory, 2001). Although cyto c release is indicative of the 
activation of the intrinsic apoptotic pathway, it may also indicate mitochondrial damage 
or dysfunction. Additionally, such cyto c release from mitochondria correlates with 
disease progression in transgenic mouse models of Huntington's disease and 
amyotrophic lateral sclerosis (Zhu et al., 2002; Wang et al., 2003b). Following release 
into the cytoplasm, cyto c is able to interact with Apaf-1, dA TP and caspase-9 to form 
the apoptosome complex, which results in the activation of caspase-9 and the subsequent 
activation of effector caspases. In addition to cyto c playing a role in apoptosis, 
increased cyto c levels and the release of cyto c from mitochondria are also associated 
with mitochondrial damage and dysfunction, both of which may occur in association 
with oxidative stress in normal aging and AD progression (Gibson et al., 2000; Hirai et 
al., 2001; Pollack et al., 2002; Manczak et al., 2005; Sullivan and Brown, 2005; 
Manczak et al., 2006). 
Thus, the correlation between cyto c-labelling and AD staging including the pathological 
hallmarks of AD has been further investigated, with particular reference to the 
intracellular localisation of cyto c. Using double-label fluorescence 
immunohistochemistry, the location of cyto c relative to the specific pathological 
hallmarks of AD, such as NFTs, DNs and A~ plaques, were investigated in human 
control, preclinical AD and AD cases. 
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4.2 MATERIALS AND METHODS 
4.2.1 Tissue source and processing 
Human brain tissue was acquired from two sources: the Sun Health Research Institute 
and the University of Sydney, as previously described (Section 2.1 ). These samples 
included sections of the SFG from four control cases (average age, age range, average 
postmortem interval, postmortem interval range; 55.25, 47-65, 23.45, 16-27.5; Table 
4.1), six preclinical AD cases (82.5, 71-91, 3-32.5, 7.65; Table 4.1) and six AD cases 
(82.5, 74-92, 3.3, 2.0-7.0; Table 4.1 ). The control cases exhibited significantly different 
~ 
ages and PMis when compared to the preclnical AD and AD cases, largely due to the 
rarity of healthy aged brain material. It was also not possible to gender match between 
case types due to the difficulty in obtaining human brain tissue. Although there was no 
robust association between sex and the number of cytochrome c-labelled cells in the 
neocortex, an interaction between these two factors cannot be discounted nor could it be 
statistically analysed with this sample of cases. 
4.2.2 Immunohistochemistry 
The SFG of six AD cases, six preclinical AD cases and four control cases were double-
immunolabelled for cyto c and human-tau, A~, NFM or chromogranin A (CgA) (Table 
2.2) as previously described (Section 2.3.3). All cases were selected based on optimal 
fixation conditions for cyto c and NFM or CgA-labelling. Tissue sections were viewed 
on a Leica DMLB2 microscope with images captured on an Optronics Magnafire cooled 
CCD camera, as well as an Optiscan F900e krypton/argon confocal scanning system 
attached to an Olympus BX50 epifluorescence microscope. 
' 
4.2.3 Qualitative, quantitative and statistical analysis 
Alzheimer's disease, preclinical AD and control tissue sections were analysed for any 
change in the cellular or neocortical distribution of cyto c-labelling. To determine the 
density of cyto c-labelled cells, images of 10 non-overlapping random fields of view in 
neocortical layer V were captured at 20x. For quantitation of the coexistence of 
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Table 4.1 Human cases used for cyto c double-labelling immunohistochemistry. 
Type Age Gender Postmortem Pathological 
(years) interval (h) Diagnosis 
AD 74 F 2 Pneumonia 
AD 74 M 2.75 Respiratory failure, AD 
AD 83 M 2.83 Dementia 
AD 84 F 3 AD 
AD 88 M 7 Dementia 
AD 92 F 2.25 Pneumonia 
Preclinical AD 71 M 32.5 Cardiac arrhythmia 
Preclinical AD 78 M 2.25 Postoperative 
Preclinical AD 81 F 3 Cardiac arrest 
Preclinical AD 84 M 3 Cardiopulmonary arrest 
Preclinical AD 90 M 2.16 Respiratory arrest 
Preclinical AD 91 M 3 Cardiac failure 
Control 47 M 27.5 Cardiac infarction 
Control 51 M 23.3 Pulmonary embolus 
Control 58 M 27 Coronary disease 
Control 65 M 16 Cardiac infarction 
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cytoskeletal and synaptic elements and cyto c in DNs 100 Ap plaques were analysed in 
the SFG of six AD cases and five preclinical AD cases. However, due to the presence of 
limited AP plaque numbers in some preclinical AD cases, 85 AP plaques were analysed 
for the co-localisation of CgA and cyto 'c in DNs across preclinical AD cases. Co-
localisation of cyto c immunoreactivity and NFTs was also assessed by analysing 100 
NFTs in the SFG of AD cases. The percentage of NFM, tau and CgA DNs, as well as 
NFTs, that co-localised with cyto c immunolabelling were calculated and all quantitative 
data was analysed by a two tailed t-test (two sample unequal variance) or a one-way 
ANOV A with a Bonferroni post-hoe analysis. Linear regression analysis was performed 
on the average number of cyto c-labelled cells, age and postmortem interval data and no 
significant correlations were present. 
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4.3 RESULTS 
4.3.1 Cellular and neocortical distribution of cyto c 
There were no changes in the cellular and neocortical localisation of cyto c between AD, 
preclinical AD and control cases examined in this study (Figure 4.1). In control, 
preclinical AD and AD cases cytochrome c-labelling was present in cells in neocortical 
layers II-VI, with a robust increase in the density of labelled cells in layers III and V 
(Figure 4. lA,B). In neocortical layers III and V, high levels of cyto c-labelling were 
present in a subset of pyramidal neurons in all case types (Figure 4.1 ). Clusters of cyto 
c-labelled pyramidal neurons (Figure 4.lC) were present in numerous cases across all 
case types, but were not specifically associated with AP plaques in preclinical AD and 
AD cases (Figure 4. lD). Cytochrome c immunolabelling was punctate and somatic, 
with labelling observed in the proximal portion of many cellular processes and 
extending into the distal regions of several processes in control, preclinical AD and AD 
cases (Figure 4. lE). Importantly, when cyto c-labelling was investigated utilising 
confocal microscopy across all case types, none of the cyto c-labelled cells observed 
exhibited non-punctate cytoplasmic staining, indicating that cyto c had not been released 
from mitochondria. The density of cyto c-labelled cells in neocortical layer V of the 
SFG did not differ significantly (p > 0.05) between case types (Figure 4. lF). The 
average number of cyto c-labelled cells did not correlate with the age or postmortem 
intervals (p > 0.05) or the particular modes or causes of death of the analysed cases. 
4.3.2 Co-localisation of cyto c and AD-associated pathology 
Analysis of cyto c immunoreactivity in relation to the pathological hallmarks of AD 
resulted in the detection of subsets of cyto c-labelled NFTs and DNs. The percentage of 
NFT-bearing neurons that were immunoreactive for cyto c in the neocortex of the SFG 
of AD cases was 6.7 ± 1.4% (Figure 4.2A). Moreover, cyto c-labelling was punctate in 
NFT-bearing neurons (Figure 4.2B,C) when assessed by scanning confocal microscopy. 
Similarly, a small percentage of tau-, NFM- and CgA-labelled DNs were also 
immunoreactive for cyto c in AD and preclinical AD cases (Figure 4.3, Table 4:2). In 
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Figure 4.1 
The cortical and cellular distribution of cyto c-labelling was not substantially different 
between control, preclinical AD and AD cases. Cytochrome c-labelled cells were 
present at an increased density in layers III and V (A, layer III shown here). 
Cytochrome c-labelled cells were present at a lower density in other neocortical layers, 
such as layer II (B). Clusters of intensely labelled pyramidal neurons (arrows) in layer 
V of an AD case (C). Such clusters of cyto c-labelled neurons were evident in layers III 
and V of the neocortex in several cases. These clusters of intensely cyto c-labelled 
(green) pyramidal neurons (D, arrows) were not specifically associated with A~ plaques 
(red, arrow heads). High magnification confocal microscopy confirmed that the cyto c-
labelling present in neocortical cells was punctate (E). Bar graph demonstrating the 
average number of cytochrome-c-labelled cells per sample field of view in layer V 
across case types (F). There was no significant difference between the average number 
of cyto c-labelled cells in layer V of the SFG in control, AD or preclinical AD cases. 
Error bars indicate SEM. Scale bar: A, B, D = 40µm, C = 200µm, E = 14µm. 
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Figure 4.2 
In AD cases cyto c immunolabelling was present in a subset ofNFT-bearing neurons. A 
low percentage of tau-labelled NFTs (A, red, arrowheads) co-localised with cyto c-
immunoreactivity (green, arrow). When observed with high magnification confocal 
' 
microscopy NFT-bearing neurons (arrows) exhibited punctate cyto c-labelling (B, C). 
Scale bar: A= lOµm, B, C = lµm. 

Figure 4.3 
The cyto c-immunoreactivity present in DNs was often diffuse and co-localised with a 
subset of tau-, NFM- and CgA-labelled DNs. Cytochrome c-labelled DNs (A, arrows) 
were seldom co-localised with the tau-labelled DNs (B, arrow heads), when 
representative images were overlayed (C). Cytochrome c-labelling (D) was observed in 
a small percentage of NFM-labelled DNs (E, arrows), including some NFM-labelled 
DNs with a cyto c-immunoreactive central core (F, arrow head). Some cyto c-
immunoreactivity (G) present within DNs (arrows) was punctate and also co-localised 
with a subset of CgA-labelled DNs (H, arrows), when representative images were 
overlayed (1). Scale bar = 11 µm. 
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AD cases, an appreciably lower 'percentage of tau-labelled DNs co-localised with cyto c 
compared to NFM- and CgA-labelled DNs (Table 4.2). There was also a trend towards 
a lower percentage ofNFM- and OgA-labelled DNs co-localising with cyto c in the SFG 
of AD cases compared to preclinical AD cases (Table 4.2). Tau-immunoreactive DNs 
were not present in the preclinical AD cases. Cytochrome c-labelled DNs were present 
in a subset of DN clusters and exhibited two generalised morphological variants. In AD 
and preclinical AD cases, bulbar cyto c-labelled DNs of variable sizes were observed 
most frequently, while elongated cyto c-labelled DNs were seldom observed (Figure 
4.3). Additionally, NFM-labelled DNs with extensive cyto c-labelled central elements 
or caps of cyto c immunoreactivity were also present (Figure 4.3B). Strikingly, when 
cyto c-labelled DNs were examined using confocal scanning microscopy the labelling 
present was frequently cytoplasmic and not punctate (Figure 4.3). 
92 
Chapter 4 - Results 
Table 4.2 Co-localisation between cytoskeletal and synaptic markers and cyto c in AP 
plaque-associated DNs. 
Labelling 
Tau with cyto c 
NFM with cyto c 
CgA with cyto c 
mean % co-localisation± SEM 
Preclinical AD 
3.63 ± 0.67 
4.87 ± 0.55 
93 
AD 
1.44 ± 0.36 
2.66 ± 0.76 
2.55 ± 0.36 
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4.4 DISCUSSION 
Cytochrome c-labelling was substantial in a subset of cortical neurons, with no 
difference in the cortical labelling pattern or the density of cyto c-labelled cells observed 
in control, preclinical AD and AD cases. Similar levels of cyto c have also been 
documented in the frontal cortex of AD and control cases using molecular methods 
(Engidawork et al., 2001), although one recent study reported increased cyto c 
immunolabelling within cortical neurons in AD compared to control cases (Blanchard et 
al., 2003). In this and previous studies, punctate cyto c immunoreactivity was observed 
in a subset of cortical cells (Blanchard et al., 2003; Manczak et al., 2005). However, the 
subset of robustly cyto c-labelled pyramidal neurons in neocortical layers Ill and V are 
described in the current study for the first time. These intensely labelled pyramidal 
neurons often occurred in clusters in layers III and V of the neocortex in all case types, 
and were independent of the presence of A~ plaques. Similar clustering of pyramidal 
neurons labelled with NF triplet protein is observed in the cortex of monkeys, and may 
represent functional modules of neurons whose axons are bundled together (Peters and 
Sethares, 1996; Peters et al., 1997). Thus, cyto c-labelling may prove to be a useful 
neurochemical marker for layer V pyramidal neurons or a particular subset of clustered 
pyramidal neurons (Molnar and Cheung, 2006). 
Punctate cellular cyto c-labelling was observed in a subset of cortical neurons including 
both intensely labelled pyramidal neurons and NFf -bearing neurons. Given that 62-
74% of NFfs in the SFG are intracellular (Vickers et al., 2003), the cyto c-labelled 
neurons bearing NFfs represent a small minority of the total proportion of intracellular 
NFfs. Furthermore, the cyto c-labelling that co-localised with NFfs was punctate, 
indicating that NFf formation does not induce cyto c release and that NFf s may be only 
mildly detrimental to the health of NFf-bearing neurons. Thus, cyto c may label a 
subset of pyramidal neurons that demonstrate some capacity for NFf formation, but are 
relatively resistant to degeneration once NFf formation has initiated. Additionally, 
increased levels of cyto c are present in the neuronal soma and proximal processes 
following a variety of in vivo experimental insults (Martin and Liu, 2002; Benjelloun et 
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al., 2003; Page et al., 2003), suggesting that cyto c may be upregulated in compromised 
neurons as a sequela of AD associated pathology, possibly prior to NFf formation. 
Cytochrome c immunolabelling was also frequently cytoplasmic within DNs in both 
preclinical AD and AD cases. Cytochrome c immunoreactivity is typically punctate and 
represents localisation to the mitochondria. Thus, evenly distributed cytoplasmic 
labelling may be indicative of cyto c release. Such cyto c release is present in CNS 
neurons in vivo following ischaemia, axotomy, contusion and traumatic axonal injury 
(Springer et al., 1999; Biiki et al., 2000; Martin and Liu, 2002; Benjelloun et al., 2003; 
Cheung et al., 2003; Wingrave et al., 2003; Domaiiksa-Janik et al., 2004; Zhao et al., 
2005). Additionally, the cyto c release in DNs indicates the possible activation of 
apoptotic pathways. Although Bax, aC8 and aC9 immunoreactivity are also present in 
DNs (MacGibbon et al., 1997; Nagy and Esiri, 1997; Tortosa et al., 1998; Rohn et al., 
2002; Blanchard et al., 2003), aC3 has not been observed in DNs in AD cases to date, 
further supporting the proposition that activation of proteins with a role in apoptotic 
pathways does not necessarily translate into the execution of apoptosis (as discussed in 
Section 3.3). Furthermore, the presence of diffuse cyto c-labelling in DNs, but not in 
neuronal perikaryon in this study may imply discrete activation of apoptotic pathways 
that is reminiscent of the cyto c release observed in axonal segments, but not in the 
corresponding cell bodies, following axonal injury (Biiki et al., 2000). 
Many overlapping subsets of DNs are described that exhibit immunoreactivity for NF 
triplet proteins, a-intemexin, APP, CgA and tau (Masliah et al., 1993; Su et al., 1996a; 
Vickers et al., 1996; Su et al., 1998; Dickson et al., 1999; Dickson et al., 2005). 
Differences in the complement of epitopes in DN s in preclinical AD cases compared to 
AD cases has lead to the suggestion that DNs mature; developing from APP, NF triplet 
protein- and a-intemexin-labelled DNs into tau-labelled DNs (Su et al., 1996a; Su et al., 
1998; Dickson et al., 1999; Dickson et al., 2005). In contrast to APP and NF triplet 
proteins, CgA is rarely co-localised with tau or NF triplet protein epitopes in DNs and 
may represent a form of reactive sprouting and synaptogenesis in these neurites 
(Dickson et al., 1999). Although cyto c-labelled DNs have previously been observed in 
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a subset of A~ plaques in the human neocortex and the hippocampus and neocortex of 
various AD mouse models (Blanchard et al., 2003), there was no data on the co-
localisation of cyto c with other DN markers. As NFM, CgA and tau label three 
predominant but overlapping subgroups of DN s (Su et al., 1998; Dickson et al., 1999), 
the co-localisation of these three DN markers and cyto c immunoreactivity was assessed. 
Cytochrome c-labelling co-localised with a reasonably low percentage of tau-, NFM-
and CgA-labelled DNs, indicating that cyto c was present within DNs at various stages 
of maturation, including the potentially reactively sprouting CgA-labelled DNs (Dickson 
et al., 1999). However, as cyto c immunoreactivity co-localised with a considerably 
lower percentage of tau-labelled DNs than with NFM- and CgA-labelled DNs, and a 
higher percentage of CgA- and NFM-labelled DNs were co-localised with cyto c in the 
preclinical AD cases compared to AD cases, cyto c-labelling may be a relatively early 
and transient alteration in DN maturation. Similarly, in transgenic mouse models of AD 
the density of cyto c-labelled DNs increases progressively with age until the later stages 
of disease progression, at which point the density of cyto c immunoreactive DN s decline 
(Blanchard et al., 2003). Continuing to study disease progression is crucial for attaining 
a better understanding of the pathological processes that occur in AD, and may lead to 
the discovery of novel therapeutic targets. 
Thus, the punctate cyto c-labelling observed in a subset ofneocortical neurons and NFTs 
suggests that cyto c may label a subset of neurons susceptible to NFT formation, but 
resistant to subsequent degeneration. Cytochrome c may well be a transient marker of 
early DNs, while the release of cyto c in a subset ofDNs may be a sign of mitochondrial 
damage or dysfunction that could potentially activate apoptotic pathways. 
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5 13-AMYLOID PLAQUE-INDUCED AXONAL PATHOLOGY IN 
TRANSGENIC MICE EXPRESSING HUMAN MUTANT 13-AMYLOID 
PRECURSOR PROTEIN GENES REPLICATES THE DYSTROPHIC 
NEURITE CHARACTERISTICS OF PRECLINICAL ALZHEIMER'S 
DISEASE 
5.1 INTRODUCTION 
Investigating the key pathological changes that occur as AD develops in order to identify 
primary causative factors has been difficult as postmortem human brain material 
provides only snap shots of disease progression. However, the use of transgenic mouse 
models of AD enables both potential therapeutics for AD, and aspects of age-associated 
disease progression to be investigated. 
Transgenic mouse models of AD expressing human APP alone or in combination with 
PS1/PS2 harbouring mutations associated with familial AD, exhibit AP plaques and 
DNs, but not NFT pathology or extensive neuronal death (Games et al., 1995; Hsiao et 
al., 1996; Sturchler-Pierrat et al., 1997; Mucke et al., 2000; Chishti et al., 2001; Richards 
et al., 2003; Cheng et al., 2004). Tg2576 and TgCRND8 mice are two widely utilised 
mouse models of AD. Tg2576 mice exhibit AP plaque deposition beginning at seven 
months of age that progressively increases until severe pathology is present at 23 months 
of age (Hsiao et al., 1996; Kawarabayashi et al., 2001; Noda-Saita et al., 2004), while 
TgCRND8 demonstrate AP plaques at three months of age and DNs at five months of 
age ( Chishti et al., 2001; Duda! et al., 2004). 
The morphological and biochemical characteristics of DNs differ between preclinical 
AD and AD cases. Preclinical AD cases exhibit tortuous DNs as well as ring- and bulb-
like DNs, which label with antibodies to NF triplet proteins and a-intemexin, but are 
rarely labelled for abnormal tau protein (Cras et al., 1991; Benzing et al., 1993; Masliah 
et al., 1993; Su et al., 1996a; Vickers et al., 1996; Su et al., 1998; Dickson et al., 1999; 
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Dickson and Vickers, 2001; Dickson et al., 2005). Whereas, AD cases demonstrate 
bulb-like DNs that are immunolabelled for NF triplet proteins and a-intemexin, 
numerous a-intemexin immunoreactive ring-like DNs and classical elongated tau-
labelled DNs (Dickson et al., 1999; Dickson et al., 2005). 
Animal models are an invaluable tool for assessing the aging-related progression of 
diseases such as AD, and also for testing potential therapeutics for human disease. 
However, for animal models to be used effectively, a clear understanding of the 
pathological processes that they model is needed. In the current study, AP plaque-
associated neuronal pathology in Tg2576 and TgCRND8 mice was investigated with a 
specific focus on the morphological and neurochemical phenotype of AP plaque-
associated DNs. Specifically, the neuronal pathology associated with AP plaques in the 
transgenic AD mouse models was strikingly similar to that present in preclinical AD 
cases. The current investigation also indicates that the earliest AP plaque-associated 
neuronal alterations were the perturbation of NF triplet proteins and a-intemexin in 
DNs. The results of this study suggest that transgenic AD mice represent an accurate 
and valuable model of the early pathological changes present in human AD. 
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5.2 MATERIALS AND METHODS 
5.2.1 Tissue source and processing 
As previously described (Section 2.1 ), human brain tissue was acquired from the Sun 
Health Research Institute and the National Health and Medical Research Council Brain 
Bank. Human cases include the ITG of seven AD cases (average age, age range; 
average postmortem interval, postmortem interval range: 79.5, 71-88 years; 7.5, 2.0-16.5 
hours; Table 5.1) and the ITG of five preclinical AD cases (84.8, 78-91 years; 2.7, 2.3-
3.0 hours; Table 5.1). There was no significant difference between the ages of the 
preclinical AD and AD cases, but the PMls of the preclinical AD cases were 
significantly lower than those of the AD cases. It was not possible to gender match 
between case types due to the difficulty in obtaining precious human brain tissue. There 
was no robust association between sex and the percentage of neuritic plaques and there 
was no difference in DN phenotype between male and female cases, however, an 
interaction between sex and these two factors cannot be discounted nor could it be 
statistically analysed with this sample of cases. 
A young cohort of 10 TgCRND8 mice expressing human APP695 harbouring the 
Swedish (KM670/671NL) and Indiana (V717F) mutations under the control of the 
Syrian hamster prion promoter on a hybrid C3H/He-C57BL/6 background (Chishti et al., 
2001) and eleven age-matched wild type control mice were sacrificed at an early-
pathology time point of 1.86-2.94 months of age. Similarly, an aged cohort consisting 
of eleven TgCRND8 mice and nine age-matched wild type controls were sacrificed at 
7.5-8.91 months of age, a time point at which extensive pathology had developed. 
TgCRND8 mice were anaesthetised with 140mg/kg sodium pentobarbitone (Virbac, 
Peakhurst, Australia) and transcardially perfused (cold O.OlM PBS) and the left 
hemispheres were immersion-fixed in 4.0% paraformaldehyde. In addition, six 13 
month-old Tg2576 mice expressing human APP695 harbouring the Swedish 
(KM670/671NL) familial AD mutation on a C57BL/6 and SJL hybrid background 
(Hsiao et al., 1996) and five age-matched wild type control mice were anaesthetised with 
sodium pentobarbitone and transcardially perfused (4% paraformaldehyde/O.OlM PBS) 
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Table 5.1 Human cases used for immunohistochemistry and DN analysis. 
Type Age Gender Postmortem Pathological 
(years) interval (h) Diagnosis 
Preclinical AD 78 M 2.25 Post-operative 
Preclinical AD 81 F 3 Cardiac arrest 
Preclinical AD 84 M 3 Cardiopulmonary arrest 
Preclinical AD 90 M 2.16 Respiratory arrest 
Preclinical AD 91 M 3 Cardiac failure 
AD 71 F 13 AD 
AD 73 M 6.5 AD 
AD 74 F 2 Pneumonia 
AD 83 M 2.83 AD 
AD 83 F 5 AD 
AD 84 F 16.5 Cardiac failure 
AD 88 M 7 Cardiac failure 
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at 13 months-of-age. Only a 13 month old cohort of Tg2576 mice was studied due to 
restrictions with mouse numbers, a time point at which substantial pathology is present 
in this mouse model (Kawarabayashi et al., 2001). The University of Tasmania Animal 
Research Ethics Committee approved all animal research included in this thesis. 
Following cryoprotection, (Section 2.1) 40µm coronal sections were cut on a cryostat. 
5.2.2 Immunohistochemistry and analysis 
To investigate the pathology present in the two transgenic mouse models of AD in 
comparison to human AD, the percentage of AB plaques that were neuritic was assessed. 
Thus, the ITG of five preclinical AD and five AD cases, all TgCRND8 and Tg2576 mice 
and their age-matched wild type control mouse cases were treated with formic acid 
(Section 2.3.1) and double labelled with antibodies to AB and a-intemexin (Table 2.2). 
In addition, the aged TgCRND8 mice and human preclinical AD and AD cases were 
also stained with thioflavine s (Section 2.2.1) and labelled for a-intemexin. Double 
labelling fluorescent immunohistochemistry was performed as previously described 
(Section 2.3.3), except that secondary fluorescent antibodies were used at a dilution of 
1:1000. One hundred neocortical Aj)-labelled and 100 thioflavine s-stained plaques per 
case/animal were analysed for the presence of a-intemexin-labelled dystrophic neurite 
clusters in the neocortex of aged TgCRND8 mice, and in the neocortex of the ITG of 
five human preclinical AD and five AD cases. The human ITG was selected for analysis 
of AB plaque deposition due to the abundance of plaques in this region in both 
preclinical AD and end-stage AD cases. The whole of the neocortex was used for mouse 
studies, as there was no predilection of AB plaques to particular cortical sub-regions in 
these animals, as compared to human cases. P-amyloid plaques were selected for 
analysis by examining non-overlapping vertical strips of neocortex from the pia to the 
white matter, up to a total of 100 plaques per case/animal. Analysis was performed for 
both AB immunolabelling and thioflavine s-staining as they label two subsets of plaques; 
specifically thioflavine s stains fibrillar aggregates within plaques, whereas the anti-AB 
antibody labels both fibrillar and non-fibrillar Ap. Alpha-intemexin was utilised as a 
DN marker for this analysis as a-intemexin-labelled DNs are present in most DN 
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clusters (Dickson et al., 2005). No quantitative analysis was performed on the Tg2576 
mouse tissue due to the low AP plaque load present. All quantitative data was analysed 
by a one-way ANOV A with a Bonferroni post-hoe analysis. 
To compare the morphological and neurochemical characteristics of DNs in the 
transgenic AD mice with the human disease, the Tg2576 mice, aged TgCRND8 mice 
and human cases were also double labelled with combinations of mouse anti-a-
intemexin, -dephosphorylated NF triplet protein, -phosphorylated NF triplet protein, and 
-hyperphosphorylated-tau (phosphorylation at either Ser202/Thr205, Ser202/Ser205 or 
Ser205/Ser208) for axons, dendritic anti-MAP2 and rabbit anti-Ap, as well as rabbit anti 
-a-intemexin and -NFM antibodies (Table 2.2). Sections from the young cohort of 
TgCRND8 mice were also double labelled with a-intemexin and dephosphorylated NF 
triplet protein. P-amyloid plaques were examined for the presence of bulb- and ring-like 
immunolabelled DNs throughout the neocortical laminae in the ITG of human cases, and 
throughout the neocortical laminae and hippocampus of the transgenic mice. With 
respect to neurofilament and a-intemexin immunolabelling, bulb-like DNs are bulbar 
axonal swellings whereas ring-like DNs are spherical structures with an unlabelled 
hollow core (Dickson et al., 1999). 
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5.3 RESULTS 
5.3.1 P-amyloid deposition and DN distribution in Tg2576 and TgCRND8 
mice 
As previously reported (Hsiao et al., 1996; Irizarry et al., 1997; Chishti et al., 2001; 
Kawarabayashi et al., 2001; Le et al., 2001; Tomidokoro et al., Dudal et al., 2004), both 
transgenic lines of AD mice exhibited AP plaques and DNs throughout the 
hippocampus, cortex, corpus callosum, and also in the striatum of TgCRND8 mice. 
Approximately 80-98% of AP plaques in aged TgCRND8 mice and Tg2576 mice were 
associated with clusters of dephosphorylated NF triplet protein-, phosphorylated NF 
triplet protein-, NFM-, and a-intemexin-labelled DNs (Figure 5.1 ). The non-neuritic AP 
plaques in aged TgCRND8 mice were generally small and not fibrillar. In Tg2576 mice, 
few non-neuritic AP plaques were observed. There were also occasional clusters of 
NFM-, phosphorylated NF triplet protein-, and a-intemexin-labelled DNs present in the 
absence of AP-labelling in aged TgCRND8 mice, but none were observed in Tg2576 
mice. 
Additionally, nine of the eleven young TgCRND8 mice demonstrated AP plaques, 
including a wide range of AP plaque deposition, with AP plaques being observed within 
the hippocampus and cerebral cortex, but rarely in the striatum. A few of the young 
TgCRND8 mice exhibited AP plaque deposition that was approximately equivalent to 
that in some 13 month old Tg2576 mice, however, the AP plaque deposition in 13 month 
old Tg2576 mice generally fell between that present in the young and aged TgCRND8 
mice. Approximately 80-98% of AP plaques in the young TgCRND8 mice were 
associated with a-intemexin- and dephosphorylated NF triplet protein-labelled DNs. 
None of the age-matched wild type controls for the Tg2576 or TgCRND8 mice 
exhibited AP immunoreactivity or DN clusters labelled for a-intemexin. 
All aged TgCRND8 mice demonstrated amyloid angiopathy, which was occasionally 
associated with thickened and bulb-like a-intemexin-labelled DNs (Figure 5.2A). 
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Approximately 80-98% of A~ plaques in both transgenic mouse models were associated 
with clusters of NFM-, and a-internexin-labelled DNs. Images of the TgCRND8 (A) 
and Tg2576 (B) neocortex double-labelled for A~ (red, A, B) and a-internexin (green, 
A) or NFM (green, B) show numerous A~ plaques co-localised with DN clusters 
(arrows). Some amyloid angiopathy (arrow heads) was also present that was not 
associated with DNs. Scale bar= SOµm. 

Figure 5.2 
B-amyloid plaques caused neuropil disruption in both TgCRND8 and Tg2576 transgenic 
mice. Alpha-internexin-labelled DNs (green, arrows) were associated with B-amyloid-
labelled amyloid angiopathy (red) in both aged TgCRND8 (A) and Tg2576 (B) mice. 
MAP2-labelled dendrites (green) appeared to bend (arrows) around AB plaques (red, C) 
and a-internexin-labelled DN clusters (red, D) in both Tg2576 (C) and TgCRND8 (D) 
mice. In addition, MAP-2-labelled dendrites (green) often appeared to terminate 
(arrows) at the margins of AB plaques (red, E) and a-internexin-labelled DN clusters 
(red, F) in both Tg2576 (E) and TgCRND8 (F) mice. Scale bar: A,B = 5µm, C-F = 
lOµm. 
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Similarly, all Tg2576 mice exhibited amyloid angiopathy that was regularly associated 
with a-intemexin-labelled DNs (Figure 5.2B). Additionally, consistent with previous 
confocal investigations-in the neocortex of human AD cases (Adlard and Vickers, 2002), 
MAP2-labelled dendrites were also observed to deflect around or terminate at the 
margins of AP plaques in the Tg2576 mice and the aged TgCRND8 mice (Figure 5.2C-
F). 
5.3.2 Percentage of neuritic AP plaques in TgCRND8 mice and human AD 
cases 
To determine how disruptive A~ plaques were to the axons (axonopathic) in the adjacent 
neuropil in transgenic AD mice relative to A~ plaques in human preclinical AD and AD, 
the percentage of A~ plaques associated with a-internexin-labelled DNs was assessed in 
the cortex of aged TgCRND8 and the ITG of human preclinical AD and AD cases. The 
percentage of AP plaques associated with a-intemexin-labelled DNs in aged TgCRND8 
mice was similar to the percentage of neuritic AP plaques present in human AD cases, 
but significantly different from the percentage of neuritic AP plaques observed in 
preclinical AD cases (Figure 5.3A; p < 0.05). In the aged TgCRND8 mice, 83.2 ± 2.3% 
(average± SEM) of AP plaques were associated with a-intemexin-labelled DNs, while 
the percentage of AP plaques associated with a-intemexin-labelled DNs in human AD 
and preclinical AD cases were 82.0 ± 1.6% and 67.2 ± 3.2%, respectively. 
In contrast, the percentage of fibrillar thioflavine s-stained plaques associated with a-
intemexin-labelled DNs in the aged TgCRND8 mice and human preclinical AD and AD 
cases were all significantly different (Figure 5.3B; p < 0.05). In aged TgCRND8 mice, 
the percentage of thioflavine s-stained plaques that co-localised with a-intemexin-
labelled DNs was 97.0 ± 0.5%. Whereas, in human AD and preclinical AD cases, the 
percentage of thioflavine s-stained plaques associated with a-intemexin-labelled DNs 
were 92.4 ± 1.4% and 86.0 ± 2.2%, respectively. 
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Figure 5.3 
P-amyloid-labelled and thioflavine s-stained plaques were highly axonopathic in aged 
TgCRND8 mice. The percentage of AP-labelled (A) and thioflavine s-stained (B) 
plaques in aged TgCRND8 mice that were associated with a-internexin-labelled DNs 
was significantly higher than the percentage of neuritic plaque present in human 
preclinical AD. The percentage of thioflavine s-stained plaques associated with a-
internexin-labelled DNs in aged TgCRND8 mice was significantly higher than that 
present in AD. Error bars indicate SEM. * p < 0.05 
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5.3.3 Morphology and neurochemistry of DNs 
Dystrophic neurites have been categorised as aberrant tortuous neurites with variable 
diameters, and as ring- and bulb-like based on the morphology of the labelled elements 
(Benzing et al., 1993; Masliah et al., 1993; Su et al., 1996a; Vickers et al., 1996; Su et 
al., 1998; Dickson et al., 1999; Dickson and Vickers, 2001; Dickson et al., 2005). Both 
Tg2576 and aged TgCRND8 mice exhibited dephosphorylated NF triplet protein-, 
phosphorylated NF triplet protein-, a-internexin- and NFM-labelled ring- and bulb-like 
DNs (Figure 5.4), along with A~ plaque-associated non-classical punctate and fine-
thread-like hyperphosphorylated-tau-labelling (Figure 5.5B,C). Interestingly, although 
the young cohort of TgCRND8 mice demonstrated dephosphorylated NF triplet protein-
and a-internexin-labelled DNs, no hyperphosphorylated-tau-labelling was associated 
with A~ plaques at this early pathology time point (Figure 5.5A). In comparison, human 
preclinical AD cases exhibited a-internexin-, dephosphorylated NF triplet protein-, 
phosphorylated NF triplet protein- and NFM-labelled ring- and bulb-like DNs (Figure 
5.4), and A~ plaque-associated punctate and fine-thread-like hyperphosphorylated-tau-
labelling (Figure 5.5D). Although, occasional classical hyperphosphorylated-tau DNs 
were present in a subset of preclinical AD cases. In contrast, the human AD cases 
exhibited abundant classical hyperphosphorylated-tau-labelled DNs (Figure 5.5), 
numerous a-internexin, phosphorylated NF triplet protein-, dephosphorylated NF triplet 
protein- and NFM-labelled bulbous DNs, along with numerous a-internexin-labelled, 
but only rare NF triplet protein-labelled ring-like DNs (Figure 5.4). 
Hyperphosphorylated-tau-labelling was not specifically co-localised with NFM- or a-
intemexin-labelled DNs in both TgCRND8 and Tg2576 mice (Figure 5.6A-F). 
However, labelling for dephosphorylated and phosphorylated NF triplet proteins often 
co-localised with labelling for NFM (phosphorylation independent) and/or a-internexin 
within DNs in both transgenic mouse models (Figure 5.6G-L). In addition, 
hyperphosphorylated-tau-labelled DNs were observed to co-localise with a-intemexin-
and NFM-labelled DNs in AD cases (Dickson et al., 1999; Dickson et al., 2005). 
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Figure 5.4 
The DN pathology present in TgCRND8 mice (A-D) and Tg2576 mice (E-H) was 
identical to that observed in human preclinical AD (1-L), but not AD (M-P). 
Representative images were acquired after double immunohistochemistry for AP (A-P) 
with a-intemexin (A, E, I, M), NFM, (B, F, J, N) dephosphorylated NF triplet protein 
(C, G, K, 0) or phosphorylated NF triplet protein (D, H, L, P). P-amyloid plaques (red) 
were associated with numerous bulb- (arrows) and ring-like (arrow heads) a-intemexin-, 
NFM-, dephosphorylated NF triplet protein- and phosphorylated NF triplet protein-
labelled DNs (green) in both transgenic mouse models and human preclinical AD. 
However, in human AD AP plaques were associated with abundant bulb-like DNs, and 
only a-intemexin-labelled ring-like DNs. Scale bar= lOµm. 
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Figure 5.5 
Abundant classical elongated hyperphosphorylated-tau-labelled DNs were observed in 
human AD, but not human preclinical AD cases or transgenic AD mice. No 
hyperphosphorylated-tau-labelling (green) was observed in association with A~ plaques 
(red) in the young TgCRND8 mice (A). Punctate (arrows) and fine thread-like (arrow 
head) labelling for hyperphosphorylated-tau (green) were observed in associated with 
A~ plaques (red) in aged TgCRND8 (B) and Tg2576 (C) mice. While human preclinical 
AD cases (D) exhibited punctate (arrows), fine thread-like (arrow head) and 
hyperphosphorylated-tau-labelling (green) associated with A~ plaques (red), and 
occasional classic elongated hyperphosphorylated-tau-labelled DNs (large arrow head). 
Numerous classic angular and elongated (large arrow heads) hyperphosphorylated-tau-
labelled DNs (green) were present in association with A~ plaques (red) in human AD 
(E). In human AD cases (F) a-intemexin-labelled (red) and hyperphosphorylated-tau-
labelled (green) DNs co-localised (arrows). Scale bar= lOµm. 

Figure 5.6 
Hyperphosphorylated-tau-labelling did not specifically co-localise with a-internexin- or 
NFM-labelled DNs. When images of a-internexin-labelled (A, D, arrows, red) DNs and 
punctate and fine-thread-like hyperphosphorylated-tau-labelling (B, E, arrow heads, 
green) in aged TgCRND8 mice (A-C) and Tg2576 mice (D-F) were overlayed (C, F) no 
specific co-localisation between these two subsets of DNs was observed. In comparison, 
when images of a-internexin-labelled DNs (G, J, red) and phosphorylated NF triplet 
protein-(H, green) or NFM-labelled (K, green) DNs in TgCRND8 (G-1) and Tg2576 (J-
L) mice were overlayed (I, L), the cytoskeletal markers co-localised within the majority 
of DNs (arrows), although some DNs were immunolabelled with a-internexin, 
phosphorylated NF triplet protein or NFM alone (arrow heads). Scale bar= lOµm. 
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5.4 DISCUSSION 
Notably, the current study has shown that two widely utilised transgenic AD mouse 
models exhibit DN pathology that is morphologically and neurochemically identical to 
that of human preclinical AD cases, but not AD cases. B-amyloid plaque deposition, as 
well as amyloid angiopathy, was observed to disrupt the surrounding neuropil in both 
TgCRND8 and Tg2576 mice. Specifically, AB plaque formation was highly axonopathic 
in aged TgCRND8 mice, and dendrites adjacent to AB plaques were also disrupted in 
both transgenic mouse models. Additionally, as AB plaque-associated 
hyperphosphorylated-tau-labelling was observed in the aged TgCRND8 mice, but not in 
the young cohort of TgCNRD8 mice, the current study supports the proposition that the 
phenotype of DNs matures as AD progresses from NF triplet protein and a-internexin-
abundant forms through to hyperphosphorylated-tau-labelled DNs. 
Both amyloid angiopathy and AP plaques were associated with abnormal neuronal 
processes in both transgenic mouse models, suggesting that AP plaque deposition locally 
disrupts adjacent neuropil. Amyloid angiopathy was observed in association with a-
intemexin-labelled DN structures in both Tg2576 and TgCRND8 mice. In addition, AP 
plaques caused both dendritic and axonal disruption, although the reaction of axons and 
dendrites to damage was different. Dystrophic neurites of axonal origin have been 
observed in association with AP plaques in Tg2576 and TgCRND8 mice in this, and 
previous studies (Irizarry et al., 1997; Chishti et al., 2001; Tomidokoro et al., 2001; 
Motoi et al., 2004; Noda-Saita et al., 2004; Delatour et al., 2004). Interestingly, 
anterograde tracer studies in transgenic AD mice that express human mutant APP and 
PS 1 describes similar axonal pathology largely restricted to cortico-cortical connections 
(Delatour et al., 2004) indicating a specific disruptive and localised effect of AP plaque 
formation. In addition, MAP2-labelled dendrites were observed to "bend" around AP 
\ ' 
plaques and were also "clipped" at AP plaque margins in the TgCRND8 and Tg2576 
mice. Similarly, AP plaques also affect the structure and organisation of adjacent 
dendrites in human AD (Knowles et al., 1998; Adlard and Vickers, 2002; Grutzendler et 
al., 2007) and other transgenic AD mouse models (Le et al., 2001; Schwab et al., 2004; 
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Grutzendler et al., 2007), supporting the idea that AP plaque formation may have a 
localised compressing effect on the neuropil. 
The percentage of neuritic AB-labelled plaques in aged TgCRND8 mice was not 
significantly different from that in AD cases, while the percentage of neuritic thioflavine 
s-stained plaques was significantly higher in aged TgCRND8 mice than in AD cases. 
Additionally, the vast majority of AP plaques in aged TgCRND8 mice and Tg2576 mice 
were observed to be associated with dephosphorylated NF triplet protein-, 
phosphorylated NF triplet protein- and NFM-labelled DNs. These data suggest that the 
AB plaques present in aged TgCRND8 mice are highly axonopathic relative to human 
preclinical AD and AD cases. The current data also corroborates previous reports 
(Dickson and Vickers, '2001 ), of the percentage of neuritic AP plaques in human AD 
being significantly higher than the percentage of neuritic AP plaques in preclinical AD 
cases (Figure 5.3A; p < 0.05). Furthermore, a higher percentage of thioflavine s-stained 
amyloid plaques were associated with DNs compared to AP-labelled plaques for aged 
TgCRND8, AD and preclinical AD cases. These data support previous in vitro reports 
of fibrillar AP being more detrimental to cell health than amorphous AP (Pike et al., 
1993; Lorenzo and Yanker, 1994; Ivins et al., 1998), and evidence from in vivo studies 
that fibrillar AP plaques are associated with increased damage to the surrounding 
neuropil in comparison to diffuse AP plaques (Dickson et al., 1988; Fukumoto et al., 
1996; Su et al., 1996a; Knowles et al., 1998; Dickson and Vickers, 2001; Le et al., 2001; 
Adlard and Vickers, 2002; D' Amore et al., 2003; Noda-Saita et al., 2004; Brendza et al., 
2005; Dickson et al., 2005). 
Dystrophic neurites labelled for tau (with variable phosphorylation), NF triplet proteins, 
MAP2, APP, PSI, synaptophysin, a-synuclein and ubiquitin are present in various 
transgenic mouse models of AD (Games et al., 1995; Masliah et al., 1996b; Irizarry et 
al., 1997; Sturchler-Pierrat et al, 1997; Chishti et al., 2001; Rockenstein et al., 2001 
Tomidokoro et al., 2001; Diez et al., 2003; Kurt et al., 2003; Boutajangout et al., 2004; 
Bussiere et al., 2004; Motoi et al., 2004; Noda-Saita et al., 2004 Schwab et al., 2004; 
Bellucci et al., 2007). However, the current investigation is the first to report that the 
107 
Chapter 5 - Results 
DN pathology in transgenic AD mice was morphologically and neurochemically 
identical to the DNs in human preclinical AD, but not AD (Table 5.2). 
The presence of abundant NF triplet protein and a-intemexin-labelled ring- and bulb-
like DNs and the lack of classical phosphorylated tau-labelled DNs in Tg2576 and 
TgCRND8 mice is characteristic of human preclinical AD, but not AD cases (Table 5.2). 
In contrast, human AD cases demonstrate numerous angular and elongated tau-labelled 
DNs, but only rare AP plaque-associated NF triplet protein-labelled ring-like DNs 
(Dickson et al., 1999; Dickson et al., 2005; Table 5.2). Conversely, the transgenic AD 
mice exhibited punctate and fine thread-like hyperphosphorylated-tau-labelling that was 
strikingly similar to the punctate and fine thread-like hyperphosphorylated-tau-labelling 
in human preclinical AD (Table 5.2). However, it should be noted that a subset of 
preclinical AD cases do demonstrate occasional hyperphosphorylated-tau DNs with 
classical elongated morphology. 
The evidence that the DN pathology present in Tg2576 and TgCRND8 mice resembles 
human preclinical AD more closely than AD cases has important implications for the 
experimental use of these, and perhaps other, mouse models. While an increasing 
number of studies utilise transgenic mouse models of AD for testing potential 
therapeutic agents (Schenk et al., 1999; Janus et al., 2000; Sigurdsson et al., 2001; 
Leissring et al., 2003; Bergamaschini et al., 2004; Chauhan et al., 2004; Arbel et al., 
2005; Singer and Marr, 2005; Asai et al., 2006; McLaurin et al., 2006), the beneficial 
effects seen in such animal models have not always translated to the human condition. 
For example immunotherapy treatment that was effective in several transgenic mouse 
models of AD, proved to be detrimental to the health of subjects in human Phase IIA 
clinical trials (Orgogozo et al., 2003). This may be because such therapeutics are able to 
efficiently reverse the early pathological changes in AD (Oddo et al., 2004), such as 
those present in transgenic mouse models of AD and human preclinical AD, but may be 
inefficient for treating AD in which neurofibrillary pathology is well established and 
overt neuronal loss has already occurred (Vickers et al., 2000; Nicoll et al., 2003; Ferrer 
et al., 2004). In support of this proposition, Oddo and colleagues (2004) discovered that 
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Table 5.2 Summary of the DN types present in aged TgCRND8 and Tg2576 transgenic 
mice, and human preclinical AD and AD cases. 
Dystrophic neurite type Transgenic AD mice Preclinical AD AD 
Bulb-like NF triplet protein-labelled + + + 
Bulb-like a.-internexin-labelled + + + 
Ring-like a.-internexin-labelled + + + 
Ring-like NF triplet protein-labelled + + 
Elongated hyperphosphorylated-tau-labelled + 
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Aj3 immunotherapy could reverse the early, but not the late stages of pathological tau 
hyperphosphorylation in a transgenic AD mouse model. In addition, two human AD 
subjects that received Aj3 immunotherapy exhibited extensive neocortical areas with 
very few Aj3 plaques and DNs, but no reduction of NFfs or neuropil threads (Nicoll et 
al., 2003; Ferrer et al., 2004). This is particularly important, as clinical trials for 
potential therapeutics involve human AD subjects, and there is currently no effective 
way to diagnose preclinical AD in humans. However, the accurate diagnosis of early AD 
cases prior to a clinical diagnosis utilising a combined biomarker/MRI imaging approach 
may soon be possible (as reviewed in Borroni et al., 2007; de Leon et al., 2007). 
Aged TgCRND8 mice demonstrated a-internexin- and NF triplet protein-labelled DNs 
and hyperphosphorylated-tau-labelling, conversely the young cohort of TgCRND8 mice 
exhibited a-intemexin- and NF triplet protein-labelled DNs, but no 
hyperphosphorylated-tau-labelling. Neurofilament-labelled DNs are also observed 
several months before phosphorylated tau-labelled DNs in TgCRND8 and other 
transgenic AD mouse models (Masliah et al., 2001; Blanchard et al., 2003; Boutajangout 
et al., 2004; Bellucci et al., 2007). These data suggest that NF triplet protein- and a-
intemexin-labelled DNs may be the earliest neuritic pathology to appear in association 
with Ap plaques, while the presence of phosphorylated tau in DNs occurs at a later time 
point (Su et al., 1998; Dickson et al., 1999; Masliah et al., 2001; Dickson et al., 2005; 
Bellucci et al., 2007). Similarly, it has been proposed that in human AD, DNs may first 
appear in preclinical AD labelled for NF triplet proteins and a-intemexin, then develop a 
I 
core of altered tau filaments before they become the elongated tau-only DNs observed in 
AD (Su et al., 1998; Dickson et al., 1999; Dickson et al., 2005). Additionally, these 
findings also suggest that tau hyperphosphorylation occurs as a secondary event to AP 
plaque deposition, which is supported by evidence that the presence of AP results in an 
increase in tau hyperphosphorylation in vitro (Busciglio et al., 1995; Ferreira et al., 
1997; De Felice et al., 2007). 
The hyperphosphorylated-tau antibody used in this study detects the 
hyperphosphorylation of tau at either Ser202/Thr205, Ser202/Ser205 or Ser205/Ser208 
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(Porzig et al., 2007). In particular, hyperphosphorylation of tau at Ser202 is a relatively 
early phosphorylation event in AD tau pathology and is an epitope associated with the 
presence of abnormal PHF-tau (Braak et al., 1994; Su et al., 1994b). In human AD this 
abnormal PHF-tau is present in both DNs and somatic NFTs. Thus, it has been 
postulated that the punctate and fine-thread-like hyperphosphorylated-tau-labelling in 
transgenic mice may be equivalent to the PHF-tau-labelled DNs of human AD, but that 
mice do not have a long enough lifespan to allow NFTs to develop (Masliah et al., 2001; 
Kurt et al., 2003). However, although DNs that exhibit phosphorylated tau epitopes are 
present in transgenic AD mice, no PHFs have been observed at the ultrastructural level 
in DNs in these animals (Lewis et al., 2001; Masliah et al., 2001; Sasaki et al., 2002; 
Kurt et al., 2003), despite mouse tau being almost homologous to human tau. The lack 
of PHFs in DNs in transgenic mouse models despite the presence of PHF-associated 
hyperphosphorylated-tau epitopes supports the proposition that transgenic AD mice 
represent an incomplete model of AD, but more comparably model early or preclinical 
AD (Phinney et al., 1999; Masliah et al., 2001; Vickers et al., 2001; Schwab et al., 
2004). 
In summary, the AB plaque-associated neuritic pathology present in Tg2576 and 
TgCRND8 mice was morphologically and biochemically identical to the cytoskeletal 
pathology of DNs present in preclinical AD, but not AD. Thus, these mice provide 
important opportunities to examine the early sequence of cellular changes that lead to 
the development of AD pathology, and the mechanisms by which the pathological 
process progresses and affects cellular function and health. Moreover, transgenic AD 
mouse models will serve as a vital platform for examining new therapeutic approaches 
that can be administered before extensive neuronal degeneration occurs. 
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6 METALLOTHIONEIN ISOFORM HA AS A POTENTIAL 
THERAPEUTIC FOR THE TREATMENT OF ALZHEIMER'S DISEASE 
6.1 INTRODUCTION 
Currently, AD patients are commonly treated with cholinesterase inhibitors (Brion, 
1996; Brodaty et al., 2001) or NMDA glutamate receptor antagonists (Livingston and 
Katona, 2004), but these therapeutics are only effective in a subset of AD patients, and 
do not affect AD progression (Parnetti et al., 1997). Thus, many research groups are 
searching for more effective therapeutic interventions for AD, and numerous potential 
therapeutic agents are currently in human clinical trials (Ruther et al., 2000; Simons et 
al., 2002; Jiang et al., 2003; Ritchie et al., 2003; Dodel et al., 2004; Sparks et al., 2005; 
Siemers et al., 2006). Assuming that AB plaques are the primary causative agent of AD, 
there are two potential approaches to slow or prevent AD: inhibit or stop AB plaque 
formation by modulating APP processing, inhibiting AB aggregation or increasing AB 
clearance, or protect neurons against the damaging effects of AB with anti-inflammatory 
drugs, antioxidants or growth factors (Vickers et al., 2000). Thus, an effective treatment 
strategy for AD would be to simultaneously inhibit AB plaque formation and to protect 
neurons against AB induced damage. Indeed, an increasing number of therapeutic 
agents with multiple modes of action are currently being investigated including 
NSAIDs, atorvastatin, verivastatin, fluvastatin, lovastatin, pravastatin, simvastatin, 
cerebrolysin and Huperzine A (Weggen et al., 2001; Simons et al., 2002; Sjogren et al., 
2003; Zhang et al., 2004b; Rockenstein et al., 2006; Wang et al., 2006). 
One such potential therapeutic agent for treating AD is metallothionein (MT) isoforms I 
and II (MTl/11), which has neuroprotective and antioxidant properties, and may also 
inhibit AB aggregation through its metal chelating ability (Maret, 1995; Aschner et al., 
1997; Adlard et al., 1998; Penkowa et al., 1999; Giralt et al., 2002; Chung et al., 2003). 
Metallothioneins are small (6-7 kDa), cysteine rich proteins that are present in most cells 
in the body including some cell types in the CNS (Hidalgo et al., 2001). Metallothionein 
isoform III (MTIII) is a growth inhibitory MT isoform that is present in neurons within 
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the hippocampus, amygdala and cerebellum in the healthy brain (Masters et al., 1994), 
but there are contradictory reports of MTIII expression in AD brains, including 
downregulation (Uchida et al., 1991; Yu et al., 2001), no change (Amoureux et al., 
1997) and upregulation of MTIII (Carrasco et al., 1999). Metallothionein isoforms I and 
II are expressed throughout the brain, predominantly by astrocytes, with a vast body of 
evidence demonstrating that MTI/11 protects the brain against damage, excess heavy 
metals and oxidative and inflammatory stress (reviewed in Hidalgo et al., 2001). In 
addition, MTI/11 are significantly upregulated in several transgenic mouse models of AD 
(Carrasco et al., 2006) and in human AD (Duguid et al., 1989; Adlard et al., 1998; 
Zambenedetti et al., 1998). Metallothioneins were considered to be strictly intracellular 
proteins, but recent studies have demonstrated an extracellular role for MTI/II (reviewed 
in Chung and West, 2004). Administration of exogenous MTl/II is highly efficacious in 
animal models of CNS injury, multiple sclerosis and Parkinson's disease (Giralt et al., 
2002; Chung et al., 2003; Penkowa and Hidalgo, 2003; Xie et al, 2004). 
Metallothionein isoforms I and II have a neuroprotective role following axonal injury in 
vitro and several types of CNS injury in vivo (Penkowa et al., 1999; Giralt et al., 2002; 
Chung et al., 2003; Chung and West, 2004). Additionally, MTI/11 null mice exhibit 
increased damage and poor recovery following physical or inflammatory injury to the 
CNS when compared to mice with endogenous MT (Penkowa et al., 1999; Giralt et al., 
2002). In this respect, the upregulation of MTI/11 in AD may, in part, be due to the 
localised mechanical injury caused by AB plaques. Metallothioneins are also powerful 
chelators and have a role in sequestering heavy metals and regulating the availability of 
metals for enzymes and transcription factors (Adlard et al., 1998). Each MT molecule is 
able to bind seven Zn2+ or 10 Cu+ metal ions, and through its metal binding properties 
MT may maintain metal homeostasis. Metal homeostasis is altered in AD with 
increased levels of extracellular metals and decreased bioavailability of metals within 
the cell, which is consistent with the dysregulation of APP processing, increased tau 
hyperphosphorylation, AB aggregation and increased oxidative stress present in AD (as 
reviewed in Adlard and Bush, 2006; Crouch et al., 2007). In addition, MTI/II may 
influence a wide variety of cellular processes via its metal chelating abilities, including 
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Af3 aggregation and A~ associated free radical production. P-amyloid has copper and 
zinc binding sites that affect the reversible precipitation of A~ into insoluble masses 
(Bush et al., 1994; Huang et al., 1997; Atwood et al., 1998) and the production of 
hydrogen peroxide that is mediated by redox-active metal ion and AP interactions 
(Cherny et al., 1999; Huang et al., 1999; Opazo et al., 2002). Regardless of the 
mechanism, free radicals are increased in AD brains (Smith et al., 1996; Smith et al., 
1997). Thus, by preventing the accumulation of redox active metals and free radical-
mediated cellular damage, MTI/II may have an important role as an antioxidant (Maret, 
1995; Aschner et al., 1997). Indeed, in mouse models of amyotrophic lateral sclerosis 
and multiple sclerosis (experimental autoimmune encephalomyelitis) MTI/11 deficiency 
resulted in increased oxidative stress and disease symptoms (Nangano et al., 2001; 
Puttaparthi et al., 2002; Penkowa et al., 2003). 
In light of the success of MTI/II administration to animal models of CNS injury and 
neurodegenerative diseases, and the biology of MTl/11 as a free radical scavenger, zinc 
and copper sink and neurotrophic factor, a pilot study for the treatment of transgenic 
Tg2576 AD mice with exogenous MTIIA was undertaken. 
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6.2 MATERIALS AND METHODS 
6.2.1 Metallothionein HA administration 
Nine Tg2576 mice expressing human APP695 harbouring the Swedish (KM670/671NL) 
familial AD mutation on a C57BL/6 and SJL hybrid background (Hsiao et al., 1996) and 
five age-matched wild type mice were injected intraperitoneally with lµg of sterile Zn-
MTIIA/g body weight (7.0 mol Zn equivalent; Bestenbalt LLC, Tallinn, Estonia) three 
times a week for 12 weeks beginning at 10 months of age. A dose of 1 µg of sterile Zn-
MTIIA/g body weight was chosen as previous studies have chr,onically injected mice 
with MTIIA intraperitonaelly with this dose daily for a maximum of seven days and 
observed neuroprotection following focal brain injury (Giralt et al., 2002). A higher 
dose of MTIIA was not utilised as previously published studies have only administered 
MTIIA daily for a maximum of seven days in mice (Giralt et al., 2002) and any possible 
detrimental effects of chronic administration of higher doses of MTIIA have yet to be 
determined. MTIIA has been successfully administered by intraperitoneal injection in 
previous studies that involved animal models of CNS disease or injury with definite or 
potential disruption of the BBB (Giralt et al., 2002; Penkowa and Hidalgo, 2003; Xie et 
al., 2004). Thus, MTIIA was administered intraperitoneally in Tg2576 mice as the BBB 
is compromised in these mice (Ujiie et al., 2003; Kumar-Singh et al., 2005; Dickenstein 
et al., 2006). Tg2576 mice were utilised for this pilot study as they are a widely utilised 
transgenic AD mouse model that have been used to test many potential therapeutic 
compounds (Weggen et al., 2001; Sung et al., 2004; Rezai-Zadeh et al., 2005; Hartman 
et al., 2006; Li et al., 2006). Metallothionein isoform IIA was chosen for this study as it 
has been shown to be efficacious in animal models of CNS injury and previously 
published literature indicates that MT-II functions are unlikely to be different from those 
of MT-I (Giralt et al., 2002; Chung et al., 2003; Penkowa and Hidalgo, 2003; Xie et al, 
2004). Metallothionein isoform IIA protein was administered as the zinc thionein form 
as mammalian MTs are predominantly bound to zinc in vivo (Vasak, 2005). Six control 
Tg2576 mice and five age-matched wild type mice were also injected intraperitoneally 
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with 20µ1 of sterile O.OlM PBS three times a week for 12 weeks starting at 10 months of 
age. 
To investigate whether a higher AB plaque load at the end point of the treatment regimes 
would more clearly delineate the potential therapeutic effects of MTIIA, a second cohort 
of older Tg2576 mice were also treated. Six Tg2576 mice and five age-matched wild 
type mice were injected intraperitoneally with lµg of sterile Zn-MTIIA/g body weight 
three times a week for 12 weeks beginning at twelve months of age. Four control 
Tg2576 mice and five age-matched wild type mice were also injected intraperitoneally 
with 20µ1 of sterile O.OlM PBS three times a week for 12 weeks starting at 12 months of 
age. All mice treated were weighed at the beginning, middle and end of the treatment 
program. 
6.2.2 Tissue pro~essing 
At the end of the treatment regimes, Tg2576 and wild type control mice were 
anaesthetised with 140mg/kg sodium pentobarbitone and transcardially perfused (4% 
paraformaldehyde/O.OlM PBS). The brain tissue was cryoprotected (Section 2.1) and 
40µm coronal sections were cut on a cryostat. 
6.2.3 Immunohistochemistry and analysis 
To examine the AB plaque load in the Tg2576 mice at the end of their treatment regime, 
the percentage area occupied by AB plaques, or 'amyloid load', was assessed in five 
tissue sections from each Tg2576 mouse. The five coronal sections per animal were 
spaced 800-1200µm apart, and the middle section of the five was situated at mid-
hippocampal level. All sections were treated with formic acid (Section 2.3.1) and 
double immunolabelled with rabbit anti-pan-AB and mouse anti-a-intemexin antibodies 
(Table 2.2). Double labelling fluorescent immunohistochemistry was performed as 
previously described (Section 2.3.3), except that secondary fluorescent antibodies were 
used at a dilution of 1:1000. Additionally, another five sections per Tg2576 mouse were 
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stained with thioflavine s (Section 2.2.1) and labelled for a-intemexin. The A~ plaque 
and thioflavine s-stained plaque loads were determined for all of the neocortex superior 
to the rhinal fissure, and the hippocampus (when present) in one hemisphere of each 
section of tissue. Specifically, low magnification images (25x) were obtained to 
determine the total area of cortex and hippocampus present in each tissue section, while 
higher magnification images ( 400x) were utilised to assess the total A~ plaque area for 
each tissue section. All image collection and area quantitation was performed blinded to 
case type. Quantitative data was analysed utilising a two tailed t-test (two sample 
unequal variance). 
To assess other possible effects of MTIIA administration sections from each Tg2576 
mouse were also immunolabelled with antibodies to A~ and a-internexin, NFM, 
hyperphosphorylated-tau, MAP2, GFAP or MTI/II (Table 2.2). In addition, age-
matched wild type mice were double immunolabelled with rabbit anti-pan-A~ and 
mouse anti-a-internexin antibodies. The presence of A~ plaque-associated DNs, 
dendritic alterations, gliosis and MTI/II-labelling was investigated. 
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6.3 RESULTS 
6.3.1 (l-amyloid and thioflavine s plaque loads following MTIIA treatment of 
Tg2576 mice 
To assess the effects of MTIIA administration on the pathology present in Tg2576 mice 
the A~ and thioflavine s plaque loads were determined following 12 weeks of treatment 
with either MTIIA or PBS beginning at either 10 or 12 months of age. There was no 
significant difference in the percentage area occupied by A~ or thioflavine s plaques in 
the cortex or hippocampus of Tg2576 mice treated with MTIIA compared to Tg2576 
mice treated with PBS, for both treatment regimes (Figure 6.1). There was, however, a 
trend towards the Tg2576 mice treated with MTIIA exhibiting lower A~ and thioflavine 
s plaque loads than Tg2576 mice treated with PBS (Figure 6.lA,B). In addition, no A~­
labelling or abnormal a-internexin-labelling was present in the age-matched control wild 
type mice injected intraperitoneally with MTIIA or PBS. 
6.3.2 (l-amyloid plaque-associated neuronal pathology and MTI/11 
immunolabelling in Tg2576 mice following MTIIA treatment 
The presence of A~ plaque-associated neuronal pathology and MTIIA immunolabelling 
in Tg2576 mice were also qualitatively analysed following 12 weeks of MTIIA or PBS 
administration, initiated at either 10 or 12 months of age. All PBS and MTIIA treated 
Tg2576 mice demonstrated a-internexin- and NFM-labelled ring- and bulb-like DNs, 
along with A~ plaque-associated non-classical punctate and fine-thread-like 
hyperphosphorylated-tau-labelling (Figure 6.2). In addition, both MTIIA and PBS 
treated mice exhibited MAP2-labelled dendrites that deflected around or terminated at 
the margins of A~ plaques (as shown in Figure 5.2C-F). Finally, there were no robust 
differences in the levels of MTI/11 and GF AP immunolabelling between PBS and 
MTIIA treated mice for both treatment regimes (Figure 6.3). 
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There were no significant differences between the Ap or thioflavine s plaque loads in the 
hippocampus or c.ortex of Tg2576 mice treated with MTIIA compared to the control 
PBS treated mice. When the percentage area of cortex occupied by AP-labelled plaques 
(A) or thioflavine s-stained plaques (B) for each animal (black circles) treated with 
MTIIA from 10-13 months of age were compared to control PBS treated Tg2576 mice, 
the average plaque loads (black lines) for the MTIIA and PBS treatment groups were not 
significantly different. Similarly, when Tg2576 mice were administered either MTIIA 
or PBS from 12-15 months of age, the average cortical area (black lines) occupied by 
AP-labelled plaques (C) or thioflavine s-stained plaques (D) were not significantly 
different. 
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Figure 6.2 
All MTIIA and PBS treated Tg2576 mice exhibited similar AB plaque-associated 
neuronal pathology. Tg2576 mice treated with either MTIIA (A) or PBS (B) from 12-15 
months of age demonstrated AB plaque (red) associated a-intemexin-labelled (green) 
bulb- (arrows) and ring-like (arrow heads) DNs. Similarly, both bulb- (arrows) and ring-
like (arrow heads) NFM-labelled (green) DNs were associated with AB plaques (red) in 
Tg2576 mice that were administered either MTIIA (C) or PBS (D) from 12-15 months 
of age. Additionally, non-classical punctate hyperphosphorylated-tau-labelling (green, 
arrows) was also associated with AB plaques (red) in Tg2576 mice that were treated with 
either MTIIA (E) or PBS (F) from 12-15 months of age. Scale bar= 1 Oµm. 

Figure 6.3 
There was no robust difference in the levels of MTI/II or GF AP immunolabelling 
between Tg2576 mice treated with MTIIA compared to PBS treated control mice for 
either treatment regime. Metallothinein I/II-labelling (green) was not robustly increased 
or decreased when Tg2576 mice treated with PBS (A) from 12-15 months of age were 
compared to comparable MTIIA treated Tg2576 mice (B). Metallothionein I/II-labelled 
astrocytes (arrows) were not specifically associated with AP-labelled (red) plaques 
(arrow heads) in Tg2576 mice. Similarly, levels of GFAP (green) immunolabelling 
were comparable in Tg2576 mice that were treated with PBS (C) and MTIIA (D) from 
12-~5 months of age. Glial fibrillary acidic protein-labelled astrocytes (arrows) were 
often specifically associated with AP-labelled (red) plaques (arrow heads). Scale bar: 
A,B =70µm, C,D = 90µm. 
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6.4 DISCUSSION 
This pilot study did not find significant changes in the A~ or thioflavine s plaque loads 
of Tg2576 mice treated with MTIIA, compared to control Tg2576 mice treated with 
PBS. However, there was a non-significant trend towards MTIIA treated transgenic 
mice exhibiting lower A~ and thioflavine s plaque loads than PBS treated Tg2576 mice. 
In addition, no changes in MTI/II or GF AP immunolabelling, AB plaque-associated DNs 
or dendrites were present when MTIIA treated Tg2576 mice were compared to PBS 
treated Tg2576 mice. Although this pilot study has not established any significant 
differences between the MTIIA and PBS treated Tg2576 mice, the administration of 
MTIIA to Tg2576 mice warrants further investigation. 
Many facets of the therapeutic administration of MTIIA to Tg2576 mice may be 
modified for future studies, including the number of animals used, route of MTIIA 
administration, dose of MTIIA utilised, age at which MTIIA treatment is initiated and 
the length of the treatment regime. The current pilot study was undertaken with a 
limited number of Tg2576 animals available, so no mice were treated with zinc to 
control for the zinc chelated to the administered MTIIA. Had the results of this pilot 
study yielded statistically significant results, a zinc only Tg2576 treatment group would 
have been added to the data set. Ideally, an increased number of Tg2576 mice in both 
the MTIIA and PBS treatment groups would also give future studies more power to 
determine whether MTIIA is having a beneficial effect on AB plaques, DNs and gliosjs. 
The range of AB and thioflavine s plaque loads present in the control PBS treated 
Tg2576 mice (Figure 6) show that the plaque load is highly variable from animal to 
animal in this transgenic mouse model. Therefore, it is likely that a higher number of 
mice need to be included in the current pilot study for any potential effects of MTIIA to 
be detected above the normal variability in AB or thioflavine s plaque load. 
Alternatively, it is also possible that MTIIA is not an efficient therapeutic agent for the 
treatment of transgenic AD mouse models and human AD. Although BBB disruption 
and leakage have been reported in both Tg2576 mice (Ujiie et al., 2003; Kumar-Singh et 
al., 2005; Dickenstein et al., 2006) and human AD (Algotsson and Winblad, 2007; 
119 
Chapter 6 - Results 
Bowman et al., 2007; Matsumoto et al., 2007; Zipser et al., 2007), it is possible that the 
disruption of the BBB in Tg2576 mice is not sufficient for therapeutic levels of 
intraperitoneally administered MTIIA to enter the CNS. Thus, future studies in Tg2576 
·mice may investigate the administration ofMTIIA intracerebrally or increase the dose of 
MTIIA delivered by intraperitoneal injection. Indeed, other studies that have shown 
successful outcomes following intraperitoneal injection of MTII have used doses of 1-
3 .3 µg/g body weight daily (Giralt et al., 2002; Penkowa and Hidalgo, 2003). In 
addition, the time at which MTIIA administration. is initiated and the length of the 
treatment regime could also affect the outcomes of this and future studies. The current 
investigation initially treated Tg2576 mice with MTIIA or PBS for 12 weeks beginning 
at 10 months of age. As Tg2576 mice first demonstrate AB plaque and AB plaque-
associated pathology at seven months of age, which progressively increases (Hsiao et al., 
1996; Kawarabayashi et al., 2001; Noda-Saita et al., 2004), and the current pilot study 
began a 12 week treatment course at either 10 or 12 months of age, future studies may 
investigate the prophylactic application of MTIIA to Tg2576 mice by beginning MTIIA 
treatment prior to the appearance of AB plaque pathology. Especially, as it is currently 
unknown whether MTIIA is able to aid in the disassembly and clearance of existing AB 
plaques. It is also possible that treating Tg2576 mice with MTIIA for longer periods of 
time would be more beneficial and result in a significant reduction in pathology. 
The current study has not shown any significant difference in AB or thioflavine s plaque 
loads, or AB plaque-associated pathology between MTIIA and PBS treated Tg2576 
mice. However, this investigation was a necessary pilot study, which provides a basis 
for future further investigation of the potential for MTIIA to be utilised as a therapeutic 
for AD. 
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7 DISCUSSION 
Alzheimer's disease is the most common form of dementia, and currently represents a 
significant social and economic burden that is likely to become an increasing problem as 
the world's population ages (Vickers et al., 2000). The characteristic pathological 
hallmarks of AD include AP plaques, DNs, NFTs and neuropil threads, and all involve 
abnormal insoluble aggregates of proteins. The proteins involved in these pathological 
proteinaceous aggregates include Ap, cytoskeletal neurofilaments and the microtubule 
associated protein tau, and all have regular physiological roles in the healthy aged brain. 
Thus, aberrant protein processing, folding, degradation and phosphorylation have all 
been implicated in the ability of Ap, neurofilaments and tau to aggregate abnormally (as 
reviewed in Miller et al., 2002; Chaudhuri and Paul, 2006; Mi and Johnson, 2006; 
Stockley and O'Neill, 2007), but the exact event or set of events that instigates the 
development of AD pathology is currently unknown. Many genetic and environmental 
factors have been associated with AD, but age is still the greatest risk factor for the 
development of this disease. Although cellular biochemical pathways have been 
proposed to link the formation of extracellular AP plaques and abnormal intracellular 
processing of the APP with the intracellular accumulation of cytoskeletal and 
cytoskeletal associated proteins in NFTs and DNs (Mandelkow et al., 1992; Ferreira et 
al., 1997; Lau and Ahlijanian, 2003; Ryder et al., 2003; De Felice et al., 2007), the 
primary cause of AD and the exact mechanisms by which AD progresses and neurons 
degenerate and die have not yet been determined. Therefore, the central aim of this 
thesis was to investigate the cellular mechanisms involved in the progression of AD that 
lead to cellular dysfunction and death. A more complete understanding of the aetiology 
and progression of AD are vital for the development of more efficient therapeutics for 
AD as current treatments for AD only relieve symptoms, and do not slow or stop its 
progression. 
Studying AD with the aim of identifying the primary causative agent or the specific 
cellular mechanisms and pathways involved in disease progression has been difficult: 
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the brain pathology associated with AD is complex, and postmortem human tissue 
provides only uncontrolled and variable time points in the dynamic process of disease 
progression. Thus, some key questions in the field of AD research still need to be 
resolved, including: 1) What is the primary causative agent of AD? 2) How does AD 
progress, and how are the pathological characteristics of AD related to one another? 3) 
What causes cells to die in AD and how? 
It has been suggested that the final pathway to cell death in AD involves NFT formation, 
cell cycle or plasticity dysregulation, apoptosis or cell death that is neither classical 
necrosis or apoptosis (reviewed in Vickers et al., 2000; Jellinger and Stadelmann, 2001). 
As highlighted in Chapter One, the literature regarding apoptosis in AD is often 
con.founding and contradictory. Numerous studies report both increased levels of DNA 
fragmentation and apoptosis-related proteins in AD brains compared to control brains 
(Su et al., 1994a; Dragunow et al., 1995; Satou et al., 1995; Smale et al., 1995; Cotman 
and Su, 1996; Lassmann, 1996; Troncoso et al., 1996; Kitamura et al., 1997; Lucassen et 
al., 1997; Nagy and Esiri, 1997; Su et al., 1997; Sugaya et al., 1997; Masliah et al., 
1998; Sheng et al., 1998; Stadelmann et al., 1998; Giannakopolous et al., 1999; 
Stadelmann et al., 1999; Lu et al., 2000; Ovennyer et al., 2000; Rohn et al., 2001a, Rohn 
et al., 2002; Blanchard et al., 2003; Pompl et al., 2003; Zhao et al., 2003a; Zhao et al., 
2003b; Del Villar and Miller, 2004; Kang et al., 2005), whereas many investigations find 
that the levels of the same apoptosis-related proteins and DNA fragmentation are similar 
or decreased in AD brains compared to healthy aged brains (Lucassen et al., 1997; 
MacGibbon et al., 1997; Nagy and Esiri, 1997; Desjardins and Ledoux, 1998; Kitamura 
et al., 1998; Stadelmann et al., 1998; Engidawork et al., 2001; Raina et al., 2001; 
Gastard et al., 2003; Wu et al., 2005). Similar discrepancies arise when the association 
of apoptotic-related proteins and DNA fragmentation with AP plaques and NFTs is 
examined (Su et al., 1994a; Lassmann et al., 1995; De la Monte et al., 1997; MacGibbon 
et al., 1997; Su et al., 1997; Tortosa et al., 1998; Broe et al., 2001; Ferrer et al., 2001; 
Giannakopolous et al., 2001; Jellinger and Stadelmann, 2001; Rohn et al., 2001 b; 
Gastard et al., 2003; Guo et al., 2004; Kobayashi et al., 2004; Wu et al., 2005). Thus, it 
is difficult to deduce the importance of apoptosis in the AD process from the existing 
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data (Roth, 2001; Raina et al., 2003). To clarify this contentious area of AD research the 
current study investigated the presence of apoptotic-like nuclei and the levels of a 
comprehensive range of apoptosis-related proteins from the intrinsic and extrinsic 
apoptotic pathways in control, preclinical AD and AD cases. There were no robust 
changes in the level of apoptotic nuclei or immunolabelling for aC3, aC8, aC9, Bax, 
Bcl-2, cyto c or TRADD that distinguished between case types. In addition, there were 
no substantial changes in the levels of Bax, Bcl-2 and TRADD mRNA extracted from 
the same set of cases that, were immunolabelled for apoptotic-related proteins. These 
results challenge the proposition that apoptosis plays a major role in the progression or 
pathogenesis of AD, and imply that apoptosis may merely represent a terminal pathway 
of cell death for neurons unable to withstand the ravages of AD pathology any longer. 
Due to the chronic nature of AD and the short period of time it takes a cell to undergo 
apoptosis, the number of apoptotic cells present within AD brains at any time should be 
very low (Perry et al., 1998; Jellinger and Stadelmann, 2000). Therefore, even though 
apoptotic morphol,ogy and apoptotic-related proteins were significantly elevated in AD 
and preclinical AD brains compared to control brains, it is still possible that the terminal 
degenerative pathway of neurons in AD is apoptotic, but that the number of cells 
undergoing apoptosis at any one time is so low that they are not discernable above the 
background level of apoptosis present in the normal aged brain. 
In agreement with other studies, this investigation found that apoptotic markers can be 
present in AD brains (Su et al., 1996b; MacGibbon et al., 1997; Nagy and Esiri, 1997; 
Su et al., 1997; Kitamura et al., 1998; Stadelmann et al., 1998; Tortosa et al., 1998; 
Giannakopolous et al., 1999; Raina et al., 2001; Rohn et al., 2001b; Rohn et al., 2002; 
Su et al., 2002; Gastard et al., 2003; Pompl et al., 2003; Zhao et al., 2003b; Del Villar 
and Miller, 2004), but still not result in extensive apoptosis. If all the cells expressing 
pro-apoptotic proteins completed apoptosis, a substantial neuronal loss would occur 
within a short period of time (Perry et al., 1998) in all case types. This suggests that 
apoptotic pathways are activated in these cells but do not proceed to completion. 
Avoidance of extensive apoptosis in AD brains (Troncoso et al., 1996; Lucassen et al., 
1997; Perry et al., 1998; Stadelmann et al., 1998; Jellinger and Stadelmann, 2000; Raina 
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et al., 2001; Raina et al., 2003) despite the presence of apoptotic markers (Satou et al., 
1995; Lucassen et al., 1997; Nagy and Esiri, 1997; Su et al., 1997; Sugaya et al., 1997 
Kitamura et al., 1998; Stadelmann et al., 1998; Stadelmann et al., 1999; Rohn et al., 
2001a; Rohn et al., 2002; Blanchard et al., 2003; Zhao et al., 2003b), may be due to sub-
lethal activation of apoptotic pathways, perhaps caused by the excitotoxins, oxidative 
stress, decreased glucose metabolism and/or A~ accumulation observed in AD and 
healthy aging (as reviewed in Cotman, 1998), or neurons may mount an effective 
defence against apoptotic cell death (Perry et al., 1998; Raina et al., 2001; Raina et al., 
2003). As neurons are post-mitotic and do not readily regenerate (reviewed in 
Chuckowree et al., 2004; Harel and Strittmatter, 2006), it is reasonable to expect that 
evolution has provided some in-built defense or safe guard against widespread neuronal 
apoptosis. The exact mechanisms that may enable neurons to withstand apoptotic 
stimuli have yet to be determined. 
In addition, it is also possible that discrete activation of apoptotic pathways occur. For 
example, in the current investigation cytoplasmic cyto c, indicating cyto c release from 
the mitochondria and the potential activation of the intrinsic apoptotic pathway, was 
present in a subset of DNs, while cyto c-labelling in the perikaryon of cortical cells was 
punctate. Similar release of cyto c has been reported in injured axonal segments, but 
was not present in the corresponding cell bodies (Btiki et al., 2000). However, it should 
be noted that, in addition to ipdicating the activation of the mitochondrial apoptotic 
pathway, cyto c release can also signify mitochondrial damage or dysfunction. 
Furthermore, increasing evidence suggests that caspases may be activated for cellular 
processes other than apoptosis, potentially by discrete activation within cellular 
compartments and/or the cleavage of limited select substrates (as reviewed by Schwerk 
and Schulze-Osthoff, 2003). 
The lack of any specific co-localisation of apoptotic-like nuclei with pathological 
hallmarks of AD such as NFTs or A~ plaques in the current study and others (Troncoso 
et al., 1996; Lucassen et al., 1997; Sugaya et al., 1997; Broe et al., 2001) is a striking 
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finding. The scarcity of apoptotic-like nuclei associated with AP plaques does not 
support the proposition that AP plaques are directly toxic to surrounding neurons. In 
'' 
addition, early- and late-stage NFTs were also not co-localised with apoptotic-like nuclei 
or cytoplasmic cyto c immunolabelling. In contrast to NFTs in the entorhinal cortex 
(Vickers et al., 1992), most neocortical NFTs in AD are intracellular (Sampson et al., 
1997; Vickers et al., 2003), suggesting that NFT-bearing neurons may be able to survive 
NFT formation for long periods of time before neurodegeneration and cell death occurs 
(as reviewed by Jellinger and Stadelmann, 2001). The notion that NFT formation is 
detrimental to cell health is being increasingly challenged, with growing evidence 
suggesting that tau phosphorylation and subsequent NFT formation may be by-products 
of protective compensatory mechanisms that protect neurons against oxidative stress 
(Lee et al., 2005). Specifically, neuronal loss does not directly correlate with NFT 
development in mouse models of AD (Andorfer et al., 2005; Santacruz et al., 2005), 
while modelling ofNFT formation and neuronal degeneration in the CAI of the human 
hippocampus has suggested that NFT-bearing neurons survive for approximately 20 
years (Morsch et al., 1999). In addition, recent research suggests that tau 
phosphorylation may protect neurons against apoptosis (Li et al., 2007). Cells 
overexpressing tau are resistant to various apoptotic stimuli, which instead induce tau 
hyperphosphorylation, GSK3 activation and decreases in B-catenin phosphorylation in 
tau expressing cells (Li et al., 2007). These data suggest an anti-apoptotic function of 
tau hyperphosphorylation, potentially by tau competitively inhibiting the 
phosphorylation, and subsequent activation, of B-catenin by GSK3 (Li et al., 2007). 
However, it has also recently been reported that reducing endogenous tau levels in 
transgenic mice expressing APP did not alter AB levels, but did ameliorate behavioural 
deficits (Roberson et al., 2007). In addition, reduced tau levels also protected transgenic 
and wild type mice from excitotoxicity (Roberson et al., 2007). 
Examining the pathology present in human AD brain tissue has provided a wealth of 
information and clues as to which proteins and cellular pathways may be fundamentally 
involved in AD, but it is difficult to assess disease progression, the potential links 
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between the pathological hallmarks of AD and the cellular/molecular pathways that lead 
the loss of nerve cell function and cell death in the snap shots that postmortem human 
tissue supplies. Consequently, studying preclinical AD cases or transgenic mouse 
models of AD may provide important insights into the initiation, staging and maturation 
of AD-associated pathology (Benzing et al., 1993; Lue et al., 1996; Vickers et al., 1996; 
Dickson et al., 1999; Dickson and Vickers, 2001; Vickers, 2001). Preclinical AD cases 
are typically associated with minor cognitive deficits, and are defined as a subset of non-
demented cases exhibiting widespread non-neuritic AB plaques (based on thioflavine s 
or tau-immunolabelling) in the neocortex, neurofibrillary pathology that is mostly 
restricted to the entorhinal formation and hippocampus, and no overt neuronal 
degeneration or loss (Morris et al., 1996; Price and Morris, 1999; Vickers et al., 2000). 
To date the study of preclinical AD cases has provided valuable information regarding 
AD initiation and progression. Preclinical AD cases demonstrate AB plaques and DNs 
with morphological and biochemical characteristics that differ from those in AD cases, 
but no tauopathy, which includes NFfs, neuropil threads and tau-labelled DNs (Morris 
et al., 1996; Price and Morris, 1998; Vickers et al., 2000). This suggests that AB plaques 
and DNs containing neurofilaments and APP, but not tau, are some of the earliest 
pathology to develop in human AD, and provides support for the AB cascade hypothesis. 
Transgenic mouse models of AD represent additional tools for researchers examining 
AD progression, as a range of pre- and post-pathology time points can be assessed with 
the added facet that the disease process can be actively and readily, interfered with. 
Although transgenic mouse models of AD have been extremely useful, aspects of the 
way in which transgenic AD mouse models fit into or compare to the schema of disease 
staging that occurs in human AD have been under appreciated. 
Transgenic mice overexpressmg APP harbouring familial AD mutations reliably 
produce AP plaques, AP plaque-associated gliosis and DNs, but do not develop NFTs 
and neuropil threads or exhibit the dramatic neuronal loss equivalent to that in human 
AD cases (Games et al., 1995; Hsiao et al., 1996; Borchelt et al., 1997; Sturchler-Pierrat 
et al., 1997; Holcomb et al., 1998; Moechars et al., 1999; Janus et al., 2000; Mucke et 
al., 2000; Chishti et al., 2001; Blanchard et al., 2003; Higgins and Jacobsen, 2003; 
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Richards et al., 2003; Cheng et al., 2004; Kawasumi et al., 2004; Oakley et al., 2006). 
Overt neurodegeneration and neuron loss has only been unequivocally demonstrated in 
APP23 mice (Calhoun et al., 1998; Higgins and Jacobsen, 2003). The similarities 
between the pathology exhibited in APP transgenic AD mice and that of preclinical AD 
cases, namely Af3 plaques, DNs and gliosis, but no overt neurofibrillary pathology and 
neuron loss, suggests that transgenic AD mice may more closely model the early 
preclinical stages of human AD. However, no thorough analysis of Af3 plaque-
associated neuronal pathology in APP transgenic AD mice had been conducted. The 
current investigation addressed this deficit by analysing DNs in two widely utilised APP 
transgenic AD mouse models, TgCRND8 and Tg2576 mice. This study determined that 
the biochemical and morphological characteristics ofDNs in the TgCRND8 and Tg2576 
mice were strikingly similar to that in human preclinical AD cases, but not AD cases. 
Specifically, both lines of transgenic AD mice and human preclinical AD cases 
demonstrated abundant NF triplet protein- and a-intemexin-immunolabelled bulb- and 
ring-like DNs and AP plaque-associated punctate and fine thread-like 
hyperphosphorylated-tau labelling, whereas human AD cases exhibited numerous 
classical hyperphpsphorylated-tau-labelled DNs, a-intemexin-labelled bulb- and ring-
like DNs and NF triplet protein-labelled bulb-like DNs (as depicted in Figure 7.1). 
Importantly, quantitation demonstrated that the AP plaques in TgCRND8 mice were 
highly axonopathic, as the percentage of AP-labelled or thioflavine s-stained plaques in 
· TgCRND8 mice associated with DNs was equivalent to or in excess of that in human 
AD cases. These results indicate that the AP plaque-associated neuronal pathology in 
these mice more accurately models the early or preclinical brain changes that occur in 
human AD, representing a valuable model for understanding and developing treatments 
for preclinical AD. 
With respect to the different transgenic AD mice it is important to note that the 
overexpression of APP harbouring familial AD mutations has resulted in the presence of 
Aj3 plaques, DNs, astrocytosis, microgliosis and no neurofibrillary pathology on a 
variety of different genetic backgrounds (Games et al., 1995; Hsiao et al., 1996; 
Sturchler-Pierrat et al., 1997; Moechars et al., 1999; Mucke et al., 2000; Chishti et al., 
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The morphological and neurochemical characteristics of A~ plaques associated with 
DNs in TgCRND8 and Tg2576 mice are identical to those in human preclinical AD, but 
not AD cases. The transgenic ..f\D mice, preclinical AD and AD cases exhibit NF- and 
a-intemexin-labelled bulb-like DNs, and a-intemexin-labelled ring-like DNs. NF-
labelled ring-like DNs are abundant in TgCRND8 and Tg2576 mice and preclinical AD 
cases, but rare in AD cases. While AD cases demonstrate numerous classical angular 
elongated tau-labelled DNs, which are rarely observed in the transgenic AD mice and 
preclinical AD cases. However, preclinical AD cases and TgCRND8 and Tg2576 mice 
do exhibit punctate and fine-thread like tau-labelling associated with A~ plaques. In 
addition, a subset of NF- and a-intemexin-labelled DNs with a core of tau 
immunolabelling are observed in AD cases. 
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• 
• 
Transgenic AD mice 
a-intemexin 
Tau 
Chapter 7 - Discussion 
2001; Higgins and Jacobsen, 2003). The development of such AD-like pathology in 
transgenic AD mice with different genetic backgrounds provides strong evidence that 
the overexpression of mutant APP results in Aj3 deposition and the subsequent 
development of Aj3 plaque associated DNs and gliosis. Thus, investigating DN 
phenotype in two mouse models of AD that overexpress different APP mutants of 
different genetic backgrounds also indicates that the preclinical AD DN phenotype 
exhibited by Tg2576 and TgCRND8 mice is robust and likely applies to other transgenic 
AD mouse models. Ideally future studies may investigate the DN phenotype and other 
AD pathology present in not only Tg2576 and TgCRND8 mice, which represent 
relatively slow and fast pathology acquisition, but also in PSAPP, TAPP and 3xTg-AD 
mice to determine whether the expression of mutant PSI and/or tau alters DN 
characteristics and the development of AD-like pathology over time. Finally, ~th 
regards to utilising transgenic AD mice as platforms to test potential 
pharmacotherapeutics, transgenic AD mice that overexpress mutant APP and PS 1 that 
rapidly develop AD pathology, such as the TgCRND8 and probably PSAPP mice, would 
be effective for testing therapeutics to be administered to the preclinical or early stages 
of human AD, before overt cell loss and neurofibrillary pathology has developed. 
Although, therapeutics for the treatment of end stage human AD should be tested in 
transgenic AD mice with established neurofibrillary pathology such as the TAPP or 
3xTg-AD mice. 
Having characterised the neuronal pathology of two widely used transgenic AD mouse 
models, the final aim of this thesis was to investigate the potential of MTIIA as a 
therapeutic intervention for AD. Although the results of this study were not statistically 
significant, there was a trend towards lower AB-labelled and thioflavine s-stained plaque 
loads in the MTIIA treated Tg2576 mice compared to the PBS treated control mice. 
Tg2576 mice are currently being bred and aged to further investigate alternate MTIIA 
treatment regimes including different doses, initiation time points and length of the 
treatment and differing routes of administration, all with higher numbers of animals in 
the treatment groups. 
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With respect to the cellular mechanisms of disease progression, it is intriguing that 
despite exhibiting AP plaques and DNs, transgenic APP AD mice do not develop the full 
spectrum of AD pathology, as the AP cascade hypothesis would predict. Why PHFs, 
NFTs, neuropil threads and classical tau-labelled DNs do not develop in transgenic APP 
AD mice is currently unknown (McGowan et al., 2006). Mouse tau is almost 
homologous to human tau and is able to form filaments in vitro (Kampers et al., 1999), 
and NFTs are produced in vivo in mice when human mutant tau harbouring mutations 
associated with hereditary frontotemporal dementia and parkinsonism, are overexpressed 
(Lewis et al., 2000; Gatz et al., 2001; Zhang et al., 2004a; Terwel et al., 2005). 
However, mice overexpressing all six human tau isoforms but not endogenous mouse 
tau develop PHFs and pathological accumulations of PHF-tau in the soma and dendrites 
of neurons (Andorfer et fil., 2003), but when the entire human wild type tau gene is 
overexpressed. in mice with endogenous tau expression, no obvious histopathological 
phenotype develops (Duff et al., 2000), suggesting that endogenous mouse tau is 
inhibitory to the formation of tau filaments (Gatz et al., 2004). It is also possible that 
other factors or cellular pathways required for the development of tauopathy are missing 
or are limited in the mouse brain (Phinney et al., 2003). Furthermore, the lack of 
extensive neuronal loss in transgenic APP AD mice may be due to the lack of 
neurofibrillary pathology, if this pathology specifically causes neurons to degenerate and 
die. Alternatively, perhaps the relatively fast development of AP plaques in transgenic 
AD mouse models and the short life span of mice does not allow enough time for AP 
plaques to cause chronic stress and damage that may result in neuronal loss. In this 
respect, it has been shown that the AP in human Aj3 plaques is chemically modified, 
including N-terminal truncation, crosslinking and isomerisation, whereas equiv~lent Aj3 
modifications are not present in transgenic AD mice (Kuo et al., 2001). The deposition 
· · of various other proteins, cations and lipids in AP plaques that occurs in human AD may 
also differ in transgenic AD mouse models (Maynard et al., 2002). Although the 
biological significance of co-deposited molecules and the chemical modification of AP 
within AP plaques are unclear (Phinney et al., 2003), it may influence the toxicity of AP 
plaques (Higgins and Jacobsen, 2003). In addition, the development of different Aj3 
plaque types in transgenic AD mouse models does not precisely mimic the progression 
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of AP plaque types exhibited in human AD. For example, 70% of AP plaques in 18-
month old Tg2576 mice were diffuse (Tomidokoro et al., 2001; Sasaki et al., 2002), 
while in APP23 mice more than 90% of AP plaques were dense-cored and diffuse AP 
plaques were predominantly exhibited in mice with high AP plaque loads (Calhoun et 
al., 1998). Instead, human AD cases exhibit a higher relative proportion of fibrillar and 
dense-core AP plaques than preclinical AD cases (Dickson and Vickers, 2001 ). 
A variant of the amyloid cascade hypothesis has been proposed, in which AP plaque 
formation causes compression of the neuropil and sufficient structural injury to initiate 
axonal cytoskeletal changes, resulting in DN formation, and potentially the subsequent 
development of neurofibrillary pathology, neurodegeneration and cell death over the 
chronic time course of this disease (as previously reviewed in Vickers, 1997; Vickers et 
al., 2000). In support of the proposition that AP plaque formation structurally displaces 
the neuropil, fewer dendrites, axons and neuronal cell bodies are located within the area 
occupied by AP plaques in human AD and transgenic AD mouse models (De Witt and 
Silver, 1996; Knowles et al., 1998; Le et al., 2001; Tomikodoro et al., 2001; Adlard and 
Vickers, 2002; Moolman et al., 2004; Tsai et al., 2004). In addition, the NF triplet 
protein and a-intemexin-labelled ring- and bulb-like DNs observed following in vitro 
and in vivo axonal injury are strikingly similar to those seen in AD brains and, as 
described in this study, transgenic AD mice (Masliah et al., 1993; Meller et al., 1994; 
DeWitt and Silver, 1996; Masliah et al., 1996b; Su et al., 1996a; Vickers et al., 1996; 
Christman et al., 1997; Irizarry et al., 1997; King et al., 1997; Nakamura et al., 1997; 
Dickson et al., 2000; Chishti et al., 2001; King et al., 2001; Le et al., 2001; Chuckowree 
and Vickers, 2003; Bussiere et al., 2004; Dickson et al., 2005). Furthermore, 
dephosphorylated NF triplet proteins are abnormally present in axons following physical 
trauma and within the axonopathic changes in human AD and transgenic AD mice 
(Masliah et al., 1993; Meller et al., 1994; DeWitt and Silver, 1996; Su et al., 1996a; 
Vickers et al., 1996; Christman et al., 1997; King et al., 1997; Nakamura et al., 1997; 
Dickson et al., 2000; King et al., 2001; Le et al., 2001; Chuckowree and Vickers, 2003; 
Dickson et al., 2005). Apoptotic-related proteins including activated caspases and 
cytoplasmic cyto c were evident in DN s in transgenic AD mice and in human AD in the 
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current investigation and others (De la Monte et al., 1997; MacGibbon et al., 1997; Nagy 
and Esiri et al., 1997; Tortosa et al., 1998; Giannakopolous et al., 2001; Rohn et al., 
2002; Su et al., 2002; Blanchard et al., 2003; Su et al., 2003; Guo et al., 2004; Wu et al., 
2005; Albrecht et al., 2007), and are also present in axons following axonal injury or 
disruption (Springer et al., 1999; BUki et al., 2000; Wingrave et al., 2003; DeRidder et 
al., 2006). This expanding body of evidence supports the mass effect variant of the 
amyloid cascade hypothesis and strongly suggests that AP plaque induced neuronal 
injury may play an important role in the initiation of DN pathology in AD and in AD 
progression. 
This thesis has substantially contributed to our growing' understanding of the staging of 
the pathological changes that underlie AD, clarifying the role of apoptosis in AD and 
strongly suggesting that transgenic APP AD mouse models accurately mimic the AP 
plaque-associated neuronal pathology of human preclinical AD. Furthermore, the 
reported pilot study of the effect of MTIIA will lead to further investigation of this 
potential therapeutic approach in the future. 
7.1 CONCLUSIONS 
• There is no difference in the levels of apoptosis-related proteins and apoptotic 
nuclear morphology between preclinical AD, AD and control cases, suggesting 
that apoptosis does not play a major role in the progression of AD or the 
pathogenesis of the pathological hallmarks of AD or neuronal degeneration. 
• Activation of apoptotic pathways can occur without extensive terminal 
apoptosis within the brain. 
• As indicated by the lack of apoptotic nuclei and the presence of punctate cyto 
c-lahelling in the soma of NFT-hearing neurons, NFTs may not he as severely 
detrimental to neuronal health as previously suggested. 
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• Cytochrome c may be a transient and early marker in AP plaque-associated 
DNs, and its presence in the cytoplasm of DNs may indicate activation of 
apoptotic pathways and/or mitochondrial dysfunction. 
• Neurofilament triplet protein and a-intemexin containing DNs precede the 
appearance of hyperphosphorylated-tau-labelled DNs, suggesting that DNs 
may mature from NP-labelled DNs to tau-labelled DNs as AD progresses. 
• The neurochemistry and morphology of DNs in two widely used transgenic 
mouse models of AD recapitulates the DN pathology present in preclinical AD 
cases, but not AD cases, indicating that transgenic APP AD mouse models 
more accurately model the preclinical stages of AD and early AP plaque-
associated neuronal pathology. 
7.2 FUTURE DIRECTIONS 
• Future studies could further investigate both the DN phenotype and other AD 
pathology present in PSAPP, TAPP and 3xTg-AD mice to determine whether 
the expression of mutant PSI and/or tau alters DN characteristics and the 
development of AD-like pathology over time. 
• It would also he of interest to build upon the data regarding apoptosis in AD, 
by investigating apoptosis in transgenic mouse models of AD including 
Tg2576, PSAPP and 3xTg-AD mice, with respect to apoptotic nuclear 
morphology and the levels of apoptotic-related proteins to compare to that 
present in human AD tissue. 
• To further increase our understanding of disease progression in AD, a set of 
hereditary AD cases expressing PSI harbouring familial mutations that exhibit 
accelerated AD progression could he examined for DN phenotype and the load 
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and distribution pattern of AfJ plaques and NFTs in comparison to a cohort of 
sporadic preclinical AD and AD cases. 
• As discussed in the current study, select subsets of neurons, notably those that 
express NF triplet proteins, are selectively vulnerable to degeneration in AD. 
To investigate the cellular basis of this select neuronal vulnerability, NFL 
knock out mice could be crossed with transgenic APPIPSJ mice to ascertain 
the importance of the NF triplet proteins to the local response of neurites to 
axonal injury in vitro, and AfJ plaque induced damage in vivo. 
• The current investigation, along with numerous other studies, highlights the 
damaging effects of AfJ plaques on the surrounding neuropil, but exactly how 
the earliest disruption of the cortical network by AfJ plaque formation 
co"elates with cognitive deficits remains unknown. Thus, yellow fluorescent 
protein transgenic mice could be crossed with APPIPSJ mice and the response 
of fluorescent neurites to AfJ plaques could be assessed in fu:ed tissue and by 
two-photon scanning laser microscopy in conjunction with behavioural testing 
at several time points. 
• Although the cu"ent pilot study did not result in any significant differences 
between MT/IA and PBS treated Tg2576 mice, the use of MTIIA as a potential 
prophylactic therapeutic agent could still be investigated. Future studies could 
utilise APP/PSJ transgenic AD mice, involve a higher number of animals per 
treatment group~ and administer a higher dose of MTIIAfrom six to twelve 
months of age. 
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9 APPENDIX - SOLUTIONS 
O.OlM PBS, pH 7.4 
1 OOmL 9% NaCl (90g of NaCl (Sigma) per lL Milli-Q® water) 
40mL Na2HP04 (BDH Laboratory supplies, Poole, UK) (28.4g per lL Milli-Q® 
water) 
lOmL 
850mL 
NaH2P04.2H20 (Sigma) (3 l.2g per lL Milli-Q® water) 
Milli-Q® water 
18.0% Sucrose Solution 
180g Sucrose (Sigma) dissolved in lL O.OlM PBS 
30.0% Sucrose Solution 
300g Sucrose (Sigma) dissolved in lL O.OlM PBS 
Tissue Storage Solution 
O.OlMPBS 
0.1 % Sodium azide (Sigma) 
IMMUNOHISTOTOCHEMISTRY SOLUTIONS 
0.25% Potassium permanganate 
0.125g KMn04 (BDH) in SOmL O.OlM PBS 
1.0% Pot-metabisulphite and oxalic acid 
O.Sg K1S20s (BDH) 
O.Sg Oxalic acid (Analytic Univar Reagents, Victoria, Australia) 
Dissolve in SOmL O.OlM PBS 
0.0125% thioflavine s 
0.00625g thioflavine s (Sigma) in SOmL O.OlM PBS 
199 
0.3% Triton/PBS 
600µL 
200mL 
Triton X (Sigma) 
O.OlMPBS 
O.OlM Citrate Buffer 
2.94g Trisodium citrate (Sigma) in 800mL Milli-Q® water 
9-Appendix 
Dissolve and adjust to pH 6 with O. lM citric acid, then make up to lL with Milli-Q® 
water. 
O.lM Citric acid 
10.Sg Citric acid (Sigma) in 400mL Milli-Q® water 
Dissolve and adjust to pH 6.0 with 2M NaOH, then make up to lL with Milli-Q® water. 
2M Sodium Hydroxide 
40.0g NaOH (Sigma) dissolved in lL Milli-Q® water 
4% Paraformaldehyde (PFA) 
40g PFA (Sigma) 
40g 
lOOmL 
400mL 
500mL 
Sucrose (Sigma) 
9% NaCl 
Na2HP04 
NaH2P04.2H20 
Heat while stirring until dissolved in a fume hood. 
1.0% Hydrogen peroxide in methanol 
lmL 30.0% H20 2 (Sigma) diluted in 30mL methanol 
50XTAE 
242g 
57.lmL 
Tris Base (Sigma) 
glacial acetic acid 
200 
'1 
9-Appendix 
lOOmL 0.5MEDTApH8.0 (BDH) 
Make up to lL with Milli-Q® water 
TE Buffer, pH 8.0 
l .6g Tris base 
0.5g EDTA (Sigma) 
Dissolve and adjust to pH 8.0 with 2M NaOH, then make up to lL with Milli-Q® water. 
5X Running Buffer, pH 8.3 
9g Tris base 
43.2g Glycine (Bio-Rad) 
3g SDS 
Combine and add 600mL ofMilli-Q® water. Store at 4°C. Prior to use combine lOOmL 
Running Buffer with 400mL Milli-Q® water. 
2.5% Agarose Gel 
1.25g Agarose (Invitrogen) 
lmL 50xTAE 
50mL Milli-Q® water 
Microwave for two minutes. Add 4µ1 ofEthidium Bromide swirl, pour. Run gel in lx 
TAE. 
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